Preventing or reducing adverse effects associated with T cell-engaging agents

JP2023547523A5Pending Publication Date: 2024-11-14F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526938
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-07-23
Filing Date
2021-11-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

T cell-engaging agents like T cell bispecific antibodies and CAR-T cells pose safety risks due to cytokine release syndrome (CRS) and on-target, off-tumor cytotoxic activity, necessitating the development of methods to prevent or reduce adverse effects while maintaining therapeutic efficacy.

Method used

Administering inhibitors of JAK and/or mTOR signaling, such as temsirolimus, sirolimus, everolimus, and ruxolitinib, to mitigate cytokine release while preserving the therapeutic efficacy of T cell-engaging agents.

Benefits of technology

The use of JAK and/or mTOR inhibitors effectively reduces cytokine release syndrome and maintains the ability of T cell-engaging agents to target and kill tumor cells, offering a safer and more effective treatment approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000096_0000
    Figure 00000096_0000
  • Figure 00000096_0001
    Figure 00000096_0001
  • Figure 00000096_0002
    Figure 00000096_0002
Patent Text Reader

Abstract

The present invention relates to the prevention or reduction of adverse effects associated with T cell engaging agents, such as cytokine release syndrome. In particular, the present invention relates to the prevention or reduction of such adverse effects using inhibitors of JAK and / or mTOR.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to the prevention or mitigation of adverse effects associated with T cell engagement agents, such as cytokine release syndrome. Specifically, this invention relates to the prevention or mitigation of such adverse effects using JAK and / or mTOR inhibitors. [Background technology]

[0002] T cell engagers, such as T cell bispecific antibodies (TCBs) or T cells expressing chimeric antigen receptors (CARs) (CAR-T cells), are showing great promise as cancer immunotherapies. However, treatment with T cell engagers can come with safety responsibilities due to on-target, on-tumor, and on-target-off-tumor cytotoxic activity and cytokine release. One of the most common adverse effects reported for T cell engagers is cytokine release syndrome (CRS). This complex clinical syndrome is characterized by fever, hypotension, and respiratory failure and is associated with the release of pro-inflammatory cytokines such as IL-6, TNF-α, IFN-γ, and IL-10 (see, e.g., Shimabukuro-Vornhagen et al., J Immunother Cancer (2018) 6, 56). Approaches to mitigate these life-threatening toxicities are greatly needed. The Src inhibitor dasatinib has been identified as a promising candidate for preventing or mitigating adverse effects on CAR-T cells (Weber et al., Blood Advances (2019) 3, 711-7; Mestermann et al., Sci Transl Med (2019) 11, eaau5907) and TCBs (Leclercq et al., J Immunother Cancer (2020) 8 (Suppl 3): A690 (abstract 653)). However, dasatinib completely disables the functionality of CAR-T cells and TCB-induced T cells without distinguishing between the desired and undesirable activities of these drugs. A method to prevent or mitigate the adverse effects while maintaining the therapeutic efficacy of T cell-engineering agents is highly desirable. Blocking individual cytokines such as IL-6 or TNF-α has been proposed as a strategy to prevent CRS without affecting TCB-induced T cell activity (Li et al., Sci Transl Med 11, eaax8861 (2019)). In addition to anti-IL-6 therapy (e.g., with tocilizumab), glucocorticoids are also used to manage CRS. However, some patients are resistant to these approaches, highlighting the growing need to develop new approaches to alleviate CRS. [Modes for carrying out the invention]

[0003] Description of the Invention The inventors have discovered that T-cell engagement therapy-induced CRS can be mitigated using inhibitors of JAK and / or mTOR signaling. mTOR inhibitors such as temsirolimus, sirolimus, and everolimus, and JAK inhibitors such as ruxolitinib, were found to potently prevent TCB-induced cytokine release while maintaining TCB-induced target cell death. The results provide evidence that the mechanisms of TCB-dependent cytokine release and target cell death can be decoupled, and suggest that mTOR and / or JAK inhibitors are attractive and potentially superior alternatives or complements to currently used strategies such as steroids or IL-6 / IL-6R blockade for mitigating T-cell engagement therapy-related CRS.

[0004] Therefore, in a first aspect, the present invention provides a T cell engaging agent for use in the treatment of a disease in an individual, where said treatment is (a) Administration of T cell-engaging agents to individuals, and (b) Administration of Janus kinase (JAK) and / or mammalian target of rapamycin (mTOR) signaling inhibitors to individuals. Includes.

[0005] The present invention further provides the use of T cell engaging agents in the manufacture of pharmaceuticals for the treatment of diseases in individuals, wherein the treatment is (a) Administration of T cell-engaging agents to individuals, and (b) Administration of JAK and / or mTOR signaling inhibitors to individuals Includes.

[0006] The present invention also provides a method for treating a disease in an individual, wherein the method is: (a) Administration of T cell-engaging agents to individuals, and (b) Administration of JAK and / or mTOR signaling inhibitors to individuals Includes.

[0007] According to any of the above embodiments, the administration of a JAK and / or mTOR signaling inhibitor may be for the purpose of preventing or mitigating adverse effects associated with the administration of a T cell engagement agent.

[0008] In another aspect, the present invention provides JAK and / or mTOR signaling inhibitors for use in preventing or mitigating adverse effects associated with the administration of T cell-engineering agents to an individual.

[0009] The present invention further provides the use of JAK and / or mTOR signaling inhibitors in the manufacture of pharmaceuticals for the prevention or mitigation of adverse effects associated with the administration of T cell engaging agents.

[0010] The present invention also provides a method for preventing or mitigating adverse effects associated with the administration of a T cell engagement agent to an individual, the method comprising the administration of a JAK and / or mTOR signaling inhibitor to the individual.

[0011] The T cell engagement agents for use, JAK and / or mTOR signaling inhibitors for use, methods of use, and other methods described above and herein may, alone or in combination, incorporate any of the features described below (unless the context indicates otherwise).

[0012] Unless otherwise defined herein, terms are used herein in the sense that they are commonly used in the art.

[0013] In some embodiments, the inhibitor of JAK and / or mTOR signaling is an mTOR inhibitor. In more specific embodiments, the inhibitor of JAK and / or mTOR signaling is an mTOR kinase inhibitor, in particular a small molecule mTOR kinase inhibitor.

[0014] "mTOR" represents mammalian target of rapamycin (also known as FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)), a serine / threonine-specific protein kinase belonging to the family of phosphatidylinositol 3-kinase (PI3K)-related kinases. It functions as a core component of two different protein complexes, mTOR complex 1 (TORC1) and mTOR complex 2 (TORC2), which regulate different cellular processes. Human mTOR is described in UniProt entry P42345 (version 218). An mTOR inhibitor is a compound that inhibits mTOR. The most well-established inhibitors of mTOR are the so-called rapalogs, which are derivatives of rapamycin. Rapalogs include sirolimus, temsirolimus, everolimus, and ridaforolimus. Second-generation mTOR inhibitors are ATP-competitive mTOR kinase inhibitors designed to compete with ATP at the catalytic site of mTOR.

[0015] Exemplary mTOR inhibitors considered useful in the present invention are provided in Table 1 below.

[0016] JPEG2023547523000001.jpg213170

[0017] <0000~096>In some embodiments, the mTOR inhibitor is a derivative of rapamycin (also known as a rapalog). <000009~ In some embodiments, the mTOR inhibitor is selected from the group consisting of sirolimus, temsirolimus, everolimus, and ridaforolimus, particularly the group consisting of sirolimus, temsirolimus, and everolimus.

[0019] In certain embodiments, the mTOR inhibitor is sirolimus. In further certain embodiments, the mTOR inhibitor is temsirolimus. In further certain embodiments, the mTOR inhibitor is everolimus.

[0020] In some embodiments, the inhibitor of JAK and / or mTOR signaling is a JAK inhibitor. In more specific embodiments, the inhibitor of JAK and / or mTOR signaling is a JAK kinase inhibitor, in particular a small molecule JAK kinase inhibitor.

[0021] "JAK" stands for Janus kinase and refers to a family of intracellular non-receptor tyrosine kinases that transmit cytokine-mediated signals via the JAK / STAT pathway. JAK has two nearly identical phosphate transfer domains, one of which exhibits kinase activity and the other which negatively regulates the activity of the first kinase. The four members of the JAK family are JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase 2). In certain aspects of this specification, JAK refers to JAK1 and / or JAK2 (JAK1 / 2). Human JAK1 and JAK2 are described in UniProt entries P23458 (version 221) and P60674 (version 224), respectively. JAK inhibitors (also called jakinibs) are compounds that inhibit the activity of one or more enzymes of the JAK family (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK / STAT signaling pathway.

[0022] Exemplary JAK inhibitors considered useful in the present invention are provided in Table 2 below.

[0023] JPEG2023547523000002.jpg249170JPEG2023547523000003.jpg237170JPEG2023547523000004.jpg206170

[0024] In some embodiments, the JAK inhibitor is a JAK1 and / or JAK2 (JAK1 / 2) inhibitor. In some embodiments, the JAK inhibitor is selected from the group consisting of ruxolitinib, baricitinib, momerotinib, upadacitinib, filgotinib, abrocitinib, itacitinib, sorucitinib, oclacitinib, fedratinib, gandotinib, restaurtinib, and pacritinib.

[0025] In certain embodiments, the JAK inhibitor is a JAK1 and JAK2 inhibitor. In certain such embodiments, the JAK inhibitor is selected from the group consisting of ruxolitinib, baricitinib, and momerotinib.

[0026] In some embodiments, the JAK inhibitor is a JAK1 inhibitor. In certain such embodiments, the JAK inhibitor is selected from the group consisting of upadacitinib, filgotinib, abrocitinib, itacitinib, sorucitinib, and oclacitinib.

[0027] In some embodiments, the JAK inhibitor is a JAK2 inhibitor. In certain such embodiments, the JAK inhibitor is selected from the group consisting of fedratinib, gandotinib, restaurtinib, and pacritinib. In certain such embodiments, the JAK inhibitor is fedratinib.

[0028] In some embodiments, the JAK inhibitor is a pan-JAK inhibitor. In certain such embodiments, the JAK inhibitor is tofacitinib or peficitinib, particularly tofacitinib.

[0029] In certain embodiments, the JAK inhibitor is ruxolitinib. In even more specific embodiments, the JAK inhibitor is baricitinib. In some embodiments, the JAK inhibitor is tofacitinib. In some embodiments, the JAK inhibitor is fedratinib.

[0030] In certain embodiments, the JAK and / or mTOR signaling inhibitor is selected from the group consisting of sirolimus, temsirolimus, everolimus, and ruxolitinib. In even more specific embodiments, the JAK and / or mTOR signaling inhibitor is selected from the group consisting of sirolimus, temsirolimus, everolimus, ruxolitinib, and baricitinib.

[0031] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of the activity of a T cell engager. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor does not cause inhibition of another activity of a T cell engager. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of a first activity of a T cell engager, but not inhibition of a second activity of a T cell engager. In some of these embodiments, the inhibition is complete inhibition.

[0032] In some embodiments, administration of a JAK and / or mTOR signaling inhibitor causes inhibition of a first activity and inhibition of a second activity of a T cell engager, where the inhibition of the first activity is stronger than the inhibition of the second activity. In some embodiments, administration of a JAK and / or mTOR signaling inhibitor causes inhibition of a first activity and inhibition of a second activity of a T cell engager, where the inhibition of the first activity is complete inhibition and the inhibition of the second activity is partial inhibition.

[0033] The "activity" of a T cell engager refers to the response in an individual's body caused by the T cell engager. Such activity may include cellular responses of T cells, particularly CD4+ T cells and / or CD8+ T cells, such as proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers, as well as effects on target cells, particularly target cells expressing the target cell antigen of the T cell engager (e.g., tumor cells), such as lysis of target cells.

[0034] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of cytokine secretion by immune cells, particularly T cells (induced by T cell engaging agents). In some embodiments, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. The immune cells may include various immune cell types such as T cells, macrophages, monocytes, and NK cells. In some embodiments, the T cells are CD8+ T cells or CD4+ cells. In some embodiments, the inhibition is complete inhibition.

[0035] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor does not cause inhibition of T cell activation (induced by a T cell engaging agent). In some embodiments, the inhibition is complete inhibition. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of T cell activation (induced by a T cell engaging agent), where the inhibition is partial inhibition.

[0036] As used herein, “T cell activation” or “T cell activation” refers to one or more cellular responses of T lymphocytes, particularly CD4+ or CD8+ T cells, selected from proliferation, differentiation, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. Appropriate assays for measuring T cell activation are known in the art and are described herein. In certain embodiments, T cell activation is the expression of activation markers, particularly CD25 and / or CD69 (sometimes measured by flow cytometry). In certain embodiments, T cell activation is determined by measuring the expression of CD25 and / or CD69 on T cells, for example, by flow cytometry.

[0037] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor does not cause inhibition of T cell cytotoxic activity (induced by a T cell engaging agent). In some embodiments, the inhibition is complete. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of T cell cytotoxic activity (induced by a T cell engaging agent), where the inhibition is partial.

[0038] The "cytotoxic activity" of T cells refers to the induction of lysis (i.e., death) of target cells by T lymphocytes, particularly CD4+ or CD8+ T cells. Cytotoxic activity typically involves degranulation of T lymphocytes, associated with the release of cytotoxic effector molecules such as granzyme B and / or perforin from the T lymphocytes.

[0039] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors causes inhibition of cytokine secretion by T cells (induced by T cell-engineer-mediated cytokines), but does not cause inhibition of T cell activation and / or cytotoxic activity (induced by T cell-engineer-mediated cytokines). In some of these embodiments, the inhibition is complete inhibition.

[0040] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of cytokine secretion by T cells (induced by the T cell engaging agent) and inhibition of T cell activation and / or cytotoxic activity (induced by the T cell engaging agent), where the inhibition of cytokine secretion is stronger than the inhibition of activation and / or cytotoxic activity. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of cytokine secretion by T cells (induced by the T cell engaging agent) and inhibition of T cell activation and / or cytotoxic activity (induced by the T cell engaging agent), where the inhibition of cytokine secretion is complete and the inhibition of activation and / or cytotoxic activity is partial.

[0041] Inhibition as used herein can be partial or complete inhibition. Complete inhibition is stronger than partial inhibition. In some embodiments, partial inhibition is 30% or less, 40% or less, 50% or less, 60% or less, or 70% or less. In some embodiments, partial inhibition is 30% or less. In some embodiments, partial inhibition is 40% or less. In some embodiments, partial inhibition is 50% or less. In some embodiments, partial inhibition is 60% or less. In some embodiments, partial inhibition is 70% or less. In some embodiments, complete inhibition is at least 80%, at least 90%, or 100%. In some embodiments, complete inhibition is at least 80%. In some embodiments, complete inhibition is at least 90%. In some embodiments, complete inhibition is 100%. In some embodiments, partial inhibition is 50% or less, and complete inhibition is at least 80%. In some aspects, complete inhibition is clinically meaningful and / or statistically significant, while / or partial inhibition is clinically meaningless and / or not statistically significant.

[0042] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors causes a decrease in the serum levels of one or more cytokines in an individual. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors causes a decrease in the secretion of one or more cytokines by immune cells, particularly T cells, in an individual. In some embodiments, the one or more cytokines are selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. Immune cells may include various immune cell types such as T cells, macrophages, monocytes, and NK cells.

[0043] In some embodiments, the reduction persists even after a predetermined time has passed since the administration of a JAK and / or mTOR signaling inhibitor (to the individual). In some embodiments, the time interval is approximately 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 20 hours, 24 hours, 36 hours, 48 ​​hours, 72 hours, or 96 hours. In some embodiments, the reduction persists even after subsequent administration of a T cell engaging agent. In particular, the reduction persists even after the administration of a JAK and / or mTOR signaling inhibitor has been discontinued / after no further administration of a JAK and / or mTOR signaling inhibitor has been made. The reduction in serum levels / cytokine secretion is particularly compared to serum levels / cytokine secretion in individuals (including the same individuals) that have not been administered a JAK and / or mTOR signaling inhibitor (i.e., in such cases, serum levels / cytokine secretion are reduced compared to serum levels / cytokine secretion without / before administration of a JAK and / or mTOR signaling inhibitor). The aforementioned decrease in serum levels / cytokine secretion is particularly compared to serum levels / cytokine secretion in individuals (including the same individuals) with administration of a T cell engaging agent (particularly the first administration) but without administration of a JAK and / or mTOR signaling inhibitor (i.e., in such cases, serum levels / cytokine secretion are decreased with / after administration of a T cell engaging agent but without / before administration of a JAK and / or mTOR signaling inhibitor). Without the aforementioned decrease, serum levels / cytokine secretion may be particularly elevated / increased in relation to (the administration of) a T cell engaging agent. In some embodiments, the aforementioned decrease is clinically significant and / or statistically significant. In some embodiments, the aforementioned decrease is at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%. In some embodiments, the aforementioned decrease is at least 30%. In some embodiments, the aforementioned decrease is at least 40%. In some embodiments, the aforementioned decrease is at least 50%. In some embodiments, the aforementioned decrease is at least 60%. In some embodiments, the reduction is at least 70%.

[0044] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors causes inhibition of adverse effects associated with the administration of T cell engagers. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors does not cause inhibition of the desired effects associated with the administration of T cell engagers. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors causes inhibition of adverse effects associated with the administration of T cell engagers, but does not cause inhibition of the desired effects associated with the administration of T cell engagers. In some of these embodiments, the inhibition is complete inhibition. In some of these embodiments, the inhibition is clinically significant and / or statistically significant.

[0045] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of adverse effects associated with the administration of a T cell engaging agent and inhibition of a desired effect associated with the administration of a T cell engaging agent, where the inhibition of adverse effects is stronger than the inhibition of the desired effect. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of adverse effects associated with the administration of a T cell engaging agent and inhibition of a desired effect associated with the administration of a T cell engaging agent, where the inhibition of adverse effects is complete inhibition and the inhibition of beneficial effects is partial inhibition. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor causes inhibition of adverse effects associated with the administration of a T cell engaging agent and inhibition of a desired effect associated with the administration of a T cell engaging agent, where the inhibition of adverse effects is clinically significant and / or statistically significant, and the inhibition of beneficial effects is not clinically significant and / or statistically significant.

[0046] "Desired effect" in this specification refers to a beneficial and desired effect obtained from drug therapy in the treatment of an individual using a T cell-engaging agent, namely, therapeutic or preventive effects such as the death of tumor cells, reduction or delay of tumor growth, reduction of tumor volume, reduction or prevention of tumor metastasis, progression-free or increased overall survival, and alleviation of disease symptoms.

[0047] "Adverse effects" may also be referred to as "side effects" or "adverse events" (especially in clinical trials), and in this specification, they refer specifically to harmful and undesirable effects obtained from drug therapy in the treatment of an individual, particularly with respect to T-cell engaging agents.

[0048] According to the present invention, adverse effects relate to the administration of T cell engagers. In some embodiments, adverse effects relate to the first administration of the T cell engager. In some embodiments, adverse effects occur at the time of the first administration of the T cell engager. In some embodiments, adverse effects occur mainly, or only at the time of the first administration of the T cell engager. In some embodiments, adverse effects occur within 12, 24, 36, 48, 72, or 96 hours after the administration of the T cell engager, particularly the first administration. In some embodiments, particularly when only a single dose of the T cell engager is administered (in the course of treatment with the T cell engager), adverse effects occur within 3, 4, 5, 6, 7, 10, 14, or 21 days after the administration of the T cell engager.

[0049] In some embodiments, the adverse effect is cytokine release syndrome (CRS).

[0050] Cytokine release syndrome (CRS) refers to an increase in cytokine levels in the target's blood, such as tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-6 (IL-6), and interleukin-10 (IL-10), during or immediately after administration (e.g., within 1 day) of a therapeutic agent (e.g., a T-cell activator), causing adverse symptoms. CRS is an adverse reaction to a therapeutic agent and is timely related to the administration of the therapeutic agent. Typically, it occurs during or immediately after administration of the therapeutic agent, i.e., within 24 hours after administration (typically infusion), mainly with the first administration. In some cases, for example after administration of CAR-T cells, CRS may also occur only during CAR-T cell proliferation, for example, several days after administration. Usually, the incidence and severity decrease with subsequent administrations. Symptoms range from symptomatic discomfort to fatal events and may include fever, chills, dizziness, hypertension, hypotension, hypoxia, dyspnea, restlessness, sweating, flushing, skin rash, tachycardia, tachypnea, headache, tumor pain, nausea, vomiting, and / or organ failure. CRS may be graded according to the modified cytokine release syndrome grading system established by Lee et al., Blood (2014) 124:188-195 or Lee et al., Biol Blood Marrow Transplant (2019) 25(4):625-638 (both incorporated herein by reference). For a review of CRS, see, for example, Shimabukuro-Vornhagen et al., Journal for ImmunoTherapy of Cancer (2018) 6:56 (both incorporated herein by reference).

[0051] In some embodiments, the adverse effects are fever, hypotension, and / or hypoxia.

[0052] In some embodiments, the adverse effect is an elevated serum level of one or more cytokines. The elevated serum level is compared, in particular, to the serum level of a healthy individual and / or to the serum level of an individual (including the same individual) that has not been administered the T cell activator (i.e., in such cases, the serum level is elevated compared to the serum level when the T cell activator is not administered). In some embodiments, the one or more cytokines are selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β.

[0053] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is performed at the time of the (clinical) manifestation of adverse effects (in the individual). Such administration may be, for example, within approximately 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, or 24 hours after the manifestation of adverse effects (i.e., the occurrence of clinical symptoms of the adverse effect, such as fever). In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is in response to the (clinical) manifestation of adverse effects (in the individual).

[0054] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is before the administration of T cell engagement agents. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is simultaneous with the administration of T cell engagement agents. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is after the administration of T cell engagement agents. When the administration of JAK and / or mTOR signaling inhibitors is before or after the administration of T cell engagement agents, such administration of JAK and / or mTOR signaling inhibitors may be, for example, within approximately 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, or 24 hours before or after the administration of T cell engagement agents. The administration of JAK and / or mTOR signaling inhibitors may be intermittent or continuous. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is orally. In some embodiments, JAK and / or mTOR signaling inhibitors are parenterally, particularly intravenously.

[0055] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a sufficient dose to cause inhibition of the activity of a T cell engagement agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is an insufficient dose to cause inhibition of another activity of the T cell engagement agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a sufficient dose to cause inhibition of the first activity of the T cell engagement agent, but an insufficient dose to cause inhibition of the second activity of the T cell engagement agent. In some of these embodiments, the inhibition is complete inhibition.

[0056] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is in a dose sufficient to cause inhibition of cytokine secretion by immune cells, particularly T cells (induced by T cell engaging agents). In some embodiments, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. The immune cells may include various immune cell types such as T cells, macrophages, monocytes, and NK cells. In some embodiments, the T cells are CD8+ T cells or CD4+ cells. In some embodiments, the inhibition is complete inhibition.

[0057] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is an insufficient dose to cause inhibition of T cell activation (induced by T cell engaging agents). In some embodiments, the inhibition is complete inhibition.

[0058] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is an insufficient dose to cause inhibition of T cell cytotoxic activity (induced by T cell engaging agents). In some embodiments, the inhibition is complete inhibition.

[0059] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is at a dose sufficient to cause inhibition of T cell cytokine secretion (induced by the T cell engaging agent), but at a dose insufficient to cause inhibition of T cell activation and / or cytotoxic activity (induced by the T cell engaging agent). In some of these embodiments, the inhibition is complete inhibition.

[0060] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a dose sufficient to cause a decrease in the serum levels of one or more cytokines in an individual. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a dose sufficient to cause a decrease in the secretion of one or more cytokines by immune cells, particularly T cells, in an individual. In some embodiments, the one or more cytokines are selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. The immune cells may include various immune cell types such as T cells, macrophages, monocytes, and NK cells.

[0061] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a sufficient dose to cause inhibition of adverse effects associated with the administration of a T cell engaging agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is an insufficient dose to cause inhibition of the desired effect associated with the administration of a T cell engaging agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a sufficient dose to cause inhibition of adverse effects associated with the administration of a T cell engaging agent, but an insufficient dose to cause inhibition of the desired effect associated with the administration of a T cell engaging agent. In some of these embodiments, the inhibition is complete inhibition. In some of these embodiments, the inhibition is clinically meaningful and / or statistically significant.

[0062] In some embodiments, administration of a JAK and / or mTOR signaling inhibitor constitutes an effective dose.

[0063] The “effective dose” or “effective amount” of a drug, such as a JAK and / or mTOR signaling inhibitor or a T-cell engagement agent, refers to the amount and duration of administration that is effective in achieving the desired therapeutic or preventive outcome.

[0064] In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is a dose equal to the dose strength available for the JAK and / or mTOR signaling inhibitor. Typically, several dose strengths (i.e., dosage forms such as tablets or capsules containing a specific amount of the active ingredient) are available for a particular JAK and / or mTOR signaling inhibitor. It would be most convenient to administer the JAK and / or mTOR signaling inhibitor at such a (commercially) available dose strength. For example, if the JAK and / or mTOR signaling inhibitor is everolimus, it may be administered in doses of 2.5 mg, 5 mg, 7.5 mg, or 10 mg (administration is preferably orally). For example, if the JAK and / or mTOR signaling inhibitor is sirolimus, it may be administered in doses of 0.5 mg, 1 mg, or 2 mg (administration is preferably orally). For example, if the JAK and / or mTOR signaling inhibitor is ruxolitinib, it may be administered in doses of 5 mg, 10 mg, 15 mg, 20 mg, or 25 mg (administration is preferably orally). If the JAK and / or mTOR signaling inhibitor is temsirolimus, it may be administered in doses of 12.5 mg or 25 mg (administration is preferably intravenous, particularly using a solution of the active ingredient at 25 mg / ml).

[0065] In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is daily. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is once daily. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is once daily at doses as described herein. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is for the duration of the adverse effect (i.e., the administration of JAK and / or mTOR signaling inhibitors is from the onset of the adverse effect until the adverse effect is reduced or eliminated). In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is discontinued after the adverse effect has been prevented or mitigated. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is stopped after the adverse effect has been reduced or eliminated. The reduction is particularly clinically significant and / or statistically significant. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times, particularly in the course of treating an individual with a T cell engagement agent. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times. In some embodiments, the administration of JAK and / or mTOR signaling inhibitors is once daily for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. The administration of JAK and / or mTOR signaling inhibitors is generally associated with the administration of a T cell engagement agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is contingent on a first administration of a T cell engaging agent. The first administration is, in particular, a first administration of the T cell engaging agent in the course of treating an individual with the T cell engaging agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is simultaneous with the first administration of the T cell engaging agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor is prior to the first administration of the T cell engaging agent.In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor occurs after a first administration of a T cell engagement agent. In some embodiments, the administration of a JAK and / or mTOR signaling inhibitor occurs after a first administration of a T cell engagement agent and before a second administration of a T cell engagement agent. If the administration of a JAK and / or mTOR signaling inhibitor occurs before or after the (first) administration of a T cell engagement agent, such administration of a JAK and / or mTOR signaling inhibitor may occur, for example, within approximately 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, 48, or 72 hours before or after the administration of the T cell engagement agent.

[0066] In some embodiments, the administration of T cell engagers is longer than the administration of JAK and / or mTOR signaling inhibitors. In some embodiments, the administration of T cell engagers continues even after the administration of JAK and / or mTOR signaling inhibitors has been discontinued. In some embodiments, the administration of T cell engagers is a single dose or repeated doses. In the course of treating an individual with a T cell engager, the T cell engager may be administered once or several times. For example, treatment of an individual with a T cell engager may include multiple treatment cycles, each containing one or more doses of the T cell engager. In some embodiments, the administration of a T cell engager includes first and second doses.

[0067] For use in the present invention, the T-cell engaging agent will be prepared, administered, and given in a manner consistent with good medical practice. Factors to be considered in this context include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the administration schedule, and other factors known to the healthcare professional.

[0068] In some embodiments, the administration of T cell-engineering agents is at an effective dose. In the case of systemic administration, the effective dose can first be estimated from in vitro assays such as cell culture assays. Subsequently, the effective dose is determined by cell culture assays. 50Doses can be prepared in animal models to achieve a circulating concentration range that includes [specific values]. Such information can be used to more accurately determine a useful dose in humans. Initial doses can also be estimated from in vivo data, such as animal models, using techniques well known in the art. Dosage and dosing intervals can be individually adjusted to provide plasma levels of the T cell activator sufficient to maintain a therapeutic effect. Typical patient doses for administration by injection range from about 0.1 to 50 mg / kg / day, typically from about 0.5 to 1 mg / kg / day. Therapeutably effective plasma levels can be achieved by administering multiple doses daily. Plasma levels can be measured, for example, by HPLC.

[0069] An effective dose of a T-cell engaging agent may be administered for the prevention or treatment of a disease. The appropriate route and dose of the T-cell engaging agent can be determined based on the type of disease to be treated, the type of T-cell engaging agent, the severity and course of the disease, the individual's clinical condition, the individual's clinical history and response to treatment, and the discretion of the attending physician. Depending on whether the administration is short-term or long-term, the medication may be administered by any appropriate route, such as intravenous or subcutaneous injection. Various medication schedules are considered herein, including but not limited to single or multiple doses, bolus administration, and pulse infusion at various time points.

[0070] T cell engagement agents and JAK and / or mTOR signaling inhibitors can be administered via any suitable route, whether the same or different routes. In some embodiments, T cell engagement agents are administered parenterally, particularly intravenously.

[0071] In some embodiments, the administration of a T cell engaging agent constitutes a first administration of the T cell engaging agent to an individual, and in particular, a first administration of the T cell engaging agent in the course of treating the individual with the T cell engaging agent.

[0072] In some embodiments, the administration of a T cell engaging agent induces (i.e., causes or increases) T cell activation. In some embodiments, the administration of a T cell engaging agent induces T cell cytotoxic activity. In some embodiments, the administration of a T cell engaging agent induces cytokine secretion by T cells. In some embodiments, the cytokine is one or more cytokines selected from the group consisting of IL-2, IL-6, IFN-γ, IL-10, TNF-α, and GM-CSF. In some embodiments, the T cells are CD8+ T cells or CD4+ cells.

[0073] In some embodiments, administration of a T cell engaging agent results in the activation of T cells, particularly cytotoxic T cells, especially at the site of cancer (e.g., within a solid tumor). This activation may include T cell proliferation, T cell differentiation, T cell cytokine secretion, T cell release of cytotoxic effector molecules, T cell cytotoxic activity, and T cell expression of activation markers. In some embodiments, administration of a T cell engaging agent results in an increase in the number of T cells, particularly cytotoxic T cells, at the site of cancer (e.g., within a solid tumor).

[0074] "T cell engaging agent" means an immunotherapeutic agent that exerts its effects through the activation of T cells, particularly cytotoxic T cells. Such T cell activity may include cellular responses of T cells, particularly CD4+ T cells and / or CD8+ T cells, such as proliferation, differentiation, expression of activation markers, cytokine secretion, release of cytotoxic effector molecules, and / or cytotoxic activity. T cell engaging agents as intended herein typically include an antigen-binding moiety that enables binding to a target cell antigen on target cells, such as tumor cells. Such T cell engaging agents exert their effects on those target cells, such as lysis of target cells, through the activation of T cells. Exemplary T-cell engagement agents include T-cell bispecific antibodies, chimeric antigen receptor (CAR)-expressing T cells (CAR-T cells), and T-cell receptor (TCR)-based approaches such as ImmTAC ("Immune mobilizing monoclonal T-cell receptors Against Cancer"; a bispecific fusion protein of an engineered TCR and an antibody fragment that can bind to T cells and target cells) or TCR-modified T cells (TCR-T cells) characterized by engineered T-cell receptors that can bind to specific antigenic determinants on target cells.

[0075] In certain embodiments of the present invention, the T cell engaging agent is a T cell bispecific antibody.

[0076] In other embodiments, the T cell engaging agent is a CAR-T cell. In some embodiments, the CAR-T cell is a universal CAR-T cell. A “universal” CAR-T cell means a CAR-T cell that binds to a target cell antigen via an adapter molecule, such as an antibody that binds to the target cell antigen. A universal CAR-T cell expresses a CAR that contains an antigen-binding moiety that binds to the adapter molecule, and the adapter molecule binds to the target cell antigen. Through different adapter molecules (which bind to different target cell antigens), universal CAR-T cells can bind to different target cell antigens without needing to express a different CAR for each target cell antigen. An adapter molecule is a molecule that (i) can bind to a CAR and (ii) can bind to a target cell antigen, such as an antibody that binds to a target cell antigen and contains an Fc region to which a CAR can bind. In some embodiments, the CAR-T cell expresses a CAR that contains an antigen-binding moiety that binds to an antibody Fc region, particularly the IgG Fc region, more specifically the IgG1 Fc region, and particularly the human Fc region. In some embodiments, CAR-T expresses a CAR that includes an antigen-binding moiety that binds to an IgG Fc region, particularly the human IgG1Fc region, containing the amino acid substitution P329G (Kabat EU index numbering). In certain such embodiments, the antigen-binding moiety is scFv. In other embodiments, CAR-T expresses a CAR that includes an antigen-binding moiety that binds to a wild-type Fc region, particularly the wild-type human IgG1Fc region. In certain such embodiments, the antigen-binding moiety is CD16 or its Fc-binding fragment (e.g., the extracellular domain of CD16).

[0077] In some embodiments, the T cell engaging agent is ImmTAC. In some embodiments, the T cell engaging agent is TCR-T cells.

[0078] The following describes T cell bispecific antibodies that may be used in the present invention.

[0079] A "T cell bispecific antibody" refers to an antibody that can bind to both T cells (usually via antigenic determinants expressed on T cells, such as CD3) and target cells (usually via antigenic determinants expressed on target cells, such as CEA, CD19, CD20, and HLA-A2 / MAGE-A4).

[0080] In preferred embodiments of the present invention, a T cell bispecific antibody can simultaneously bind to an antigenic determinant on a T cell (i.e., a first antigen such as CD3) and an antigenic determinant on a target cell (i.e., a second antigen such as CEA, CD19, CD20, or HLA-A2 / MAGE-A4). In some embodiments, the T cell bispecific antibody can crosslink T cells and target cells by simultaneous binding to CD3 and the target cell antigen. In a more preferred embodiment, such simultaneous binding results in the lysis of target cells, particularly tumor cells expressing the target cell antigen (e.g., CEA, CD19, CD20, or HLA-A2 / MAGE-A4). In some embodiments, such simultaneous binding results in T cell activation. In some embodiments, such simultaneous binding results in a T cell cellular response selected from the group of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. In some embodiments, binding of the T cell bispecific antibody to CD3 without simultaneous binding to the target cell antigen does not result in T cell activation. In some embodiments, T cell bispecific antibodies can redirect the cytotoxic activity of T cells to target cells. In preferred embodiments, such redirection is independent of MHC-mediated peptide antigen presentation by target cells and / or T cell specificity.

[0081] The term "bispecificity" means that an antibody can bind to at least two different antigenic determinants. Typically, a bispecific antibody contains two antigen-binding sites, each specific to a different antigenic determinant. In certain embodiments, a bispecific antibody can simultaneously bind to two antigenic determinants, particularly two antigenic determinants expressed on two different cells.

[0082] As used herein, the term “antigenic determinant” is synonymous with “antigen” and “epitope,” and refers to a site on a polypeptide macromolecule to which an antigen-binding moiety binds, forming an antigen-antigen complex (e.g., a contiguous extension of amino acids or a conformation composed of discontinuous amino acids from different regions). Useful antigenic determinants may be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, released in serum, and / or in the extracellular matrix (ECM).

[0083] As used herein, the term “antigen-binding moiety” refers to a polypeptide molecule that binds (including specifically binds) to an antigenic determinant. In some embodiments, an antigen-binding moiety can direct the entity to which it is attached (e.g., a second antigen-binding moiety) to a target site, e.g., a specific type of tumor cell having an antigenic determinant. In further embodiments, an antigen-binding moiety can activate signaling via its target antigen, e.g., a T cell receptor complex antigen. Antigen-binding moieties include antibodies and fragments thereof, as further defined herein. A particular antigen-binding moiety includes the antigen-binding domain of an antibody, comprising an antibody heavy chain variable region and an antibody light chain variable region. In certain embodiments, an antigen-binding moiety may include an antibody constant region, as further defined herein and known in the art. Useful heavy chain constant regions include any of five isotypes: α, δ, ε, γ, or μ. Useful light chain constant regions include any of two isotypes: κ and λ.

[0084] "Specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. As used herein, the terms "bind" or "binding" generally refer to "specific binding." The ability of an antigen-binding portion it binds to a particular antigenic determinant; can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques well known to those skilled in the art, such as surface plasmon resonance (SPR) technology (e.g., analysis on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323 - 329 (2000)), and classical binding assays (Heeley, Endocr Res 28, 217 - 229 (2002)). In some embodiments, the degree of binding of the antigen-binding portion to an irrelevant protein is less than about 10% of the binding of the antigen-binding portion to the antigen, as measured, for example, by SPR. In certain embodiments, an antigen-binding portion that binds to an antigen, or an antibody comprising such antigen-binding portion, has a dissociation constant (K -8 of ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10 -8 M or less, such as 10 -13 M to 10 -9 M, such as 10 -13 M to 10 D M).

[0085] "Affinity" refers to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). As used herein, unless otherwise specified, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antigen-binding portion and an antigen, or a receptor and its ligand). The affinity of molecule X for partner Y is usually expressed by the dissociation constant (K D ), which is the ratio of the dissociation rate constant to the association rate constant (k off and k onIt is the ratio of the rate constants. Therefore, as long as the ratio of the rate constants remains the same, equivalent affinity can include different rate constants. Affinity can be measured by well-established methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).

[0086] Unless otherwise specified, “CD3” refers to any natural CD3 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus macaques), and rodents (e.g., mice and rats). The term encompasses “full-length,” untreated CD3, as well as any form of CD3 resulting from intracellular processing. The term also encompasses naturally occurring variants of CD3, such as splice variants or allele variants. In some embodiments, CD3 refers to human CD3, particularly the epsilon subunit of human CD3 (CD3ε). The amino acid sequence of human CD3ε is shown in UniProt (www.uniprot.org) accession number P07766 (version 144) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeqNP_000724.1. See also Sequence ID No. 1. The amino acid sequence CD3ε for the cynomolgus monkey [Macaca fascicularis] is shown in NCBI GenBank number BAB71849.1. See also SEQ ID NO: 2.

[0087] As used herein, “target cell antigen” refers to an antigenic determinant presented on the surface of target cells, such as cancer cells or cells in a tumor, such as tumor stromal cells (in which case, “tumor cell antigen”). Preferably, the target cell antigen is not CD3 and / or expressed on cells different from CD3. In some embodiments, the target cell antigen is CEA, particularly human CEA. In some embodiments, the target cell antigen is CD20, particularly human CD20. In other embodiments, the target cell antigen is HLA-A2 / MAGE-A4, particularly human HLA-A2 / MAGE-A4. In some embodiments, the target cell antigen is CD19, particularly human CD19.

[0088] As used herein, the terms “first,” “second,” and “third” are used for convenience to distinguish between antigen-binding moieties and other components when more than one of each type of moiety is present. Unless otherwise specified, the use of these terms is not intended to confer any particular order or orientation of bispecific antibodies.

[0089] As used herein, the term “valence” refers to the presence of a specified number of antigen-binding sites in an antibody. Therefore, the term “monovalent binding to antigen” refers to the presence of one (and fewer than one) antigen-specific antigen-binding sites in the antibody.

[0090] The term "antibody" as used herein is used in its broadest sense and encompasses, but is not limited to, a wide range of antibody structures, including monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments insofar as they exhibit the desired antigen-binding activity.

[0091] The terms "full-length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to antibodies having a structure substantially similar to that of a natural antibody.

[0092] An "antibody fragment" is a molecule other than an intact antibody, containing a portion of an intact antibody that binds to an antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and single-domain antibodies. For a review of a specific antibody fragment, see Hudson et al., Nat Med. 9, 129-134 (2003). For a review of scFv fragments, see, for example, Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); also see International Publication No. 93 / 16185; and U.S. Patents 5571894 and 5587458. For a discussion of Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and having increased in vivo half-lives, see U.S. Patent No. 5,869,046. Diabodies are antibody fragments having two antigen-binding sites that may be bivalent or bispecific. See, for example, EP404097; International Publication No. 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments containing all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (see, for example, Domantis, Inc., Waltham, MA; U.S. Patent No. 6,248,516). Antibody fragments can be produced by a variety of techniques, but are not limited to those described herein, including proteolysis of intact antibodies and production by recombinant host cells (e.g., Escherichia coli or phages).

[0093] The term "variable region" or "variable domain" refers to the domains in the heavy or light chain of an antibody that are involved in the binding of the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, and each domain contains four conserved framework regions (FRs) and three hypervariable regions (HVRs). For example, Kindt et al., Kuby Immunology, 6 th See ed., WH Freeman and Co., page 91 (2007). A single VH or VL domain is sufficient to confer antigen-binding specificity. As used herein with respect to variable region sequences, “Kabat numbering” refers to the numbering system defined by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0094] As used herein, the amino acid positions of all constant regions and domains of the heavy and light chains are numbered according to the Kabat numbering system, referred herein as “Kabat numbering” or “Kabat numbering,” as described herein in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Specifically, the Kabat numbering system (see Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), pp. 647–660) is used for the light chain constant domains CL of kappa and lambda isotypes, and the Kabat EU index numbering system (see pp. 661–723), which is further clarified in this specification by being referred to as "Kabat EU index numbering," is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3).

[0095] As used herein, the terms “hypervariable region” or “HVR” refer to each region of the antibody variable domain whose sequence is hypervariable and which determines antigen-binding specificity, such as “complementarity-determining region” (“CDR”). Typically, an antibody contains six HVRs; three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL (LCDR1, LCDR2, LCDR3). Illustrative CDRs as used herein are: (a) Hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); and (c) This includes antigen contact occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)).

[0096] Unless otherwise specified, the CDR is determined in accordance with Kabat et al. above. Those skilled in the art will understand that the name of the CDR may also be determined in accordance with Chothia, McCallum, or other scientifically recognized nomenclature above.

[0097] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The variable domain FR generally consists of four FR domains: FR1, FR2, FR3, and FR4. Therefore, the HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0098] The "class" of an antibody or immunoglobulin refers to the type of constant domain or constant region present in the heavy chain of the antibody or immunoglobulin. There are five main classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IGA1, and IgA2. The heavy chain constant domains corresponding to the various classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0099] A "Fab molecule" refers to a protein consisting of the VH and CH1 domains of the immunoglobulin heavy chain ("Fab heavy chain") and the VL and CL domains of the light chain ("Fab light chain").

[0100] A "crossover" Fab molecule (also called a "Crossfab") refers to a Fab molecule in which the variable or constant domains of the Fab heavy chain and light chain are exchanged (i.e., substituted for each other). In other words, a crossover Fab molecule includes a peptide chain composed of a light chain variable domain VL and a heavy chain constant domain 1 CH1 (VL-CH1, N-terminal to C-terminal direction), and a peptide chain composed of a heavy chain variable domain VH and a light chain constant domain CL (VH-CL, N-terminal to C-terminal direction). For clarity, in a crossover Fab molecule in which the variable domains of the Fab light chain and Fab heavy chain are exchanged, the peptide chain containing the heavy chain constant domain 1 CH1 is referred to herein as the "heavy chain" of the (crossover) Fab molecule. Conversely, in a crossover Fab molecule in which the constant domains of the Fab light chain and Fab heavy chain are exchanged, the peptide chain containing the heavy chain variable domain VH is referred to herein as the "heavy chain" of the (crossover) Fab molecule.

[0101] In contrast, a "conventional" Fab molecule refers to a Fab molecule in its natural format, that is, a Fab molecule comprising a heavy chain consisting of a variable domain and a constant domain (VH-CH1, from the N-terminus to the C-terminus) and a light chain consisting of a variable domain and a constant region (VL-CL, from the N-terminus to the C-terminus).

[0102] The term "immunoglobulin molecule" refers to a protein that has the structure of a naturally occurring antibody. For example, IgG class immunoglobulins are heterotetrameric glycoproteins with approximately 150,000 daltons, composed of two disulfide-linked light chains and two heavy chains. From the N-terminus to the C-terminus, each heavy chain has a variable domain (VH), also called a variable heavy chain domain or heavy chain variable region, followed by three constant domains (CH1, CH2, CH3), also called heavy chain constant regions. Similarly, from the N-terminus to the C-terminus, each light chain has a variable domain (VL), also called a variable light chain domain or light chain variable region, followed by a constant light chain (CL) domain, also called a light chain constant region. The heavy chain of an immunoglobulin can be assigned to one of five types called α(IgA), δ(IgD), ε(IgE), γ(IgG), or μ(IgM), some of which can be further classified into subtypes, such as γ1(IgG1), γ2(IgG2), γ3(IgG3), γ4(IgG4), α1(IgA1), and α2(IgA2). The light chain of an immunoglobulin can be assigned to one of two types called kappa (κ) or lambda (λ), based on the amino acid sequence of its constant domain. An immunoglobulin essentially consists of two Fab molecules and an Fc domain linked via the hinge region of the immunoglobulin.

[0103] The terms “Fc domain” or “Fc region” are used herein to define the C-terminal region of an immunoglobulin heavy chain, including at least a portion of the constant region. This term includes both the native sequence Fc region and variant Fc regions. While the boundaries of the Fc region of an IgG heavy chain may vary slightly, the Fc region of a human IgG heavy chain is typically defined as extending from Cys226 or Pro230 to the carboxyl terminus. However, antibodies produced by host cells may undergo post-translational cleavage of one or more amino acids, particularly one or two, from the C-terminus of the heavy chain. Therefore, antibodies produced by host cells through the expression of certain nucleic acid molecules encoding a full-length heavy chain may contain the full-length heavy chain or cleaved variants of the full-length heavy chain. This is true when the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbered according to the Kabat EU index). Therefore, the C-terminal lysine (Lys447) or C-terminal glycine (Gly446) and lysine (K447) in the Fc domain may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues within the Fc domain or constant domain follows the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 (see also above). As used herein, a “subunit” of the Fc domain refers to one of the two polypeptides that form the dimeric Fc domain, i.e., the polypeptide containing the C-terminal constant domain of an immunoglobulin heavy chain capable of stable self-assembly. For example, the subunit of the IgG Fc domain includes the IgG CH2 and IgG CH3 constant domains.

[0104] "Modifications that promote the association of the first and second subunits of the Fc domain" are manipulations of the peptide backbone or post-translational modifications of the Fc domain subunits that reduce or prevent homodimer formation by association between a polypeptide containing an Fc domain subunit and a polypeptide identical to that subunit. As used herein, association-promoting modifications particularly include separate modifications performed on each of two Fc domain subunits that are desirable to associate (i.e., the first and second subunits of the Fc domain), and these modifications are complementary to each other in order to promote the association of the two Fc domain subunits. For example, association-promoting modifications alter the structure or charge of one or both of these Fc domain subunits so that their association is sterically or electrostatically desirable, respectively. Thus, (hetero)dimerization occurs between a polypeptide containing a first Fc domain subunit and a polypeptide containing a second Fc domain subunit, which may not be identical in the sense that the further components fused to each subunit (e.g., antigen-binding moieties) are not the same. In some embodiments, association-promoting modifications include amino acid mutations, specifically amino acid substitutions, within the Fc domain. In certain embodiments, the modification that facilitates association includes distinct amino acid mutations, specifically amino acid substitutions, in each of the two subunits of the Fc domain.

[0105] The term "effector function" refers to the biological activity resulting from the Fc region of an antibody, which varies depending on the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cell-mediated cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); antibody-dependent cell-mediated phagocytosis (ADCP); cytokine secretion; immune complex-mediated antigen uptake by antigen-presenting cells; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.

[0106] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues of the reference polypeptide, after the sequences have been aligned and gaps introduced if necessary to obtain the maximum percentage sequence identity, and no conservative substitutions are considered part of the sequence identity. Alignment for determining percentage amino acid sequence identity can be achieved using various methods within the art, such as publicly available computer software like BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software, or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm necessary to achieve the maximum alignment with respect to the full length of the sequences being compared. However, for the purposes of this text, the % amino acid sequence identity value is generated using the ggsearch program of the FASTA package version 36.3.8c, or subsequently using the BLOSUM50 comparison matrix. The FASTA program package was created by WRPearson and DJLipman (1988), “Improved Tools for Biological Sequence Analysis”, PNAS 85:2444-2448; WRPearson (1996) “Effective protein sequence comparison” Meth.Enzymol.266:227-258; and Pearson et al. (1997) Genomics 46:24-36, and is publicly available at http: / / fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml.Alternatively, a public server accessible at http: / / fasta.bioch.virginia.edu / fasta_www2 / index.cgi can be used to compare sequences using the ggsearch(global protein:protein) program with default options (BLOSUM50;open:-10;ext:-2;Ktup=2) to ensure that a global, rather than local, alignment is performed. Percent amino acid identity is provided in the output alignment header.

[0107] An "activated Fc receptor" is an Fc receptor that, following the binding of an antibody's Fc domain, triggers a signaling event that stimulates receptor-hosting cells to perform effector functions. Human activated Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).

[0108] "Reduced binding," for example, a decrease in binding to the Fc receptor, refers to a decrease in affinity for each interaction, as measured, for example, by SPR. To clarify, this term also includes reducing affinity to zero (or below the detection limit of the analytical method), i.e., complete disappearance of the interaction. Conversely, "increased binding" refers to an increase in binding affinity for each interaction.

[0109] "Fused" means that the constituent components (e.g., the Fab molecule and the Fc domain subunit) are linked by peptide bonds, either directly or via one or more peptide linkers.

[0110] In certain embodiments, T cell bispecific antibodies bind to CD3 and target cell antigens. Therefore, in some embodiments, T cell bispecific antibodies include an antigen-binding moiety that binds to CD3 and an antigen-binding moiety that binds to target cell antigens.

[0111] In some embodiments, the first and / or second antigen-binding moiety is a Fab molecule. In some embodiments, the first antigen-binding moiety is a crossover Fab molecule in which either the variable or constant regions of the Fab light chain and Fab heavy chain are exchanged. In such embodiments, the second antigen-binding moiety is preferably a conventional Fab molecule.

[0112] In some embodiments of a T cell bispecific antibody, where both the first and second antigen-binding moieties are Fab molecules, and in one of the antigen-binding moieties (particularly the first antigen-binding moiety), the variable domains VL and VH of the Fab light chain and Fab heavy chain are substituted for each other, i) In the constant domain CL of the first antigen-binding region, the amino acid at position 124 is substituted with a positively charged amino acid (numbered by Kabat), and in the constant domain CH1 of the first antigen-binding region, the amino acid at position 147 or the amino acid at position 213 is substituted with a negatively charged amino acid (numbered by Kabat EU index); or ii) In the constant domain CL of the second antigen-binding region, the amino acid at position 124 is substituted with a positively charged amino acid (numbered by Kabat), and in the constant domain CH1 of the second antigen-binding region, the amino acid at position 147 or position 213 is substituted with a negatively charged amino acid (numbered by the Kabat EU index).

[0113] The T cell bispecific antibody does not contain either of the modifications mentioned in i) and ii). The constant domains CL and CH1 of the antigen-binding moiety with VH / VL exchange are not substituted for each other (i.e., remain unexchanged).

[0114] In more specific cases, i) In the constant domain CL of the first antigen-binding moiety, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CH1 of the first antigen-binding moiety, the amino acid at position 147 or the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering); or ii) In the constant domain CL of the second antigen-binding moiety, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CH1 of the second antigen-binding moiety, the amino acid at position 147 or position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0115] In some embodiments, the amino acid at position 124 in the constant domain CL of the second antigen-binding moiety is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), and the amino acid at position 147 or 213 in the constant domain CH1 of the second antigen-binding moiety is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0116] In a further embodiment, in the constant domain CL of the second antigen-binding moiety, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), and in the constant domain CH1 of the second antigen-binding moiety, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0117] In a preferred embodiment, in the constant domain CL of the second antigen-binding moiety, the amino acid at position 124 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), in the constant domain CH1 of the second antigen-binding moiety, the amino acid at position 147 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0118] In some embodiments, in the constant domain CL of the second antigen-binding moiety, the amino acid at position 124 is substituted with lysine (K) (Kabat numbering), the amino acid at position 123 is substituted with lysine (K) (Kabat numbering), and in the constant domain CH1 of the second antigen-binding moiety, the amino acid at position 147 is substituted with glutamic acid (E) (Kabat EU index numbering), and the amino acid at position 213 is substituted with glutamic acid (E) (Kabat EU index numbering).

[0119] In some embodiments, in the constant domain CL of the second antigen-binding moiety, the amino acid at position 124 is substituted with lysine (K) (Kabat numbering), the amino acid at position 123 is substituted with arginine (R) (Kabat numbering), and in the constant domain CH1 of the second antigen-binding moiety, the amino acid at position 147 is substituted with glutamic acid (E) (Kabat EU index numbering), and the amino acid at position 213 is substituted with glutamic acid (E) (Kabat EU index numbering).

[0120] In certain embodiments, when the amino acid substitution according to the above embodiment is performed in the constant domain CL and constant domain CH1 of the second antigen-binding moiety, the constant domain CL of the second antigen-binding moiety is a kappa isotype.

[0121] In some embodiments, the first antigen-binding portion and the second antigen-binding portion are optionally fused to each other via a peptide linker.

[0122] In some embodiments, the first and second antigen-binding portions are each Fab molecules, wherein (i) the second antigen-binding portion is fused to the N-terminus of the Fab heavy chain of the first antigen-binding portion at the C-terminus of the Fab heavy chain, or (ii) the first antigen-binding portion is fused to the N-terminus of the Fab heavy chain of the second antigen-binding portion at the C-terminus of the Fab heavy chain.

[0123] In some embodiments, T cell bispecific antibodies provide monovalent binding to CD3.

[0124] In certain embodiments, a T cell bispecific antibody comprises a single antigen-binding moiety that binds to CD3 and two antigen-binding moieties that bind to a target cell antigen. Therefore, in some embodiments, a T cell bispecific antibody comprises a third antigen-binding moiety that binds to the target antigen, particularly a Fab molecule, more specifically a conventional Fab molecule. The third antigen-binding moiety may incorporate, alone or in combination, all the features described herein with respect to the second antigen-binding moiety (e.g., CDR sequence, variable region sequence, and / or amino acid substitutions in the constant region). In some embodiments, the third antigen-binding moiety is identical to the first antigen-binding moiety (e.g., a conventional Fab molecule containing the same amino acid sequence).

[0125] In certain embodiments, the T cell bispecific antibody further comprises an Fc domain consisting of a first subunit and a second subunit. In some embodiments, the Fc domain is an IgG Fc domain. In certain embodiments, the Fc domain is an IgG1 Fc domain. In other embodiments, the Fc domain is an IgG4 Fc domain. In even more specific embodiments, the Fc domain is an IgG4 Fc domain containing an amino acid substitution at position S228 (Kabat EU index numbering), in particular the amino acid substitution S228P. This amino acid substitution reduces Fab arm exchange in vivo of the IgG4 antibody (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). In even more specific embodiments, the Fc domain is a human Fc domain. In a particularly preferred embodiment, the Fc domain is a human IgG1 Fc domain. An exemplary sequence of the human IgG1 Fc region is given in Sequence ID No. 3.

[0126] In some embodiments in which the first antigen-binding portion, the second antigen-binding portion, and, if present, the third antigen-binding portion are each Fab molecules, (a) (i) the second antigen-binding portion is fused to the N-terminus of the Fab heavy chain of the first antigen-binding portion at the C-terminus of the Fab heavy chain, and the first antigen-binding portion is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, or (ii) the first antigen-binding portion is fused to the N-terminus of the Fab heavy chain of the second antigen-binding portion at the C-terminus of the Fab heavy chain, and the second antigen-binding portion is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain; (b) if present, the third antigen-binding portion is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain.

[0127] In some embodiments, a T cell bispecific antibody essentially comprises first, second, and third antigen-binding moieties (particularly Fab molecules), an Fc domain composed of a first subunit and a second subunit, and optionally one or more peptide linkers.

[0128] The components of a T cell bispecific antibody can be fused to each other directly, or preferably via one or more suitable peptide linkers. When the fusion of the Fab molecule is to the N-terminus of a subunit of the Fc domain, it is typically via the immunoglobulin hinge region.

[0129] The antigen-binding moiety may be directly attached to or fused to the Fc domain via a peptide linker containing one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art and are described herein. Suitable non-immunogenic peptide linkers include, for example, (G4S) n (SG4) n (G4S) n G4 (SG4) n Or (G4S) n A G5 peptide linker is included. "n" is usually an integer from 1 to 10, typically from 2 to 4. In some embodiments, the peptide linker has a length of at least 5 amino acids, in some embodiments a length of 5 to 100, and in further embodiments a length of 10 to 50 amino acids. In some embodiments, the peptide linker is (GxS) n or (GxS) n G m Herein, G=glycine, S=serine, and (x=3, n=3, 4, 5 or 6, and m=0, 1, 2 or 3) or (x=4, n=1, 2, 3, 4 or 5, and m=0, 1, 2, 3, 4 or 5), in some embodiments x=4 and n=2 or 3, in further embodiments x=4 and n=2, and in yet further embodiments x=4, n=1 and m=5. In some embodiments, the peptide linker is (G4S)2. In other embodiments, the peptide linker is G4SG5. Furthermore, the linker may include (part of) an immunoglobulin hinge region. In particular, when the Fab molecule is fused to the N-terminus of an Fc domain subunit, it may be fused via the immunoglobulin hinge region or part thereof, with or without an additional peptide linker.

[0130] In certain embodiments, the Fc domain includes modifications that facilitate the association of the first and second subunits of the Fc domain. The site where the most extensive protein-protein interaction between the two subunits of the human IgG Fc domain occurs is the CH3 domain. Therefore, in some embodiments, the modifications are located in the CH3 domain of the Fc domain.

[0131] In certain embodiments, the modification that facilitates the association of the first and second subunits of the Fc domain is a so-called “knob-into-hole” modification, comprising a “knob” modification on one of the two subunits of the Fc domain and a “hole” modification on the other of the two subunits of the Fc domain. The “knob-into-hole” technique is described, for example, in U.S. Patent No. 5,731,168; No. 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996); and Carter, J Immunol Meth 248, 7-15 (2001). Generally, this method introduces a ridge ("knob") on the contact surface of the first polypeptide and a corresponding cavity ("hole") on the contact surface of the second polypeptide, so that the ridge can be positioned within the cavity, thereby promoting heterodimer formation and hindering homodimer formation. The ridges are constructed by replacing smaller amino acid side chains (e.g., tyrosine or tryptophan) from the contact surface of the first polypeptide. Complementary cavities of the same or similar size as the ridges are created at the contact surface of the second polypeptide by replacing larger amino acid side chains (e.g., alanine or threonine) with smaller amino acid side chains.

[0132] Accordingly, in some embodiments, an amino acid residue in the CH3 domain of the first subunit of the Fc domain is replaced with an amino acid residue having a larger side-chain volume, thereby creating a ridge within the CH3 domain of the first subunit that can be placed in the cavity within the CH3 domain of the second subunit, and an amino acid residue in the CH3 domain of the second subunit of the Fc domain is replaced with an amino acid residue having a smaller side-chain volume, thereby creating a cavity within the CH3 domain of the second subunit that can accommodate the ridge within the CH3 domain of the first subunit. Preferably, the amino acid residue having a larger side-chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W). Preferably, the amino acid residue having a smaller side-chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V). The ridges and cavities can be created by modifying the nucleic acid encoding the polypeptide, for example, by site-directed mutagenesis or by peptide synthesis.

[0133] In certain such embodiments, in the first subunit of the Fc domain, the threonine residue at position 366 is replaced with a tryptophan residue (T366W), in the second subunit of the Fc domain, the tyrosine residue at position 407 is replaced with a valine residue (Y407V), optionally the threonine residue at position 366 is replaced with a serine residue (T366S), and the leucine residue at position 368 is replaced with an alanine residue (L368A) (numbered according to the Kabat EU index). In a further embodiment, in the first subunit of the Fc domain, the serine residue at position 354 is further replaced with a cysteine ​​residue (S354C), or the glutamic acid residue at position 356 is further replaced with a cysteine ​​residue (E356C) (particularly the serine residue at position 354 is replaced with a cysteine ​​residue), and in the second subunit of the Fc domain, the tyrosine residue at position 349 is further replaced with a cysteine ​​residue (Y349C) (numbered according to the Kabat EU index). In a preferred embodiment, the first subunit of the Fc domain contains amino acid substitutions S354C and T366W, and the second subunit of the Fc domain contains amino acid substitutions Y349C, T366S, L368A and Y407V (numbered according to the Kabat EU index).

[0134] In some embodiments, the Fc domain includes one or more amino acid substitutions that reduce binding to and / or effector function of the Fc receptor.

[0135] In certain embodiments, the Fc receptor is an Fcγ receptor. In some embodiments, the Fc receptor is a human Fc receptor. In some embodiments, the Fc receptor is an activated Fc receptor. In certain embodiments, the Fc receptor is an activated human Fcγ receptor, more specifically human FcγRIIIa, FcγRI, or FcγRIIa, most specifically human FcγRIIIa. In some embodiments, the effector function is one or more selected from complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), and cytokine secretion. In certain embodiments, the effector function is ADCC.

[0136] Typically, the same one or more amino acid substitutions are present in each of the two subunits of the Fc domain. In some embodiments, one or more amino acid substitutions reduce the binding affinity of the Fc domain to the Fc receptor. In some embodiments, one or more amino acid substitutions reduce the binding affinity of the Fc domain to the Fc receptor by at least half, at least one-fifth, or at least one-tenth.

[0137] In some embodiments, the Fc domain contains amino acid substitutions at positions selected from the group E233, L234, L235, N297, P331, and P329 (numbered according to the Kabat EU index). In more specific embodiments, the Fc domain contains amino acid substitutions at positions selected from the group L234, L235, and P329 (numbered according to the Kabat EU index). In some embodiments, the Fc domain contains amino acid substitutions L234A and L235A (numbered according to the Kabat EU index). In some such embodiments, the Fc domain is an IgG1Fc domain, particularly a human IgG1Fc domain. In some embodiments, the Fc domain contains an amino acid substitution at position P329. In even more specific embodiments, the amino acid substitution is P329A or P329G, particularly P329G (numbered according to the Kabat EU index). In some embodiments, the Fc domain includes further amino acid substitutions at position P329 and at positions selected from E233, L234, L235, N297, and P331 (numbered according to the Kabat EU index). In more specific embodiments, the further amino acid substitutions are E233P, L234A, L235A, L235E, N297A, N297D, or P331S. In certain embodiments, the Fc domain includes amino acid substitutions at positions P329, L234, and L235 (numbered according to the Kabat EU index). In even more specific embodiments, the Fc domain includes amino acid mutations L234A, L235A, and P329G ("P329G LALA", "PGLALA", or "LALAPG"). Specifically, in a preferred embodiment, each subunit of the Fc domain includes amino acid substitutions L234A, L235A, and P329G (KabatEU index numbering), namely, in each of the first and second subunits of the Fc domain, the leucine residue at position 234 is replaced with an alanine residue (L234A), the leucine residue at position 235 is replaced with an alanine residue (L235A), and the proline residue at position 329 is replaced with a glycine residue (P329G) (KabatEU index numbering).In some such embodiments, the Fc domain is the IgG1Fc domain, particularly the human IgG1Fc domain.

[0138] In some embodiments, the target cell antigen of a T cell bispecific antibody is carcinoembryonic antigen (CEA).

[0139] "Carcinoembryonic antigen" or "CEA" (also known as carcinoembryonic antigen-associated cell adhesion molecule 5 (CEACAM5)) refers to any naturally occurring CEA from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. The term encompasses "full-length," untreated CEA, as well as any form of CEA resulting from intracellular processing. The term also encompasses naturally occurring variants of CEA, such as splice variants or allele variants. In some embodiments, CEA is human CEA. The amino acid sequence of human CEA is shown at UniProt (www.uniprot.org) accession number P06731, or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004354.2. In some embodiments, CEA is cell membrane-bound CEA. In some embodiments, CEA is CEA expressed on the surface of cells, for example, on the surface of cancer cells.

[0140] T cell bispecific antibodies useful for the present invention that bind to CEA are described, for example, in PCT International Publication No. 2014 / 131712 (which is incorporated herein by reference in its entirety).

[0141] In some embodiments, the T cell bispecific antibody comprises a first antigen-binding moiety that binds to CD3 and a second antigen-binding moiety that binds to CEA.

[0142] In some embodiments, the first antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9.

[0143] In some embodiments, the second antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17.

[0144] In some embodiments, T cell bispecific antibodies are (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9; and (ii) A second antigen-binding region that binds to CEA, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17. Includes.

[0145] In some embodiments, the first antigen-binding portion includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 10 and the light chain variable region sequence of SEQ ID NO: 11.

[0146] In some embodiments, the second antigen-binding moiety includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the second antigen-binding moiety includes the heavy chain variable region sequence of SEQ ID NO: 18 and the light chain variable region sequence of SEQ ID NO: 19.

[0147] In some embodiments, the T cell bispecific antibody includes a third antigen-binding moiety that binds to CEA and / or an Fc domain comprising a first subunit and a second subunit, as described herein.

[0148] In a preferred embodiment, the T cell bispecific antibody is (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9, wherein the first antigen-binding moiety is a crossover Fab molecule in which either the variable region or the constant region of the Fab light chain and Fab heavy chain, particularly the constant region, is exchanged. (ii) A second antigen-binding portion and a third antigen-binding portion that bind to CEA, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 12, HCDR2 of SEQ ID NO: 13, and HCDR3 of SEQ ID NO: 14, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 15, LCDR2 of SEQ ID NO: 16, and LCDR3 of SEQ ID NO: 17, wherein each of the second antigen-binding portion and the third antigen-binding portion is a Fab molecule, in particular a conventional Fab molecule, (iii) An Fc domain comprising a first subunit and a second subunit, The second antigen-binding moiety is fused to the N-terminus of the first antigen-binding moiety at the C-terminus of the Fab heavy chain, the first antigen-binding moiety is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the third antigen-binding moiety is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the Fc domain and Includes.

[0149] In some embodiments, the first antigen-binding portion of a T cell bispecific antibody (binding to CEA and CD3) includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 10 and the light chain variable region sequence of SEQ ID NO: 11.

[0150] In some embodiments, the second and (if present) third antigen-binding moieties of a T cell bispecific antibody (binding to CEA and CD3) include a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 19. In some embodiments, the second and (if present) third antigen-binding moieties include the heavy chain variable region of SEQ ID NO: 18 and the light chain variable region of SEQ ID NO: 19.

[0151] An Fc domain according to the above embodiment can incorporate all of the features described above in relation to an Fc domain, either individually or in combination.

[0152] In some embodiments, the Fc domain of a T cell bispecific antibody (binding to CEA and CD3) includes modifications that promote association between a first subunit and a second subunit of the Fc domain, and / or the Fc domain includes one or more amino acid substitutions that reduce binding to and / or effector function of the Fc receptor.

[0153] In some embodiments, the antigen-binding portion and the Fc region are fused to each other by a peptide linker, particularly by peptide linkers such as SEQ ID NOs: 21 and 23.

[0154] In some embodiments, the T cell bispecific antibody (binding to CEA and CD3) comprises a polypeptide (particularly two polypeptides) containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 20; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 21; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 22; and a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 23. In some embodiments, the T cell bispecific antibody (which binds to CEA and CD3) comprises a polypeptide (particularly two polypeptides) containing the sequence of SEQ ID NO: 20, a polypeptide containing the sequence of SEQ ID NO: 21, a polypeptide containing the sequence of SEQ ID NO: 22, and a polypeptide containing the sequence of SEQ ID NO: 23.

[0155] In a preferred embodiment, the T-cell bispecific antibody is cibisatamab (WHO Drug Information (International Generic Name for Medicinal Substances), Recommended INN: List 80, 2018, Vol. 32, No. 3, p. 438).

[0156] In some embodiments, the target cell antigen of the T cell bispecific antibody is CD20.

[0157] "CD20," also known as "B lymphocyte antigen B1," refers, unless otherwise specified, to any natural CD20 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length," untreated CD20, as well as any form of CD20 resulting from intracellular processing. The term also encompasses naturally occurring variants of CD20, such as splice variants or allele variants. In some embodiments, CD20 is human CD20. Human CD20 is described in UniProt (www.uniprot.org) accession number P11836 (entry version 200), and the amino acid sequence of human CD20 is also shown in Sequence ID No. 36.

[0158] T-cell bispecific antibodies useful for the present invention that bind to CD20 are described, for example, in International Publication No. 2016 / 020309 (which is incorporated herein by reference in its entirety).

[0159] In some embodiments, the T cell bispecific antibody comprises a first antigen-binding moiety that binds to CD3 and a second antigen-binding moiety that binds to CD20.

[0160] In some embodiments, the first antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9.

[0161] In some embodiments, the second antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 24, HCDR2 of SEQ ID NO: 25, and HCDR3 of SEQ ID NO: 26, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 27, LCDR2 of SEQ ID NO: 28, and LCDR3 of SEQ ID NO: 29.

[0162] In some embodiments, T cell bispecific antibodies are (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9; and (ii) A second antigen-binding region that binds to CD20, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 24, HCDR2 of SEQ ID NO: 25, and HCDR3 of SEQ ID NO: 26; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 27, LCDR2 of SEQ ID NO: 28, and LCDR3 of SEQ ID NO: 29. Includes.

[0163] In some embodiments, the first antigen-binding portion includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 10 and the light chain variable region sequence of SEQ ID NO: 11.

[0164] In some embodiments, the second antigen-binding portion includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 30, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the second antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 30 and the light chain variable region sequence of SEQ ID NO: 31.

[0165] In some embodiments, the T cell bispecific antibody includes a third antigen-binding moiety that binds to CD20 and / or an Fc domain comprising a first subunit and a second subunit, as described herein.

[0166] In a preferred embodiment, the T cell bispecific antibody is (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 4, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 6, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9, wherein the first antigen-binding moiety is a crossover Fab molecule in which either the variable region or the constant region of the Fab light chain and Fab heavy chain, particularly the variable region, is exchanged. (ii) A second antigen-binding portion and a third antigen-binding portion that bind to CD20, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 24, HCDR2 of SEQ ID NO: 25, and HCDR3 of SEQ ID NO: 26, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 27, LCDR2 of SEQ ID NO: 28, and LCDR3 of SEQ ID NO: 29, wherein each of the second antigen-binding portion and the third antigen-binding portion is a Fab molecule, in particular a conventional Fab molecule, (iii) An Fc domain comprising a first subunit and a second subunit, The second antigen-binding moiety is fused to the N-terminus of the first antigen-binding moiety at the C-terminus of the Fab heavy chain, the first antigen-binding moiety is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the third antigen-binding moiety is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the Fc domain and Includes.

[0167] In some embodiments, the first antigen-binding portion of the T cell bispecific antibody (binding to CD20 and CD3) is a crossover Fab molecule in which the variable regions of the Fab light chain and Fab heavy chain are exchanged, and the second and (if present) third antigen-binding portions of the T cell bispecific antibody are conventional Fab molecules in which the amino acid at position 124 of the constant domain CL is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 147 of the constant domain CH1 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0168] In particular, in the above embodiment, in the constant domain CL of the second and third Fab molecules of (ii), the amino acid at position 124 may be substituted with lysine (K) (numbered by Kabat), and the amino acid at position 123 may be substituted with lysine (K) or arginine (R), especially arginine (R) (numbered by Kabat), and in the constant domain CH1 of the second and third Fab molecules of (ii), the amino acid at position 147 may be substituted with glutamic acid (E) (numbered by Kabat EU index), and the amino acid at position 213 may be substituted with glutamic acid (E) (numbered by Kabat EU index).

[0169] In some embodiments, the first antigen-binding portion of a T cell bispecific antibody (binding to CD20 and CD3) includes a heavy chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 10 and the light chain variable region sequence of SEQ ID NO: 11.

[0170] In some embodiments, the second and (if present) third antigen-binding moieties of a T cell bispecific antibody (binding to CD20 and CD3) include a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 30, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 31. In some embodiments, the second and (if present) third antigen-binding moieties include the heavy chain variable region of SEQ ID NO: 30 and the light chain variable region of SEQ ID NO: 31.

[0171] An Fc domain according to the above embodiment can incorporate all of the features described above in relation to an Fc domain, either individually or in combination.

[0172] In some embodiments, the Fc domain of a T cell bispecific antibody (binding to CD20 and CD3) includes modifications that promote association between a first subunit and a second subunit of the Fc domain, and / or the Fc domain includes one or more amino acid substitutions that reduce binding to and / or effector function of the Fc receptor.

[0173] In some embodiments, the antigen-binding portion and the Fc region are fused to each other by a peptide linker, particularly peptide linkers such as SEQ ID NO: 33 and SEQ ID NO: 35.

[0174] In some embodiments, the T cell bispecific antibody (binding to CD20 and CD3) comprises a polypeptide (particularly two polypeptides) containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 32; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 33; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 34; and a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 35. In some embodiments, the T cell bispecific antibody (which binds to CD20 and CD3) comprises a polypeptide (particularly two polypeptides) containing the sequence of SEQ ID NO: 32, a polypeptide containing the sequence of SEQ ID NO: 33, a polypeptide containing the sequence of SEQ ID NO: 34, and a polypeptide containing the sequence of SEQ ID NO: 35.

[0175] In a preferred embodiment, the T-cell bispecific antibody is grofitamab (WHO Drug Information (International Generic Name for Medicinal Substances), Recommended INN: List 83, 2020, Vol. 34, No. 1, p. 39).

[0176] In some embodiments, the target cell antigen of the T cell bispecific antibody is HLA-A2 / MAGE-A4.

[0177] "MAGE-A4" represents "melanoma-associated antigen 4," a member of the MAGE family of cancer-testicular antigens (CTAs). The MAGE-A family of proteins contains 12 highly homologous genes clustered at Xq26-28 and characterized by the presence of a conserved domain (MAGE homology domain, MHD). Human MAGE-A4 is described in UniProt (www.uniprot.org) accession number P43358 (entry version 163), and the amino acid sequence of human MAGE-A4 is shown in Sequence ID No. 57 herein. As used herein, "MAGE-A4" refers to any natural MAGE-A4 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats), unless otherwise specified. This term encompasses "full-length," untreated MAGE-A4, as well as any form of MAGE-A4 resulting from intracellular processing. The term also includes naturally occurring variants of MAGE-A4, such as splice variants or allele variants. In one embodiment, MAGE-A4 refers to human MAGE-A4, particularly the protein of SEQ ID NO: 57.

[0178] "MAGE-A4 p230-239 "or "p230-239 peptide" refers to a MAGE-A4-derived peptide having the amino acid sequence GVYDGREHTV (SEQ ID NO: 58; positions 230-239 of the MAGE-A4 protein in SEQ ID NO: 57).

[0179] "HLA-A2", "HLA-A * 02", "HLA-A02", or "HLA-A * 2 (used interchangeably) refers to the human leukocyte antigen serotype in the HLA-A serotype group. The HLA-A2 protein (encoded by each HLA gene) constitutes the α chain of each class I MHC (major histocompatibility complex) protein, further containing a β2 microglobulin subunit. A specific HLA-A2 protein is HLA-A201 (HLA-A0201, HLA-A02.01, or HLA-A* (Also known as 02:01). In certain embodiments, the HLA-A2 protein described herein is HLA-A201. An exemplary sequence of human HLA-A2 is given in SEQ ID NO: 59.

[0180] "HLA-A2 / MAGE-A4" is a complex of an HLA-A2 molecule and a MAGE-A4-derived peptide (also referred to herein as "MAGE-A4 peptide"), specifically the p230-239 peptide ("HLA-A2 / MAGE-A4"). p230-239 This refers to ").

[0181] A T cell bispecific antibody useful for the present invention that binds to HLA-A2 / MAGE-A4 is described, for example, in PCT application number PCT / EP2020 / 086614 (which is incorporated herein by reference in its entirety).

[0182] In some embodiments, the T cell bispecific antibody has a first antigen-binding moiety that binds to CD3, and HLA-A2 / MAGE-A4, particularly HLA-A2 / MAGE-A4 p230-239 It contains a second antigen-binding moiety that binds to [the target molecule].

[0183] In some embodiments, the first antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 37, HCDR2 of SEQ ID NO: 38, and HCDR3 of SEQ ID NO: 39, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 40, LCDR2 of SEQ ID NO: 41, and LCDR3 of SEQ ID NO: 42.

[0184] In some embodiments, the second antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 45, HCDR2 of SEQ ID NO: 46, and HCDR3 of SEQ ID NO: 47, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 48, LCDR2 of SEQ ID NO: 49, and LCDR3 of SEQ ID NO: 50.

[0185] In some embodiments, T cell bispecific antibodies are (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 37, HCDR2 of SEQ ID NO: 38, and HCDR3 of SEQ ID NO: 39; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 40, LCDR2 of SEQ ID NO: 41, and LCDR3 of SEQ ID NO: 42; and (ii) A second antigen-binding region that binds to HLA-A2 / MAGE-A4, comprising a heavy chain variable region including heavy chain CDR (HCDR)1 of SEQ ID NO: 45, HCDR2 of SEQ ID NO: 46, and HCDR3 of SEQ ID NO: 47; and a light chain variable region including light chain CDR (LCDR)1 of SEQ ID NO: 48, LCDR2 of SEQ ID NO: 49, and LCDR3 of SEQ ID NO: 50. Includes.

[0186] In some embodiments, the first antigen-binding portion includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 43 and the light chain variable region sequence of SEQ ID NO: 44.

[0187] In some embodiments, the second antigen-binding moiety includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the second antigen-binding moiety includes the heavy chain variable region sequence of SEQ ID NO: 51 and the light chain variable region sequence of SEQ ID NO: 52.

[0188] In some embodiments, the T cell bispecific antibody includes, as described herein, a third antigen-binding moiety that binds to HLA-A2 / MAGE-A4 and / or an Fc domain comprising a first subunit and a second subunit.

[0189] In a preferred embodiment, the T cell bispecific antibody is (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 37, HCDR2 of SEQ ID NO: 38, and HCDR3 of SEQ ID NO: 39, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 40, LCDR2 of SEQ ID NO: 41, and LCDR3 of SEQ ID NO: 42, wherein the first antigen-binding moiety is a crossover Fab molecule in which either the variable region or the constant region of the Fab light chain and Fab heavy chain, particularly the variable region, is exchanged. (ii) A second antigen-binding portion and a third antigen-binding portion that bind to HLA-A2 / MAGE-A4, comprising a heavy chain variable region including heavy chain CDR (HCDR)1 of SEQ ID NO: 45, HCDR2 of SEQ ID NO: 46, and HCDR3 of SEQ ID NO: 47, and a light chain variable region including light chain CDR (LCDR)1 of SEQ ID NO: 48, LCDR2 of SEQ ID NO: 49, and LCDR3 of SEQ ID NO: 50, wherein each of the second antigen-binding portion and the third antigen-binding portion is a Fab molecule, in particular a conventional Fab molecule, (iii) An Fc domain comprising a first subunit and a second subunit, The second antigen-binding moiety is fused to the N-terminus of the first antigen-binding moiety at the C-terminus of the Fab heavy chain, the first antigen-binding moiety is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the third antigen-binding moiety is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the Fc domain and Includes.

[0190] In some embodiments, the first antigen-binding portion of the T cell bispecific antibody (binding to HLA-A2 / MAGE-A4 and CD3) is a crossover Fab molecule in which the variable regions of the Fab light chain and Fab heavy chain are exchanged, and the second and (if present) third antigen-binding portions of the T cell bispecific antibody are conventional Fab molecules in which the amino acid at position 124 of the constant domain CL is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 147 of the constant domain CH1 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0191] In particular, in the above embodiment, in the constant domain CL of the second and third Fab molecules of (ii), the amino acid at position 124 may be substituted with lysine (K) (numbered by Kabat), and the amino acid at position 123 may be substituted with lysine (K) or arginine (R), especially arginine (R) (numbered by Kabat), and in the constant domain CH1 of the second and third Fab molecules of (ii), the amino acid at position 147 may be substituted with glutamic acid (E) (numbered by Kabat EU index), and the amino acid at position 213 may be substituted with glutamic acid (E) (numbered by Kabat EU index).

[0192] In some embodiments, the first antigen-binding moiety of a T cell bispecific antibody (binding to HLA-A2 / MAGE-A4 and CD3) includes a heavy chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 43, and a light chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the first antigen-binding moiety includes the heavy chain variable region sequence of SEQ ID NO: 43 and the light chain variable region sequence of SEQ ID NO: 44.

[0193] In some embodiments, the second and (if present) third antigen-binding moieties of a T cell bispecific antibody (binding to HLA-A2 / MAGE-A4 and CD3) include a heavy chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 51, and a light chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the second and (if present) third antigen-binding moieties include the heavy chain variable region of SEQ ID NO: 51 and the light chain variable region of SEQ ID NO: 52.

[0194] An Fc domain according to the above embodiment can incorporate all of the features described above in relation to an Fc domain, either individually or in combination.

[0195] In some embodiments, the Fc domain of a T cell bispecific antibody (binding to HLA-A2 / MAGE-A4 and CD3) includes modifications that promote association between a first subunit and a second subunit of the Fc domain, and / or the Fc domain includes one or more amino acid substitutions that reduce binding to and / or effector function of the Fc receptor.

[0196] In some embodiments, the antigen-binding portion and the Fc region are fused to each other by a peptide linker, particularly peptide linkers such as SEQ ID NOs. 54 and SEQ ID NOs. 56.

[0197] In some embodiments, the T cell bispecific antibody (binding to HLA-A2 / MAGE-A4 and CD3) comprises a polypeptide (particularly two polypeptides) containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 53; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 54; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 55; and a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 56. In some embodiments, the T cell bispecific antibody (which binds to HLA-A2 / MAGE-A4 and CD3) comprises a polypeptide (particularly two polypeptides) containing the sequence of SEQ ID NO: 53, a polypeptide containing the sequence of SEQ ID NO: 54, a polypeptide containing the sequence of SEQ ID NO: 55, and a polypeptide containing the sequence of SEQ ID NO: 56.

[0198] In some embodiments, the target cell antigen of a T cell bispecific antibody is CD19.

[0199] "CD19" represents differentiated cluster 19 (also known as B lymphocyte antigen CD19 or B lymphocyte surface antigen B4) and, unless otherwise specified, refers to any natural CD19 from any vertebrate source, including mammals such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys), and rodents (e.g., mice and rats). The term encompasses "full-length," untreated CD19, as well as any form of CD19 resulting from intracellular processing. The term also encompasses naturally occurring variants of CD19, such as splice variants or allele variants. In some embodiments, CD19 is human CD19. See Human Proteins UniProt (www.uniprot.org) accession number P15391 (version 211) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_001761.3. An example sequence of human CD19 is given in sequence number 60.

[0200] Useful T-cell bispecific antibodies for the present invention that bind to CD19 are described, for example, in EP applications Nos. 20181056.1 and 20180968.8 (which are incorporated herein by reference in their entirety).

[0201] In some embodiments, the T cell bispecific antibody comprises a first antigen-binding moiety that binds to CD3 and a second antigen-binding moiety that binds to CD19.

[0202] In some embodiments, the first antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 61, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 62, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9.

[0203] In another embodiment, the first antigen-binding region includes a heavy chain variable region containing heavy chain CDR (HCDR)1 of SEQ ID NO: 64, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 65, and a light chain variable region containing light chain CDR (LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9.

[0204] In some embodiments, the second antigen-binding region includes a heavy chain variable region comprising heavy chain CDR (HCDR)1 of SEQ ID NO: 67, HCDR2 of SEQ ID NO: 68, and HCDR3 of SEQ ID NO: 69, and a light chain variable region comprising light chain CDR (LCDR)1 of SEQ ID NO: 70, LCDR2 of SEQ ID NO: 71, and LCDR3 of SEQ ID NO: 72.

[0205] In some embodiments, T cell bispecific antibodies are (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 61, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 62, or a heavy chain variable region including HCDR1 of SEQ ID NO: 64, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 65; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9; and (ii) A second antigen-binding region that binds to CD19, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 67, HCDR2 of SEQ ID NO: 68, and HCDR3 of SEQ ID NO: 69; and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 70, LCDR2 of SEQ ID NO: 71, and LCDR3 of SEQ ID NO: 72. Includes.

[0206] In some embodiments, the first antigen-binding portion includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63, or a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 66, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 35. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 63 or the heavy chain variable region sequence of SEQ ID NO: 66, and the light chain variable region sequence of SEQ ID NO: 11.

[0207] In some embodiments, the second antigen-binding moiety includes a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the second antigen-binding moiety includes the heavy chain variable region sequence of SEQ ID NO: 73 and the light chain variable region sequence of SEQ ID NO: 74.

[0208] In some embodiments, the T cell bispecific antibody includes a third antigen-binding moiety that binds to CD19 and / or an Fc domain comprising a first subunit and a second subunit, as described herein.

[0209] In a preferred embodiment, the T cell bispecific antibody is (i) A first antigen-binding moiety that binds to CD3, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 61, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 62, or a heavy chain variable region including HCDR1 of SEQ ID NO: 64, HCDR2 of SEQ ID NO: 5, and HCDR3 of SEQ ID NO: 65, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 7, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9, wherein the variable region or constant region of the Fab light chain and Fab heavy chain, particularly the variable region, is exchanged, and is a crossover Fab molecule, (ii) A second antigen-binding portion and a third antigen-binding portion that bind to CD19, comprising a heavy chain variable region including heavy chain CDR(HCDR)1 of SEQ ID NO: 67, HCDR2 of SEQ ID NO: 68, and HCDR3 of SEQ ID NO: 69, and a light chain variable region including light chain CDR(LCDR)1 of SEQ ID NO: 70, LCDR2 of SEQ ID NO: 71, and LCDR3 of SEQ ID NO: 72, wherein each of the second antigen-binding portion and the third antigen-binding portion is a Fab molecule, in particular a conventional Fab molecule, (iii) An Fc domain comprising a first subunit and a second subunit, The second antigen-binding moiety is fused to the N-terminus of the first antigen-binding moiety at the C-terminus of the Fab heavy chain, the first antigen-binding moiety is fused to the N-terminus of the first subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the third antigen-binding moiety is fused to the N-terminus of the second subunit of the Fc domain at the C-terminus of the Fab heavy chain, and the Fc domain and Includes.

[0210] In some embodiments, the first antigen-binding portion of the T cell bispecific antibody (binding to CD19 and CD3) is a crossover Fab molecule in which the variable regions of the Fab light chain and Fab heavy chain are exchanged, and the second and (if present) third antigen-binding portions of the T cell bispecific antibody are conventional Fab molecules in which the amino acid at position 124 of the constant domain CL is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 123 is independently substituted with lysine (K), arginine (R), or histidine (H) (Kabat numbering), the amino acid at position 147 of the constant domain CH1 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering), and the amino acid at position 213 is independently substituted with glutamic acid (E) or aspartic acid (D) (Kabat EU index numbering).

[0211] In particular, in the above embodiment, in the constant domain CL of the second and third Fab molecules of (ii), the amino acid at position 124 may be substituted with lysine (K) (numbered by Kabat), and the amino acid at position 123 may be substituted with lysine (K) or arginine (R), especially arginine (R) (numbered by Kabat), and in the constant domain CH1 of the second and third Fab molecules of (ii), the amino acid at position 147 may be substituted with glutamic acid (E) (numbered by Kabat EU index), and the amino acid at position 213 may be substituted with glutamic acid (E) (numbered by Kabat EU index).

[0212] In some embodiments, the first antigen-binding portion of a T cell bispecific antibody (binding to CD19 and CD3) includes a heavy chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 63, or a heavy chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 66, and a light chain variable region sequence that is at least approximately 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the first antigen-binding portion includes the heavy chain variable region sequence of SEQ ID NO: 63 or the heavy chain variable region sequence of SEQ ID NO: 66, and the light chain variable region sequence of SEQ ID NO: 11.

[0213] In some embodiments, the second and (if present) third antigen-binding moieties of a T cell bispecific antibody (binding to CD19 and CD3) include a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 73, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 74. In some embodiments, the second and (if present) third antigen-binding moieties include the heavy chain variable region of SEQ ID NO: 73 and the light chain variable region of SEQ ID NO: 74.

[0214] An Fc domain according to the above embodiment can incorporate all of the features described above in relation to an Fc domain, either individually or in combination.

[0215] In some embodiments, the Fc domain of a T cell bispecific antibody (binding to CD19 and CD3) includes modifications that promote association between a first subunit and a second subunit of the Fc domain, and / or the Fc domain includes one or more amino acid substitutions that reduce binding to and / or effector function of the Fc receptor.

[0216] In some embodiments, the antigen-binding portion and the Fc region are fused to each other by a peptide linker, particularly a peptide linker such as SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 77.

[0217] In some embodiments, a T cell bispecific antibody (binding to CD19 and CD3) comprises a polypeptide (particularly two polypeptides) containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 78; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 75; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 77; and a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 79. In some embodiments, the T cell bispecific antibody (which binds to CD19 and CD3) comprises a polypeptide (particularly two polypeptides) containing the sequence of SEQ ID NO: 78, a polypeptide containing the sequence of SEQ ID NO: 75, a polypeptide containing the sequence of SEQ ID NO: 77, and a polypeptide containing the sequence of SEQ ID NO: 79.

[0218] In other embodiments, a T cell bispecific antibody (binding to CD19 and CD3) comprises a polypeptide (particularly two polypeptides) containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 78; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 76; a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 77; and a polypeptide containing a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 80. In some embodiments, the T cell bispecific antibody (which binds to CD19 and CD3) comprises a polypeptide (particularly two polypeptides) containing the sequence of SEQ ID NO: 78, a polypeptide containing the sequence of SEQ ID NO: 76, a polypeptide containing the sequence of SEQ ID NO: 77, and a polypeptide containing the sequence of SEQ ID NO: 80.

[0219] In some aspects, the disease (treated by T-cell engaging agents) is cancer.

[0220] As used herein, “treatment” (and its grammatical variations such as “treat” or “treating”) refers to a clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, which may be carried out for preventive purposes or in the course of clinicopathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of the disease, alleviating symptoms, reducing the direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and achieving remission or improving the prognosis.

[0221] The term "cancer" refers to a physiological condition in mammals typically characterized by uncontrolled cell proliferation. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias. Non-exclusive examples of cancer include blood cancers such as leukemia, bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, bile duct cancer, thyroid cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, stomach cancer, prostate cancer, skin cancer, squamous cell carcinoma, sarcomas, bone cancer, and kidney cancer. Other cell proliferation disorders include, but are not limited to, tumors located in the abdomen, bones, breasts, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal glands, parathyroid glands, pituitary gland, testes, ovaries, thymus, thyroid gland), eyes, head and neck, (central and peripheral) nervous system, lymphatic system, pelvis, skin, soft tissue, spleen, chest, and genitourinary system. Precancerous conditions or precancerous lesions and cancer metastases are also included.

[0222] In some embodiments, cancer is a cancer that expresses the target cell antigen of a T cell engaging agent (e.g., a T cell bispecific antibody).

[0223] In some embodiments, the cancer is a carcinoembryonic antigen (CEA) expressing cancer (particularly in embodiments where the target cell antigen of a T cell engager, e.g., a T cell bispecific antibody, is CEA). "CEA-positive cancer" or "CEA-expressing cancer" means cancer characterized by the expression or overexpression of CEA in cancer cells. CEA expression can be determined, for example, by immunohistochemistry (IHC) or flow cytometry assay. In some embodiments, the cancer expresses CEA. In some embodiments, the cancer expresses CEA in at least 20%, preferably at least 50%, or at least 80% of tumor cells, as determined by immunohistochemistry (IHC) using an antibody specific for CEA.

[0224] In some embodiments, cancer is colon cancer, lung cancer, ovarian cancer, stomach cancer, bladder cancer, pancreatic cancer, endometrial cancer, breast cancer, kidney cancer, esophageal cancer, prostate cancer, or other cancers described herein.

[0225] In certain embodiments, cancer is a cancer selected from the group consisting of colorectal cancer, lung cancer, pancreatic cancer, breast cancer, and gastric cancer. In preferred embodiments, cancer is colorectal cancer (CRC). In some embodiments, colorectal cancer is metastatic colorectal cancer (mCRC). In some embodiments, colorectal cancer is microsatellite-stable (MSS) colorectal cancer. In some embodiments, colorectal cancer is microsatellite-stable metastatic colorectal cancer (MSS mCRC).

[0226] In some embodiments, the cancer is a CD20-expressing cancer (particularly in embodiments where the target cell antigen of a T-cell engaging agent, e.g., a T-cell bispecific antibody, is CD20). "CD20-positive cancer" or "CD20-expressing cancer" means cancer characterized by the expression or overexpression of CD20 in cancer cells. CD20 expression can be determined, for example, by quantitative real-time PCR (measuring CD20 mRNA levels), flow cytometry, immunohistochemistry (IHC), or Western blot assay. In some embodiments, the cancer expresses CD20. In some embodiments, the cancer expresses CD20 in at least 20%, preferably at least 50%, or at least 80% of tumor cells, as determined by immunohistochemistry (IHC) using an antibody specific to CD20.

[0227] In some embodiments, the cancer is B-cell carcinoma, particularly CD20-positive B-cell carcinoma. In some embodiments, the cancer is selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), multiple myeloma (MM), or Hodgkin lymphoma (HL). In certain embodiments, the cancer is selected from the group consisting of non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). In more specific embodiments, the cancer is NHL, particularly recurrent / refractory (r / r) NHL. In some embodiments, the cancer is DLBCL. In some embodiments, the cancer is FL. In some embodiments, the cancer is MCL. In some embodiments, the cancer is MZL.

[0228] In some embodiments, cancer is a MAGE-A4 expressing cancer (particularly in embodiments where the target cell antigen of a T cell engaging agent, such as a T cell bispecific antibody, is HLA-A2 / MAGE-A4). "MAGE-A4 positive cancer" or "MAGE-A4 expressing cancer" means cancer characterized by the expression or overexpression of MAGE-A4 in cancer cells.

[0229] In some embodiments, cancer is a cancer selected from the group consisting of lung cancer, head and neck cancer, bladder cancer, esophageal cancer, skin cancer, gastric cancer, and ovarian cancer.

[0230] In some embodiments, the cancer is a CD19-expressing cancer (particularly in embodiments where the target cell antigen of a T-cell engaging agent, e.g., a T-cell bispecific antibody, is CD19). "CD19-positive cancer" or "CD19-expressing cancer" means cancer characterized by the expression or overexpression of CD19 in cancer cells. CD19 expression can be determined, for example, by quantitative real-time PCR (measuring CD19 mRNA levels), flow cytometry, immunohistochemistry (IHC), or Western blot assay. In some embodiments, the cancer expresses CD19. In some embodiments, the cancer expresses CD19 in at least 20%, preferably at least 50%, or at least 80% of tumor cells, as determined by immunohistochemistry (IHC) using a CD19-specific antibody.

[0231] In some embodiments, the cancer is B-cell carcinoma, particularly CD19-positive B-cell carcinoma. In some embodiments, the cancer is B-cell lymphoma or B-cell leukemia. In some embodiments, the cancer is non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), or chronic lymphocytic leukemia (CLL).

[0232] In some embodiments, cancer is treatable by T-cell engaging agents. In some embodiments, T-cell engaging agents are indicated for the treatment of cancer.

[0233] In some aspects, cancer is a solid tumor cancer. A “solid tumor cancer” means a malignant tumor that forms a distinct tumor mass (including tumor metastases) at a specific location within a patient’s body, such as a sarcoma or carcinoma, in contrast to blood cancers such as leukemia, which generally do not form solid tumors. Non-exclusive examples of solid tumor cancers include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, stomach cancer, prostate cancer, skin cancer, squamous cell carcinoma, bone cancer, liver cancer, and kidney cancer. Other solid tumors and cancers intended in the context of the present invention include, but are not limited to, tumors located in the abdomen, bones, breasts, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal glands, parathyroid glands, pituitary gland, testes, ovaries, thymus, thyroid gland), eyes, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, muscle, spleen, thoracic region, and genitourinary system. Precancerous conditions or precancerous lesions and cancer metastases are also included.

[0234] In some embodiments, where the target cell antigen of a T cell engagement agent, such as a T cell bispecific antibody, is CD19, the disease (to be treated by the T cell bispecific antibody) is an autoimmune disease. In certain embodiments, the autoimmune disease is lupus, particularly systemic lupus erythematosus (SLE) or lupus nephritis (LN).

[0235] In this specification, “individual” or “subject” means a mammal. Mammals include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, horses), primates (e.g., humans, and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is human. In some embodiments, the individual has a disease, in particular a disease that is treatable or should be treated by a T-cell activator. In some embodiments, the individual has cancer, in particular cancer that is treatable or should be treated by a T-cell activator. In particular, the individual in this specification is any single human subject that is eligible for treatment and has experienced or has experienced one or more signs, symptoms, or other indicators of cancer. In some embodiments, the individual has cancer or has been diagnosed with cancer, in particular any of the cancers described above. In some embodiments, the individual has locally advanced or metastatic cancer or has been diagnosed with locally advanced or metastatic cancer. The individual may or may not have been previously treated with a T-cell engaging agent (e.g., a T-cell bispecific antibody) or another drug. In certain embodiments, the patient has not been previously treated with a T-cell engaging agent (e.g., a T-cell bispecific antibody). The patient may have been treated with a therapy comprising one or more drugs other than a T-cell engaging agent (e.g., other than a T-cell bispecific antibody) before T-cell engaging agent therapy is initiated.

[0236] In some embodiments, the individual has elevated serum levels of one or more cytokines. In some embodiments, the elevated serum levels are associated with the administration of a T-cell engaging agent to the individual. The elevated serum levels are compared, in particular, to the serum levels of a healthy individual and / or to the serum levels of an individual (including the same individual) that has not been administered a T-cell engaging agent (i.e., in such cases, the serum levels are elevated compared to the serum levels when no T-cell engaging agent is administered). In some embodiments, the one or more cytokines are selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β.

[0237] A cytokine according to any aspect of the present invention may be one or more cytokines selected from the group consisting of interleukin (IL)-6, interferon (IFN)-γ, IL-10, tumor necrosis factor (TNF)-α, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein (MCP)-1, IL-1β, IL-8, IL-4, and IL-2. In some aspects, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. In some aspects, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, and GM-CSF. In some aspects, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, and TNF-α. In some embodiments, the cytokine is one or more cytokines selected from the group consisting of IL-6, IFN-γ, and IL-10. In some embodiments, the cytokine is IL-6. In some embodiments, the cytokine is IFN-γ. In some embodiments, the cytokine is IL-10. In some embodiments, the cytokine is TNF-α. In some embodiments, the cytokine is GM-CSF. In some embodiments, the cytokine is MCP-1. In some embodiments, the cytokine is IL-1β. In some embodiments, the cytokine is IL-8. In some embodiments, the cytokine is IL-4. In some embodiments, the cytokine is IL-2.

[0238] Preferably, the T cells according to any aspect of the present invention are cytotoxic T cells. In some aspects, the T cells are CD4 + or CD8 + These are T cells. In some embodiments, T cells are CD8 + In some aspects of T cells, T cells are CD4 + T cells

[0239] In some embodiments, treatment with or administration of T cell engaging agents may result in a response in an individual. In some embodiments, the response may be a complete response. In some embodiments, the response may be a response that persists after discontinuation of treatment. In some embodiments, the response may be a complete response that persists after discontinuation of treatment. In some embodiments, the response may be a partial response. In some embodiments, the response may be a partial response that persists after discontinuation of treatment. In some embodiments, treatment or administration with T cell engaging agents and JAK and / or mTOR signaling inhibitors may improve the response compared to treatment or administration with T cell engaging agents alone (i.e., without JAK and / or mTOR signaling inhibitors). In some embodiments, treatment or administration with T cell engaging agents and JAK and / or mTOR signaling inhibitors may increase the response rate in a patient population compared to the corresponding patient population treated with T cell engaging agents alone (i.e., without JAK and / or mTOR signaling inhibitors).

[0240] T-cell engaging agents may be used alone or in combination with other agents in treatment. For example, a T-cell engaging agent may be co-administered with at least one additional therapeutic agent. In certain embodiments, the additional therapeutic agent may be an anticancer agent, such as a chemotherapeutic agent, an inhibitor of tumor cell proliferation, or an activator of tumor cell apoptosis.

[0241] JAK and / or mTOR signaling inhibitors can be used alone or in combination with one or more other agents to prevent or mitigate adverse effects associated with the administration of T cell engagement agents, particularly CRS. JAK and / or mTOR signaling inhibitors can be used, for example, with IL-6R antagonists (e.g., tocilizumab), steroids (e.g., corticosteroids such as methylprednisolone or dexamethasone), or TNF-α antagonists (e.g., etanercept).

[0242] TIFF2023547523000005.tif250170TIFF2023547523000006.tif248170TIFF2023547523 000007.tif250170TIFF2023547523000008.tif243170TIFF2023547523000009.tif24917 0TIFF2023547523000010.tif248170TIFF2023547523000011.tif248170TIFF2023547523 000012.tif249170TIFF2023547523000013.tif243170TIFF2023547523000014.tif41170 [Brief explanation of the drawing]

[0243] [Figure 1] Assay setup: MKN45 NucLightRed (NLR) target cells were co-cultured with 10nM CEA-TCB, mTOR or JAK inhibitors, and peripheral blood mononuclear cells (PBMCs). E:T=50,000, PBMC:5,000 target cells. Target cell death dynamics were tracked using the Incucyte® system (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400ms). [Figure 2] Real-time cell death of MKN45 NLR cells by 10 nM CEA-TCB in the presence of sirolimus (A), everolimus (B), and temisirolimus (C) at concentrations ranging from 0 nM to 1000 nM in the assay described in Figure 1. % death was measured by normalizing the total red area with the value at t=0 and the value of target cells + PBMC + mTOR inhibitor control wells at each time point. Mean technical replicate values ​​from one representative donor + SEM. [Figure 3]The effects of escalating concentrations of sirolimus (A), everolimus (B), and temsirolimus (C) on TCB-mediated target cell death measured at 72 hours in the assay described in Figure 1. Percentage death at 72 hours was measured by normalizing the total red area with the value at t=0 and the value of target cells + PBMCs + mTOR inhibitor control wells at each time point. Mean + / - SD of technical replication from one representative donor. [Figure 4] Effects of increasing concentrations of everolimus (A), sirolimus (B), and temsirolimus (C) on PBMC viability measured at 72 hours in the assay described in Figure 1. Technical replication was pooled, and PBMC viability was measured by flow cytometry using Live / Dead™ Fixable Aqua Dead Cell Stain. One representative donor. [Figure 5] The effect of everolimus escalating concentrations on CD69 expression on CD4+(A) and CD8+(C) T cells, and CD25 expression on CD4+(B) and CD8+(D) T cells, 72 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD69 and CD25 expression on CD4+ and CD8+ T cells was measured by flow cytometry at 72 hours. One representative donor. [Figure 6] The effect of increasing sirolimus concentrations on CD69 expression on CD4+(A) and CD8+(C) T cells, and CD25 expression on CD4+(B) and CD8+(D) T cells, 72 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD69 and CD25 expression on CD4+ and CD8+ T cells was measured by flow cytometry at 72 hours. One representative donor. [Figure 7]The effect of increasing temsirolimus concentrations on CD69 expression on CD4+(A) and CD8+(C) T cells, and CD25 expression on CD4+(B) and CD8+(D) T cells, 72 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD69 and CD25 expression on CD4+ and CD8+ T cells was measured by flow cytometry at 72 hours. One representative donor. [Figure 8] The effects of increasing concentrations of sirolimus, everolimus, and temsirolimus on cytokine release (IFN-γ(A), IL-2(B), TNF-α(C), IL-6(D), GM-CSF(E), IL-8(F), IL-4(G), IL-10(H), MCP-1(I)) measured 72 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. Supernatants from technical replication were pooled and cytokines were analyzed using Luminex. One representative donor. [Figure 9] (A) Real-time cell death of MKN45 NLR cells by 10 nM CEA-TCB in the presence of ruxolitinib concentrations ranging from 0 nM to 100 nM in the assay shown in Figure 1. (B) Effect of escalating ruxolitinib concentrations on target cell death measured at 69 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. % death was measured by normalizing the total red area with the value at t=0 and the value of target cells + PBMC + ruxolitinib control well at each time point. Mean technical replication of one representative donor (A). Mean ±SD of n=3 donors. [Figure 10] Effect of escalating ruxolitinib concentration on PBMC survival at 69 hours in the assay shown in Figure 1. Technical replication was pooled, and PBMC survival was measured by flow cytometry using Live / Dead™ Fixable Aqua Dead Cell Stain. One representative donor. [Figure 11]The effect of escalating ruxolitinib concentrations on CD25 expression on CD8+(A) T cells and CD4+(B) T cells, and CD69 expression on CD8+(C) T cells and CD4+(D) T cells, 69 hours after treatment with 10 nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD25 and CD69 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry at 69 hours. Mean ± / - SD for n=3 donors. [Figure 12] Effect of escalating ruxolitinib concentration on cytokine release (IFN-γ(A), IL-2(B), TNF-α(C), IL-6(D), GM-CSF(E), IL-8(F), IL-4(G), IL-10(H), MCP-1(I)) induced by 10 nM CEA-TCB at 69 hours in the assay shown in Figure 1. Supernatants from technical replication were pooled at 69 hours, and cytokines were analyzed by Luminex. Mean ±SD for n=3 donors. [Figure 13] In vitro cell death assay setup. Cell Trace™ Violet (CTV)-labeled WSU DLCL2 tumor cells were co-cultured with PBMCs [E:T=200'000:20'000] and CD20-TCB in the presence of escalating doses of ruxolitinib, temsirolimus, sirolimus, and everolimus from 0 nM to 1000 nM. [Figure 14] Efficacy of increasing concentrations of ruxolitinib (A), temsirolimus (B), sirolimus (C), and everolimus (D) on CTV WSU ​​DLCL2 tumor cell death in the assay shown in Figure 13 for 1nM CD20-TCB. At 24 hours, tumor cells and PBMCs from technical replication were pooled and stained with LIVE / DEAD™ near-infrared dead cell dye to allow exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. Mean + / - SEM from n=3 donors. [Figure 15]Effect of escalating ruxolitinib concentration on CD25 expression on CD4+(B) T cells and CD8+(D) T cells, and on CD69 expression on CD4+(A) T cells and CD8+(C) T cells in the assay for 1nM CD20-TCB shown in Figure 13. At 24 hours, tumor cells and PBMCs from technical replication were pooled, and CD69 and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry. Mean + / - SEM from n=3 donors. [Figure 16] Effect of escalating temsirolimus concentration on CD25 expression on CD4+(B) T cells and CD8+(D) T cells, and on CD69 expression on CD4+(A) T cells and CD8+(C) T cells in the assay for 1nM CD20-TCB shown in Figure 13. At 24 hours, tumor cells and PBMCs from technical replication were pooled, and CD69 and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry. Mean + / - SEM from n=3 donors. [Figure 17] Effects of serolimus escalation on CD25 expression on CD4+(B) T cells and CD8+(D) T cells, and CD69 expression on CD4+(A) T cells and CD8+(C) T cells in the assay for 1nM CD20-TCB shown in Figure 13. At 24 hours, tumor cells and PBMCs from technical replication were pooled, and CD69 and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry. Mean values ​​+ / - SEM from n=3 donors. [Figure 18] Effect of everolimus escalating concentration on CD25 expression on CD4+(B) T cells and CD8+(D) T cells, and on CD69 expression on CD4+(A) T cells and CD8+(C) T cells in the assay for 1nM CD20-TCB shown in Figure 13. At 24 hours, tumor cells and PBMCs from technical replication were pooled, and CD69 and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry. Mean + / - SEM from n=3 donors. [Figure 19]Effect of escalating ruxolitinib concentrations on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), and IL-6 (E) in the assay for 1 nM CD20-TCB shown in Figure 13. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean + / - SEM for n=3 donors. [Figure 20] Effect of escalating temsirolimus concentration on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), and IL-6 (E) in the assay for 1 nM CD20-TCB shown in Figure 13. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean + / - SEM for n=3 donors. [Figure 21] Effect of serolimus escalation concentration on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), and IL-6 (E) in the assay for 1 nM CD20-TCB shown in Figure 13. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean + / - SEM for n=3 donors. [Figure 22] Effect of everolimus escalating concentration on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), and IL-6 (E) in the assay for 1 nM CD20-TCB shown in Figure 13. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean + / - SEM for n=3 donors. [Figure 23]Real-time cell death of MKN45 NLR cells by 10 nM CEA-TCB in the presence of 5 μg / mL anti-TNF-α antibody (aTNF-α; Biolegend #502922 (antibody Mab11)), 5 μg / mL anti-IL-6R antibody (aIL-6R; Roche in-house), 1 μM dexamethasone (dexa), 0.1 μM dexamethasone, 50 nM dasatinib (dasa), 50 nM ruxolitinib (ruxo), 50 nM temsirolimus (temsi), 40 nM sirolimus (siro), and 50 nM everolimus (evero) in the assay shown in Figure 1. % death was measured by normalizing the total red area with the value at t=0 and the value of target cells + PBMC + corresponding compound control well at each time point. Mean + SD of technical replication for one representative donor. [Figure 24] Effect of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD69(A) and CD25(B) expression on CD4+ T cells induced by 10nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD69 and CD25 expression on CD4+ T cells was measured by flow cytometry at 66 hours. Mean + / -SD for n=3 donors. [Figure 25] Effect of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD69(A) and CD25(B) expression on CD8+ T cells induced by 10nM CEA-TCB in the assay shown in Figure 1. Technical replications were pooled, and CD69 and CD25 expression on CD8+ T cells was measured by flow cytometry at 66 hours. Mean + / - SD for n=3 donors. [Figure 26-1]Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on cytokine release (IFN-γ(A), IL-2(B), TNF-α(C), IL-4(D), IL-8(E), IL-10(F), GM-CSF(G)), MCP-1(H)) induced by 10nM CEA-TCB in the assay shown in Figure 1. Supernatants from technical replication were pooled for 66 hours, and cytokines were analyzed using Luminex. Mean values ​​±SD for n=3 donors. [Figure 26-2] Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on cytokine release (IFN-γ(A), IL-2(B), TNF-α(C), IL-4(D), IL-8(E), IL-10(F), GM-CSF(G)), MCP-1(H)) induced by 10nM CEA-TCB in the assay shown in Figure 1. Supernatants from technical replication were pooled for 66 hours, and cytokines were analyzed using Luminex. Mean values ​​±SD for n=3 donors. [Figure 27] Efficacy of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) against CD20-TCB-induced B cell death. WSU target cells were co-cultured with PBMCs (E:T=200000:20000) with gradually increasing concentrations of CD20-TCB and corresponding compounds. Technical replication was pooled over 24 hours, and CD19+ B cells were measured by flow cytometry. Dead B cells were excluded from CD19+ B cells using Live / Dead™ Fixable Aqua Dead Cell Stain. One representative donor was used. [Figure 28]Efficacy of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced B cell death. WSU target cells were co-cultured with PBMCs (E:T=200000:20000) with 1nM CD20-TCB and the corresponding compounds. Technical replication was pooled over 24 hours, and CD19+ B cells were measured by flow cytometry. Dead B cells were excluded from CD19+ B cells using Live / Dead™ Fixable Aqua Dead Cell Stain. Mean + / - SD for n=3 donors. [Figure 29] Efficacy of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced T cell activation. WSU target cells were co-cultured in PBMCs (E:T=200000:20000) with gradually increasing concentrations of CD20-TCB and corresponding compounds. Technical replication was pooled over 24 hours, and the expression of CD69 on CD4+(A) T cells and CD8+(C) T cells, and CD25 on CD4+(B) T cells and CD8+(D) T cells was measured by flow cytometry. One representative donor was used. [Figure 30] Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD69(A) and CD25(B) expression on CD4+ T cells. WSU target cells were co-cultured with PBMCs (E:T=200000:20000), 1nM CD20-TCB, and corresponding compounds. Technical replication was pooled over 24 hours, and CD69 and CD25 expression on CD4+ T cells was measured by flow cytometry. Mean + / - SD for n=3 donors. [Figure 31] Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD69(A) and CD25(B) expression on CD8+ T cells. WSU target cells were co-cultured with PBMCs (E:T=200000:20000), 1nM CD20-TCB, and corresponding compounds. Technical replication was pooled over 24 hours, and CD69 and CD25 expression on CD8+ T cells was measured by flow cytometry. Mean + / - SD for n=3 donors. [Figure 32-1] Effects of anti-TNF-α antibodies (aTNF-α), anti-IL-6R antibodies (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced cytokine release (TNF-α (A), IFN-γ (B), IL-2 (C), IL-1β (D), IL-6 (E), IL-4 (F), IL-10 (G), GM-CSF (H)). WSU target cells were co-cultured with PBMCs (E:T=200000:20000) and gradually increasing concentrations of CD20-TCB and corresponding compounds. Supernatants from technical replication were pooled for 24 hours, and cytokines were analyzed using Luminex. One representative donor was used. [Figure 32-2]Effects of anti-TNF-α antibodies (aTNF-α), anti-IL-6R antibodies (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced cytokine release (TNF-α (A), IFN-γ (B), IL-2 (C), IL-1β (D), IL-6 (E), IL-4 (F), IL-10 (G), GM-CSF (H)). WSU target cells were co-cultured with PBMCs (E:T=200000:20000) and gradually increasing concentrations of CD20-TCB and corresponding compounds. Supernatants from technical replication were pooled for 24 hours, and cytokines were analyzed using Luminex. One representative donor was used. [Figure 33-1] Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced cytokine release (TNF-α (A), IFN-γ (B), IL-2 (C), IL-1β (D), IL-6 (E), IL-4 (F), IL-10 (G), GM-CSF (H)). WSU target cells were co-cultured with PBMCs (E:T=200000:20000), 1nM CD20-TCB, and corresponding compounds. Supernatants from technical replication were pooled for 24 hours, and cytokines were analyzed using Luminex. n=3 donors, mean value + / - SD. [Figure 33-2]Effects of anti-TNF-α antibody (aTNF-α), anti-IL-6R antibody (aIL-6R), dexamethasone (dexa), dasatinib (dasa), ruxolitinib (ruxo), temsirolimus (temsi), sirolimus (siro), and everolimus (evero) on CD20-TCB-induced cytokine release (TNF-α (A), IFN-γ (B), IL-2 (C), IL-1β (D), IL-6 (E), IL-4 (F), IL-10 (G), GM-CSF (H)). WSU target cells were co-cultured with PBMCs (E:T=200000:20000), 1nM CD20-TCB, and corresponding compounds. Supernatants from technical replication were pooled for 24 hours, and cytokines were analyzed using Luminex. n=3 donors, mean value + / - SD. [Figure 34] In vitro cell death assay setup. Cell Trace™ Violet (CTV) labeled WSU DLCL2 tumor cells were co-cultured with PBMCs [E:T=200'000:20'000] and stimulated with CD20-TCB for 18 hours. At 18 hours, 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus was added to the system. [Figure 35] CTV-labeled WSU DLCL2 target cell death at 18 hours in the assay shown in Figure 34 before the addition of ruxolitinib, temsirolimus, sirolimus, and everolimus for three representative donors (D1-D3). At 18 hours, tumor cells and PBMCs from technical replication were pooled and stained with LIVE / DEAD™ near-infrared dead cell dye to allow for the exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. [Figure 36] CD25 expression on CD8+(A) T cells and CD4+(B) T cells at 18 hours in the assay shown in Figure 34, before the addition of ruxolitinib, temsirolimus, sirolimus, and everolimus, for three representative donors (D1-D3). At 18 hours, technical replication was pooled, and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry. [Figure 37]CTV-labeled WSU DLCL2 target cell killing at 44 hours in the assay of Figure 34 after addition of ibrutinib, temsirolimus, sirolimus, and everolimus. At 44 hours, tumor cells and PBMCs from technical replicates were pooled and stained with LIVE / DEADTM Near-IR Dead Cell Stain to enable exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. One representative donor. [Figure 38] Expression of CD25 on CD4+(B) T cells and CD8+(D) T cells, and expression of CD69 on CD4+(A) T cells and CD8+(C) T cells in the assay of Figure 34 after addition of ibrutinib, temsirolimus, sirolimus, and everolimus. At 44 hours, tumor cells and PBMCs from technical replicates were pooled and the expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was measured by flow cytometry. One representative donor. [Figure 39] Levels of IL-2 (A), IFN-γ (B), TNF-α (C), IL-6 (D), IL-1β (E), GM-CSF (F) before (18 hours) and after (44 hours) addition of ibrutinib, temsirolimus, sirolimus, and everolimus in the assay of Figure 34. At 18 hours and 44 hours, supernatants from technical replicates were pooled and cytokines were analyzed by Luminex. One representative donor. [Figure 40] CTV-labeled WSU DLCL2 target cell killing before (18 hours) and after (44 hours) addition of ibrutinib, temsirolimus, sirolimus, and everolimus to 1 nM CD2-CD20-TCB in the assay of Figure 34. At 18 hours and 44 hours, tumor cells and PBMCs from technical replicates were pooled and stained with LIVE / DEADTM Near-IR Dead Cell Stain to enable exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. n = mean of 3 donors + / - SEM. [Figure 41]Expression of CD69 (A) and CD25 (B) on CD4+ T cells before (18 hours) and after (44 hours) addition of luliconib, temsirolimus, sirolimus, and everolimus to 1 nM CD20-TCB in the assay of Figure 34. At 18 hours and 44 hours, tumor cells and PBMCs from technical replicates were pooled, and the expression of CD25 and CD69 on CD4+ T cells was measured by flow cytometry. Mean values + / − SEM of n = 3 donors. [Figure 42] Expression of CD69 (A) and CD25 (B) on CD8+ T cells before (18 hours) and after (44 hours) addition of luliconib, temsirolimus, sirolimus, and everolimus to 1 nM CD20-TCB in the assay of Figure 34. At 18 hours and 44 hours, tumor cells and PBMCs from technical replicates were pooled, and the expression of CD25 and CD69 on CD8+ T cells was measured by flow cytometry. Mean values + / − SEM of n = 3 donors. [Figure 43-1] Levels of IFN-γ (A), IL-2 (B), TNF-α (C), IL-6 (D), and IL-1β (E) before (18 hours) and after (44 hours) addition of luliconib, temsirolimus, sirolimus, and everolimus to 1 nM CD20-TCB in the assay of Figure 34. At 18 hours and 44 hours, supernatants from technical replicates were pooled, and cytokines were analyzed by Luminex. Mean values + / − SEM of n = 3 donors. [Figure 43-2] Levels of IFN-γ (A), IL-2 (B), TNF-α (C), IL-6 (D), and IL-1β (E) before (18 hours) and after (44 hours) addition of luliconib, temsirolimus, sirolimus, and everolimus to 1 nM CD20-TCB in the assay of Figure 34. At 18 hours and 44 hours, supernatants from technical replicates were pooled, and cytokines were analyzed by Luminex. Mean values + / − SEM of n = 3 donors. [Figure 43-3]Levels of IFN-γ (A), IL-2 (B), TNF-α (C), IL-6 (D), and IL-1β (E) before (18 hours) and after (44 hours) the addition of ruxolitinib, temsirolimus, sirolimus, and everolimus to 1 nM CD20-TCB in the assay shown in Figure 34. At 18 and 44 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean + / - SEM from n=3 donors. [Figure 44] Real-time cell death of A375 NucLightRed (NLR) cells with 8nM MAGEA4-TCB in the presence of ruxolitinib at increasing concentrations ranging from 0nM to 1000nM. A375 NLR target cells were co-cultured with MAGEA4-TCB (8nM), ruxolitinib, and PBMCs, E:T=50,000 PBMC:5000 target cells. Cell death was tracked using Incucyte® (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400ms). % death was measured by normalizing the total red area with the value at t=0 and the value in the target cells + PBMC + ruxolitinib control well at each time point. Mean + SD of technical replication for one representative donor. [Figure 45-1] Effect of escalating ruxolitinib concentration (c) on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by cytometry bead array (CBA). Mean + / - SD of technical replication from one representative donor. [Figure 45-2] Effect of escalating ruxolitinib concentration (c) on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by cytometry bead array (CBA). Mean + / - SD of technical replication from one representative donor. [Figure 45-3] Effect of escalating ruxolitinib concentration (c) on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by cytometry bead array (CBA). Mean + / - SD of technical replication from one representative donor. [Figure 46] Real-time cell death of A375 NucLightRed (NLR) cells by 8nM MAGEA4-TCB in the presence of sirolimus (A), temsirolimus (B), and everolimus (C) at increasing concentrations ranging from 0nM to 1000nM. A375 NLR target cells were co-cultured with 8nM MAGEA4-TCB, an mTOR inhibitor, and PBMCs, E:T=50,000 PBMC:5000 target cells. Cell death was tracked using Incucyte® (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400ms). % death was measured by normalizing the total red area with the value at t=0 and the value in the target cell + PBMC + mTOR inhibitor control well at each time point. Mean technical replication of one representative donor + SEM. [Figure 47-1] Effects of escalating concentrations (c) of sirolimus, temsirolimus, and everolimus on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by CBA. Mean + / - SD of technical replication from one representative donor. [Figure 47-2]Effects of escalating concentrations (c) of sirolimus, temsirolimus, and everolimus on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by CBA. Mean + / - SD of technical replication from one representative donor. [Figure 47-3] Effects of escalating concentrations (c) of sirolimus, temsirolimus, and everolimus on levels of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), IL-1β (F), IL-8 (G), MCP-1 (H), and IL-10 (I) induced by 8nM MAGEA4-TCB. At 72 hours, supernatant was collected and cytokines were analyzed by CBA. Mean + / - SD of technical replication from one representative donor. [Figure 48] Efficacy of baricitinib escalating in concentration against CD20-TCB-induced CTV-labeled WSU DLCL2 target cell death. At 24 hours, tumor cells and PBMCs from technical replication were pooled and stained with LIVE / DEAD™ near-infrared dye to allow exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. One representative donor. [Figure 49] Efficacy of escalating baricitinib concentration on CTV-labeled WSU DLCL2 target cell death induced by 1nM 1CD20-TCB. At 24 hours, tumor cells and PBMCs from technical replication were pooled and stained with LIVE / DEAD™ near-infrared dye to allow exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. Mean values ​​from n=2 donors. [Figure 50]Effect of baricitinib escalation on CD69 on CD4+(A) and CD8+(B) T cells induced by CD20-TCB on CD25 expression on CD4+(C) and CD8+(D) T cells. At 24 hours, technical replication was pooled and CD69 and CD25 expression on CD4+ and CD8+ T cells was measured by flow cytometry. One representative donor. [Figure 51] Effect of baricitinib escalation on CD69(A) and CD25(B) expression on CD4+ T cells in 1nM CD20-TCBs. At 24 hours, technical replication was pooled and CD69 and CD25 expression on CD4+ T cells was measured by flow cytometry. Mean values ​​from n=2 donors. [Figure 52] Efficacy of baricitinib dose escalation on CD69(A) and CD25(B) expression on CD8+ T cells in 1nM CD20-TCB. At 24 hours, technical replication was pooled and CD69 and CD25 expression on CD8+ T cells was measured by flow cytometry. Mean values ​​from n=2 donors. [Figure 53-1] Effect of escalating baricitinib concentrations on IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) levels in a dose-response elimination assay of CD20-TCB. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. One representative donor. [Figure 53-2] Effect of escalating baricitinib concentrations on IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) levels in a dose-response elimination assay of CD20-TCB. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. One representative donor. [Figure 54-1]Effect of baricitinib escalation on IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) levels in 1nM CD20-TCB. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. n=2 donors (mean values). [Figure 54-2] Effect of baricitinib escalation on IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) levels in 1nM CD20-TCB. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. n=2 donors (mean values). [Figure 55] Real-time cell death of MKN45 NLR cells by 1 nM CEA-TCB in the presence of baricitinib (A) and ruxolitinib (B) at concentrations ranging from 0 nM to 1000 nM. MKN45 NLR target cells were co-cultured with PBMCs (E:T=50,000 PBMC:5000 target cells) in medium supplemented with 1 nM CEA-TCB and a JAK inhibitor. Cell death was tracked using Incucyte® (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400 ms). % death was measured by normalizing the total red area with the value at t=0 and the value in the control well of target cells + PBMC + ruxolitinib or baricitinib at each time point. Mean technical replication of one representative donor + SEM. [Figure 56] Effect of escalating concentrations of baricitinib and ruxolitinib on CD25 expression on CD4+(A) T cells and CD8+(B) T cells 72 hours after treatment with 10 nM CEA-TCB. Technical replication was pooled, and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry at 69 hours. Mean ± / - SD for n=3 donors. [Figure 57-1]Effects of escalating concentrations of baricitinib and ruxolitinib on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) after treatment with 10 nM CEA. At 24 hours, supernatants from technical replication were pooled and cytokines were analyzed by Luminex. % inhibition was calculated by normalizing cytokine levels at each kinase inhibitor concentration to the condition without kinase inhibitor addition. Mean + / - SEM from n=3 donors. [Figure 57-2] Effects of escalating concentrations of baricitinib and ruxolitinib on the release of IFN-γ (A), IL-2 (B), TNF-α (C), GM-CSF (D), IL-6 (E), and IL-8 (F) after treatment with 10 nM CEA. At 24 hours, supernatants from technical replication were pooled and cytokines were analyzed by Luminex. % inhibition was calculated by normalizing cytokine levels at each kinase inhibitor concentration to the condition without kinase inhibitor addition. Mean + / - SEM from n=3 donors. [Figure 58] Real-time cell death of A375 NucLightRed (NLR) cells with 25 nM MAGEA4-TCB in the presence of escalating concentrations of baricitinib (A) and ruxolitinib (B) ranging from 0 nM to 1000 nM. A375 NLR target cells were co-cultured with PBMCs (E:T=50,000 PBMC:5000 target cells) in medium supplemented with 25 nM MAGEA4-TCB and a JAK inhibitor. Cell death was tracked using Incucyte® (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400 ms). Cell death [%] was measured by normalizing the total red area with the value at t=0 and the value of target cells + PBMC + JAK inhibitor control well at each time point. Mean + / - SD of technical replication for one representative donor. [Figure 59]Effect of escalating baricitinib concentrations (0-100 nM) on GM-CSF (A), IL-2 (B), IFN-γ (C), TNF-α (D), IL-1β (E), and IL-6 (F) levels induced by 25 nM MAGEA4-TCB. At 69 hours, supernatant was collected and cytokines were analyzed by CBA. Mean + / - SD of technical replication from one representative donor. [Figure 60] Effect of escalating concentrations (0-100 nM) of ruxolitinib on GM-CSF (A), IL-2 (B), IFN-γ (C), TNF-α (D), IL-1β (E), and IL-6 (F) levels induced by 25 nM MAGEA4-TCB. At 69 hours, supernatant was collected and cytokines were analyzed by CBA. Mean + / - SD of technical replication from one representative donor. [Figure 61] CTV-labeled WSU tumor cell death by PGLALA CAR-T cells (A) and CD16 CAR-T cells (B) in the presence and absence of 100 nM ruxolitinib or 100 nM sirolimus. PGLALA CAR-T cells and CD16 CAR-T cells were co-cultured with CTV-labeled WSU tumor cells (E:T=10:1) and escalating concentrations of anti-CD20 IgG containing PGLALA-FC (for PGLALA CAR-T cells) or wild-type Fc (for CD16 CAR-T cells) in the presence and absence of 100 nM ruxolitinib (ruxo) or 100 nM sirolimus (siro). At 24 hours, technical replicates were pooled and stained with LIVE / DEAD™ near-infrared dye to allow exclusion of dead CTV-labeled WSU DLCL2 tumor cells by flow cytometry. One representative donor. [Figure 62]Effects of 100 nM ruxolitinib and 100 nM sirolimus on GM-CSF (A), IFN-γ (B), IL-2 (C), and TNF-α (D) induced by PGLALA CAR-T cells. PGLALA CAR-T cells were co-cultured with CTV-labeled WSU tumor cells (E:T=10:1) and escalating concentrations of PGLALA-Fc anti-CD20 IgG, in the presence and absence of 100 nM ruxolitinib (ruxo) or 100 nM sirolimus (siro), respectively. At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. n=2 donor mean values. [Figure 63] Effect of 100 nM ruxolitinib and 100 nM sirolimus on GM-CSF (A), IFN-γ (B), IL-2 (C), and TNF-α (D) induced by CD16 CAR-T cells. CD16 CAR-T cells were co-cultured with CTV-labeled WSU tumor cells (E:T=10:1) and escalating concentrations of wild-type Fc anti-CD20 IgG in the presence and absence of 100 nM ruxolitinib (ruxo) or 100 nM sirolimus (siro). At 24 hours, supernatant from technical replication was pooled and cytokines were analyzed by Luminex. Mean values ​​from n=2 donors. [Figure 64] Setup of the in vitro cell death assay. PBMCs were co-cultured for 24 hours with CellTrace™ Violet (CTV)-labeled SUDLH-8 tumor cells (E:T=10:1) in medium supplemented with different kinase inhibitors (100 nM) in the presence of gradually increasing concentrations of CD19-TCB. [Figure 65-1]Effect of 100 nM dasatinib (Src inhibitor), sirolimus (mTOR inhibitor), and ruxolitinib (JAK1 / 2 inhibitor) on CD19-TCB-induced SUDLH-8 killing (A) and T cell activation (B, C, D, E) in the assay of Figure 64 (24 hours). Representative flow cytometry plots of dead CTV-labeled SUDLH-8 cells excluded from live cells using Live / Dead staining (A), CD69 expression on CD4+ (B) T cells and CD8+ (C) T cells, and CD25 expression on CD4+ (D) T cells and CD8+ (E) T cells. Representative donor of 1 out of 3, 10 nM CD19-TCB. [Figure 65-2] Effect of 100 nM dasatinib (Src inhibitor), sirolimus (mTOR inhibitor), and ruxolitinib (JAK1 / 2 inhibitor) on CD19-TCB-induced SUDLH-8 killing (A) and T cell activation (B, C, D, E) in the assay of Figure 64 (24 hours). Representative flow cytometry plots of dead CTV-labeled SUDLH-8 cells excluded from live cells using Live / Dead staining (A), CD69 expression on CD4+ (B) T cells and CD8+ (C) T cells, and CD25 expression on CD4+ (D) T cells and CD8+ (E) T cells. Representative donor of 1 out of 3, 10 nM CD19-TCB. [Figure 66] Effect of 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evo), and 100 nM ruxolitinib (ruxo) on CD19-TCB-dependent killing of CTV-labeled SUDLH-8 cells in the assay of Figure 64. Killing of CTV-labeled SUDLH-8 cells was measured by flow cytometry at 24 hours using Live / Dead staining that enables exclusion of dead cells. n = mean + standard deviation (SD) of 3 donors. [Figure 67]Effect of 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evo), and 100 nM ruxolitinib (ruxo) on CD19-TCB-dependent T cell activation in the assay shown in Figure 64. CD69 and CD25 expression on CD4+ (A, B) T cells and CD8+ (C, D) T cells was measured by flow cytometry at 24 hours. Mean + SD for n=3 donors. [Figure 68] Effect of 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evo), and 100 nM ruxolitinib (ruxo) on CD19-TCB-dependent cytokine release in the assay shown in Figure 64. Levels of IL-2 (A), IFN-γ (B), TNF-α (C), IL-6 (D), and GM-CSF (E) in the supernatant were measured using Luminex (24 hours). One representative donor was selected from three individuals. [Figure 69] Setup of the in vitro cell death assay. PBMCs were co-cultured for 24 hours with CTV-labeled SUDLH-8 cells (E:T=10:1) in medium supplemented with different JAK kinase inhibitors (100 nM) in the presence of gradually increasing concentrations of CD19-TCB. [Figure 70] Effect of 100 nM ruxolitinib (ruxo), 100 nM baricitinib (bari), and 100 nM tofacitinib (tofa) on CD19-TCB-dependent death of CTV-labeled SUDLH-8 cells in the assay shown in Figure 69. Death of CTV-labeled SUDLH-8 cells was measured by flow cytometry at 24 hours using Live / Dead staining to allow exclusion of dead cells. Mean + SD of n=3 donors. [Figure 71]Effect of 100 nM ruxolitinib (ruxo), 100 nM baricitinib (bari), and 100 nM tofacitinib (tofa) on CD19-TCB-dependent T cell activation in the assay shown in Figure 69. CD69 and CD25 expression on CD4+ (A, B) T cells and CD8+ (C, D) T cells was measured by flow cytometry at 24 hours. Mean + SD for n=3 donors. [Figure 72] Effect of 100 nM ruxolitinib (ruxo), 100 nM baricitinib (bari), and 100 nM tofacitinib (tofa) on CD19-TCB-dependent cytokine release in the assay shown in Figure 69. Levels of IL-2 (A), IFN-γ (B), TNF-α (C), IL-6 (D), and GM-CSF (E) in the supernatant were measured using Luminex (24 hours). One representative donor was selected from three individuals. [Figure 73] Setup of the in vitro cell death assay. PBMCs were co-cultured for 24 hours with CTV-labeled SUDLH-8 cells (E:T=10:1) in medium supplemented with different kinase inhibitors (100 nM), dexamethasone (100 nM), 5 μg / mL anti-TNF-α antibody (aTNF-α), or 5 μg / mL anti-IL-6R antibody (aIL-6R) in the presence of gradually increasing concentrations of CD19-TCB. [Figure 74] Effect of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (A), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (B) on CD19-TCB-dependent death of CTV-labeled SUDLH-8 cells in the assay shown in Figure 73. Death of CTV-labeled SUDLH-8 cells was measured by flow cytometry at 24 hours using Live / Dead staining to allow exclusion of dead cells. n = mean + SD of 3 donors, one-way ANOVA (Friedman test) results: *p ≤ 0.0332, **p ≤ 0.0021. [Figure 75-1]The effects of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (A, B), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (C, D) on CD19-TCB-dependent T cell activation in the assay shown in Figure 73. The expression of CD25 (A, C) and CD69 (B, D) on CD4+ T cells was measured by flow cytometry at 24 hours. n = mean + SD of 3 donors, one-way ANOVA (Friedman test) results: *p ≤ 0.0332, **p ≤ 0.0021. [Figure 75-2] The effects of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (A, B), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (C, D) on CD19-TCB-dependent T cell activation in the assay shown in Figure 73. The expression of CD25 (A, C) and CD69 (B, D) on CD4+ T cells was measured by flow cytometry at 24 hours. n = mean + SD of 3 donors, one-way ANOVA (Friedman test) results: *p ≤ 0.0332, **p ≤ 0.0021. [Figure 76-1]The effects of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (A, B), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (C, D) on CD19-TCB-dependent T cell activation in the assay shown in Figure 73. The expression of CD25 (A, C) and CD69 (B, D) on CD8+ T cells was measured by flow cytometry at 24 hours. n = mean + SD of 3 donors, one-way ANOVA (Friedman test) results: *p ≤ 0.0332, **p ≤ 0.0021. [Figure 76-2] The effects of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (A, B), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (C, D) on CD19-TCB-dependent T cell activation in the assay shown in Figure 73. The expression of CD25 (A, C) and CD69 (B, D) on CD8+ T cells was measured by flow cytometry at 24 hours. n = mean + SD of 3 donors, one-way ANOVA (Friedman test) results: *p ≤ 0.0332, **p ≤ 0.0021. [Figure 77-1]Effect of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (AD), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (EH) on CD19-TCB-dependent cytokine release in the assay shown in Figure 73. Levels of IFN-γ (A, E), IL-2 (B, F), TNF-α (C, G), and GM-CSF (D, H) in the supernatant were measured by Luminex (24 hours). Mean value + standard error of the mean value for n=3 donors (SEM). [Figure 77-2] Effect of 100 nM dexamethasone (dexa), 5 μg / mL anti-TNF-α antibody (aTNF-α) or 5 μg / mL anti-IL-6R antibody (aIL-6R) (AD), or 100 nM dasatinib (dasa), 100 nM sirolimus (siro), 100 nM temsirolimus (temsi), 100 nM everolimus (evero), or 100 nM ruxolitinib (ruxo) (EH) on CD19-TCB-dependent cytokine release in the assay shown in Figure 73. Levels of IFN-γ (A, E), IL-2 (B, F), TNF-α (C, G), and GM-CSF (D, H) in the supernatant were measured by Luminex (24 hours). Mean value + standard error of the mean value for n=3 donors (SEM). [Figure 78] In vitro cell death assay setup: PBMCs were co-cultured with CTV-labeled NALM-6 cells (E:T=10:1) for 24 hours in the presence of gradually increasing concentrations of CD19-TCB. At 24 hours, the culture medium was supplemented with 100 nM dasatinib, 100 nM sirolimus, or 100 nM ruxolitinib. [Figure 79]Effect of 100 nM dasatinib (dasa), 100 nM sirolimus (siro), and 100 nM ruxolitinib (ruxo) on CD19-TCB-induced tumor cell death when added to the system after 24 hours of activation in the assay shown in Figure 78. Death of CTV-labeled NALM-6 cells was measured by flow cytometry at 24 and 48 hours using Live / Dead staining, which allows for the exclusion of dead cells. One of two representative donors. [Figure 80] The effects of 100 nM dasatinib (dasa), 100 nM sirolimus (siro), and 100 nM ruxolitinib (ruxo) on CD19-TCB-induced cytokine release when added to the system after 24 hours of activation in the assay shown in Figure 78. Levels of IFN-γ (A), TNF-α (B), IL-2 (C), and IL-6 (D) in the supernatant were measured by Luminex (at 24 and 48 hours). One representative donor was selected from two individuals. [Figure 81] Timeline and administration schedule for in vivo experiments. Humanized NSG mice were concurrently treated with 0.5 mg / kg of CD19-TCB (intravenous) and (i) 6 x 50 mg / kg of dasatinib (oral), (ii) 6 x 30 mg / kg of ruxolitinib (oral), (iii) 4 x 5 mg / kg of sirolimus (oral), (iv) 2 x 1 mg / kg, 1 x 0.5 mg / kg, and 1 x 0.25 mg / kg of dexamethasone (oral), or (v) 2 x 10 mg / kg, 1 x 5 mg / kg, and 1 x 2.5 mg / kg of methylprednisolone (oral), or pre-treated with 30 mg / kg of obinutuzumab (Gazyva®) (GpT) (intravenous), followed by treatment with 0.5 mg / kg of CD19-TCB (intravenous). [Figure 82]Efficacy of obinutuzumab (Gazyva®) prior treatment (GpT), ruxolitinib (ruxo), dasatinib (dasa), sirolimus (siro), dexamethasone (dexa), and methylprednisolone (MP) on CD19-TCB-induced B cell depletion in experiments described in Figure 81. CD20+ B cell counts were measured by flow cytometry of blood samples collected 48 hours (A) and 72 hours (B) after treatment with CD19-TCB. Mean + / - SEM for n=4 mice or n=3 mice (dexa, MP, and GpT), one-way ANOVA (Kruskal-Wallis test) with *p ≤ 0.0332 and **p ≤ 0.0021. [Figure 83] The effects of obinutuzumab (Gazyva®) pretreatment (GpT), ruxolitinib (ruxo), dasatinib (dasa), sirolimus (siro), dexamethasone (dexa), and methylprednisolone (MP) on CD19-TCB-induced B cell depletion in the experiment described in Figure 81. CD20+ B cell counts were measured by flow cytometry in spleens collected 72 hours after CD19-TCB treatment. Mean values ​​+ / - SEM for n=4 mice or n=3 mice (vehicle, dexa, MP, and GpT). [Figure 84] The effects of obinutuzumab (Gazyva®) pretreatment (GpT), ruxolitinib (ruxo), dasatinib (dasa), sirolimus (siro), dexamethasone (dexa), and methylprednisolone (MP) on CD19-TCB-induced cytokine release in the experiment described in Figure 81. Levels of human IFN-γ (hIFN-γ) (A), human IL-2 (hIL-2) (B), human TNF-α (hTNF-α) (C), and human IL-6 (hIL-6) (D) were measured by Luminex in serum collected 6 hours after CD19-TCB treatment. Mean values ​​+ / - SEM for n=4 mice or n=3 mice (dexa, MP, and GpT). [Figure 85]Real-time cell death of MKN45 NucLightRed (NLR) cells with 10 nM CEA-TCB in the presence of escalating concentrations of fedratinib ranging from 0 nM to 1000 nM. MKN45 NLR target cells were co-cultured with PBMCs (E:T=50,000 PBMC:5,000 target cells) in medium supplemented with 10 nM CEA-TCB and fedratinib. Cell death was tracked using Incucyte® (1 scan every 3 hours, 10x zoom, phase and red acquisition time 400 ms). Cell death [%] was measured by normalizing the total red area with the value at t=0 and the value in the target cells + PBMC + fedratinib control well at each time point. Mean + / - SEM of technical replication from one donor. [Figure 86] Effect of escalating fedratinib concentrations on CD25(B,D) and CD69(A,C) expression on CD4+(A,B) T cells and CD8+(C,D) T cells 72 hours after treatment with 10 nM CEA-TCB. Technical replication was pooled, and CD25 expression on CD4+ T cells and CD8+ T cells was measured by flow cytometry at 72 hours. One donor. [Figure 87] Effect of escalating concentrations (0-1000 nM) of fedratinib on IFN-γ(A), IL-2(B), TNF-α(C), IL-6(D), and IL-8(E) levels induced by 10 nM CEA-TCB. At 72 hours, supernatant from technical replication was pooled and cytokine levels were analyzed by Luminex. One donor. [Figure 88]CD19-TCB kills lymphoma PDX cells in vitro. Lymphoma PDX cells were thawed on the day of the assay, labeled with CTV dye, and cultured with PBMCs (E:T=10:1) in the presence of CD19-TCB for 24 hours. (A) Death of CTV-labeled PDX cells was measured by flow cytometry in pooled technical replication (mean + / -SD for n=3 PBMC donors). (BE) Expression of CD69 (B,D) and CD25 (C,E) on CD4+ (B,C) T cells and CD8+ (D,E) T cells was measured by flow cytometry as readings of T cell activation in pooled technical replication (mean + / -SD for n=3 PBMC donors). [Figure 89] In vivo experiment timeline and administration schedule. Humanized NSG mice were transplanted with lymphoma PDX (5 million cells, sc). When the tumor reached a size of 200 mm3, the mice were randomized to 8 or 7 groups based on their tumor size and administered as follows: vehicle (intravenous), 0.5 mg / kg CD19-TCB (intravenous) alone, 20 mg / kg dasatinib ("Srci", dotted arrow, oral) with 0.5 mg / kg CD19-TCB (solid black arrow, intravenous), 5 mg / kg sirolimus ("mTORi", dashed arrow, oral), 30 mg / kg Patients were treated weekly with ruxolitinib ("JAKi", dotted arrow, oral), dexamethasone at 1 mg / kg and 0.5 mg / kg twice, or dexamethasone at 0.25 mg / kg four times ("dexa", dashed arrow, oral), a kinase inhibitor and dexamethasone alone, or with obinutuzumab ("GpT", gray solid arrow, intravenous) at 30 mg / kg three days prior to the first treatment with CD19-TCB. Kinase inhibitors were administered twice on the first day of CD19-TCB administration (D16, once one hour before CD19-TCB administration and once thereafter), once (sirolimus) or twice (dasatinib, ruxolitinib) over the following two days (D17, D18), and similarly once one hour before each subsequent CD19-TCB administration. [Figure 90]Tumor growth curves of sirolimus alone or in combination with CD19-TCB compared to vehicle, obinutuzumab prior treatment (GpT), or CD19-TCB as monotherapy. Tumor volume was measured 2-3 times per week using calipers. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) with *p≦0.05, **p≦0.01, and ***p≦0.001. [Figure 91] Tumor growth curves of ruxolitinib alone or in combination with CD19-TCB compared to vehicle, prior obinutuzumab therapy (GpT), or CD19-TCB as monotherapy. Tumor volume was measured 2-3 times per week using calipers. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) with *p≦0.05, **p≦0.01, and ***p≦0.001. [Figure 92] Tumor growth curves of dasatinib alone or in combination with CD19-TCB compared to vehicle, prior obinutuzumab therapy (GpT), or CD19-TCB as monotherapy. Tumor volume was measured 2-3 times per week using calipers. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) with *p≦0.05, **p≦0.01, ***p≦0.001. [Figure 93] Tumor growth curves of dexamethasone alone or in combination with CD19-TCB compared to vehicle, prior obinutuzumab therapy (GpT), or CD19-TCB as monotherapy. Tumor volume was measured 2-3 times per week using calipers. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) with *p≦0.05, **p≦0.01, and ***p≦0.001. [Figure 94-1]Effects of sirolimus (mTOR inhibitor), ruxolitinib (JAK1 / 2 inhibitor), dasatinib (Src inhibitor), and dexamethasone on CD19-TCB-mediated release of (A) IL-2, (B) IFN-γ, (C) TNF-α, and (D) IL-6. Cytokine levels in serum collected 6 hours after the first CD19-TCB infusion were measured by Luminex. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) for *p≦0.05, **p≦0.01, and ***p≦0.001. [Figure 94-2] Effects of sirolimus (mTOR inhibitor), ruxolitinib (JAK1 / 2 inhibitor), dasatinib (Src inhibitor), and dexamethasone on CD19-TCB-mediated release of (A) IL-2, (B) IFN-γ, (C) TNF-α, and (D) IL-6. Cytokine levels in serum collected 6 hours after the first CD19-TCB infusion were measured by Luminex. Mean + SD of n=6-8 mice, one-way ANOVA (Kruskal-Wallis test) for *p≦0.05, **p≦0.01, and ***p≦0.001. [Figure 95] In vivo experiment timeline and administration schedule. Humanized NSG mice were treated with vehicle or 0.15 mg / kg of CD20-TCB (intravenous) alone, or in combination with different doses of mTOR inhibitors (oral) (2, 5, or 10 mg / kg sirolimus, 10 mg / kg temsirolimus, and 10 mg / kg everolimus), JAK inhibitors (oral) (30 or 60 mg / kg ruxolitinib), and Src inhibitors (oral) (10 or 50 mg / kg dasatinib), or pre-treated with 30 mg / kg obinutuzumab (Gazyva®) (GpT) (intravenous). n=4 mice per group. [Figure 96]The effects of obinutuzumab (Gazyva®) pretreatment (GpT), ruxolitinib, dasatinib, sirolimus, everolimus, and temsirolimus on CD20-TCB-induced B cell depletion at 48 hours (A) and 72 hours (B) in the experiment described in Figure 95. The percentage of CD19+ B cells in human CD45+ (huCD45) cells was measured by flow cytometry of blood samples taken 48 and 72 hours after CD20-TCB treatment. Mean values ​​+ / - SEM for n=4 mice or n=3 mice (everolimus group). A statistical comparison with the vehicle group is summarized in Table (C). The p-value was calculated by the Kruskal-Wallis test. [Figure 97] Levels of IFN-γ in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), a JAK inhibitor (ruxolitinib), a Src inhibitor (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean value + / - SEM of n=4 mice or mean value + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 98] Levels of IL-2 in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with mTOR inhibitors (sirolimus, temsirolimus, everolimus), JAK inhibitors (ruxolitinib), Src inhibitors (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours post-treatment (everolimus group). [Figure 99]Levels of TNF-α in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with mTOR inhibitors (sirolimus, temsirolimus, everolimus), JAK inhibitors (ruxolitinib), Src inhibitors (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 100] Levels of IL-6 in mouse serum 4 hours (A) and 24 hours (B) after treatment with CD20-TCB alone or in combination with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), a JAK inhibitor (ruxolitinib), a Src inhibitor (dasatinib), or obinutuzumab (Gazyva®) prior treatment (GpT), as shown in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 101] Levels of IP-10 (CXCL10) in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with mTOR inhibitors (sirolimus, temsirolimus, everolimus), JAK inhibitors (ruxolitinib), Src inhibitors (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 102] Levels of MCP-1 (CCL2) in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) with CD20-TCB alone or in combination with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), a JAK inhibitor (ruxolitinib), a Src inhibitor (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean value + / - SEM of n=4 mice or mean value + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 103]Levels of IL-8 in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with mTOR inhibitors (sirolimus, temsirolimus, everolimus), JAK inhibitors (ruxolitinib), Src inhibitors (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours (everolimus group). [Figure 104] Levels of GM-CSF in mouse serum at 4 hours (A) and 24 hours (B) post-treatment (GpT) of CD20-TCB alone or in combination with mTOR inhibitors (sirolimus, temsirolimus, everolimus), JAK inhibitors (ruxolitinib), Src inhibitors (dasatinib), or obinutuzumab (Gazyva®) as described in Figure 95. Mean + / - SEM of n=4 mice or mean + / - SEM of n=3 mice at 24 hours (everolimus group). [Examples]

[0244] Examples The following are examples of the methods and compositions of the present invention. Given the general description provided above, it will be understood that various other embodiments may be carried out.

[0245] Example 1. The mTOR inhibitor sirolimus prevents TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0246] To evaluate the inhibitory effect of sirolimus on TCB-mediated target cell death, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), MKN45 NucLight Red (NLR) target cells, and 10 nM CEA-TCB (SEQ ID NOs. 4-23) in media supplemented with sirolimus at increasing concentrations (Figure 1). Time-dependent loss of red fluorescent protein signal was captured as a reading of target cell death using the Incucyte® system (Essen Bioscience). Sirolimus doses ranging from 1 μM (approx. 915 ng / mL) to 12.5 nM (approx. 11.4 ng / mL) partially reduced 10 nM CEA-TCB-mediated death of MKN45 NLR target cells (Figures 2A and 3A).

[0247] At the end of the assay (72 hours), PBMCs were stained with live / dead staining to examine the effect of sirolimus on PBMC viability. At concentrations ranging from 1 μM (approximately 915 ng / mL) to 12.5 nM (approximately 11.4 ng / mL), sirolimus did not directly affect PBMC viability in samples treated with 10 nM CEA-TCB (Figure 4B). CD25 and CD69 expression on live CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Sirolimus did not affect CD69 expression on CD8+ T cells, but at concentrations above 25 nM, it reduced CD69 expression on CD4+ T cells from approximately 45% to approximately 25%. At concentrations above 25 nM, sirolimus reduced CD25 expression in CD4+ T cells from approximately 45% to approximately 15%, and in CD8+ T cells from approximately 75% to 40% (Figure 6).

[0248] Finally, to determine the effect of sirolimus on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured by Luminex. In the presence of any concentration of sirolimus, levels of IFN-γ, TNF-α, IL-2, IL-6, MCP-1, IL-8, IL-10, IL-4, and GM-CSF in samples treated with 10 nM CEA-TCB were found to be significantly lower compared to samples not treated with sirolimus (Figure 8). Sirolimus concentrations across the entire range from 12.5 nM to 1 μM had a similar effect on CEA-TCB-induced cytokine release, demonstrating that sirolimus strongly downregulates cytokine release.

[0249] While sirolimus does not completely inhibit target cell death and T cell activation caused by TCBs, it potently reduces cytokine release even at the lowest dose tested.

[0250] Similar experiments were conducted with other TCBs. WSU DLCL2 cells were co-cultured with PBMCs in the presence of 1 nM CD20-TCB (SEQ ID NOs. 4-11, 24-35) while gradually increasing the dose of sirolimus from 0 nM to 1000 nM (Figure 13). The death of CTV-labeled WSU target cells (Figure 14C) and the expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells (Figure 17) were measured at 24 hours as readings of the effect of sirolimus on TCB efficacy and T cell activation, respectively. Finally, to evaluate the effect of sirolimus concentration escalation on CD20-TCB-induced cytokine release, levels of IFN-γ, IL-2, TNF-α, GM-CSF, and IL-6 were measured by Luminex (Figure 21). Consistent with findings from CEA-TCB, sirolimus did not completely inhibit CD20-TCB-mediated target cell death and T cell activation, but it potently reduced CD20-TCB-induced cytokine release at concentrations above 12.5 nM.

[0251] Example 2. The mTOR inhibitor temsirolimus prevents TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0252] To evaluate the inhibitory effect of temsirolimus on TCB-mediated target cell death, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), NucLight Red (NLR) target cells, and 10 nM CEA-TCB in media supplemented with escalating concentrations of temsirolimus (Figure 1). The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading of target cell death. Temsirolimus doses ranging from 1 μM (approximately 10³¹ ng / mL) to 12.5 nM (approximately 12.9 ng / mL) partially reduced 10 nM CEA-TCB-mediated death of MKN45 NLR target cells (Figures 2C and 3C).

[0253] At the end of the assay (72 hours), PBMCs were stained with live / dead staining to examine the effect of temsirolimus on PBMC viability. At concentrations ranging from 1 μM (approximately 1031 ng / mL) to 12.5 nM (approximately 12.9 ng / mL), temsirolimus did not directly affect PBMC viability in samples treated with 10 nM CEA-TCB (Figure 4C). CD25 and CD69 expression on live CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Temsirolimus did not affect CD69 expression on CD8+ T cells, but at concentrations above 25 nM, it reduced CD69 expression on CD4+ T cells from approximately 45% to approximately 25%. At concentrations above 25 nM, temsirolimus reduced CD25 expression in CD4+ T cells from approximately 45% to approximately 15%, and in CD8+ T cells from approximately 75% to 40% (Figure 7).

[0254] To determine the effect of temsirolimus on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured using Luminex. In the presence of arbitrary concentrations of temsirolimus, levels of IFN-γ, TNF-α, IL-2, IL-6, MCP-1, IL-8, IL-10, IL-4, and GM-CSF in samples treated with 10 nM CEA-TCB were significantly lower compared to samples not treated with temsirolimus (Figure 8). Temsirolimus concentrations across the entire range from 12.5 nM to 1 μM had a similar effect on CEA-TCB-induced cytokine release, demonstrating that temsirolimus strongly downregulates cytokine release.

[0255] While temsirolimus does not completely inhibit target cell death and T cell activation caused by TCBs, it potently reduces cytokine release even at the lowest dose tested.

[0256] Similar experiments were conducted using CD20-TCB. WSU DLCL2 cells were co-cultured with PBMCs in the presence of 1 nM CD20-TCB, with the dose of temsirolimus being gradually increased from 0 nM to 1000 nM (Figure 13). The death of CTV-labeled WSU target cells (Figure 14B) and the expression of CD25 and CD69 on CD4+ and CD8+ cells (Figure 16) were measured at 24 hours as readings of the effects of temsirolimus on TCB efficacy and T cell activation, respectively. Finally, to evaluate the effect of increased temsirolimus concentration on CD20-TCB-induced cytokine release, the levels of IFN-γ, IL-2, TNF-α, GM-CSF, and IL-6 were measured using Luminex (Figure 20). Consistent with findings from CEA-TCB, temsirolimus did not completely inhibit CD20-TCB-mediated target cell death and T cell activation, but it potently reduced CD20-TCB-induced cytokine release at concentrations above 12.5 nM.

[0257] Example 3. The mTOR inhibitor everolimus prevents TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0258] To evaluate the inhibitory effect of everolimus on TCB-mediated target cell death, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), NucLight Red (NLR) target cells, and 10 nM CEA-TCB in medium supplemented with everolimus at increasing concentrations (Figure 1). The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading of target cell death. Everolimus doses ranging from 1 μM (approx. 959 ng / mL) to 12.5 nM (approx. 12.0 ng / mL) partially reduced 10 nM CEA-TCB-mediated death of MKN45 NLR target cells (Figures 2B and 3B).

[0259] At the end of the assay (72 hours), PBMCs were stained with live / dead staining to examine the effect of everolimus on PBMC viability. At concentrations ranging from 1 μM (approx. 959 ng / mL) to 12.5 nM (approx. 12.0 ng / mL), everolimus did not directly affect PBMC viability in samples treated with 10 nM CEA-TCB (Figure 4A). CD25 and CD69 expression on live CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Everolimus did not affect CD69 expression on CD8+ T cells, but at concentrations above 25 nM, it reduced CD69 expression on CD4+ T cells from approximately 45% to approximately 25%. At concentrations above 25 nM, everolimus reduced CD25 expression in CD4+ T cells from approximately 45% to approximately 15%, and in CD8+ T cells from approximately 70% to 40% (Figure 5).

[0260] To determine the effect of everolimus on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured by Luminex. In the presence of any concentration of everolimus, levels of IFN-γ, TNF-α, IL-2, IL-6, MCP-1, IL-8, IL-10, IL-4, and GM-CSF in samples treated with 10 nM CEA-TCB were significantly lower compared to samples not treated with everolimus (Figure 8). Everolimus concentrations across the entire range from 12.5 nM to 1 μM had a similar effect on CEA-TCB-induced cytokine release, demonstrating that everolimus strongly downregulates cytokine release.

[0261] While everolimus does not completely inhibit target cell death and T cell activation caused by TCBs, it potently reduces cytokine release even at the lowest dose tested.

[0262] Similar experiments were conducted using CD20-TCB. WSU DLCL2 cells were co-cultured with PBMCs in the presence of 1 nM CD20-TCB, with everolimus doses gradually increasing from 0 nM to 1000 nM (Figure 13). Death of CTV-labeled WSU target cells (Figure 14D) and the expression of CD25 and CD69 on CD4+ and CD8+ cells (Figure 18) were measured at 24 hours as readings of the effects of everolimus on TCB efficacy and T cell activation, respectively. Finally, to evaluate the effect of everolimus concentration escalation on CD20-TCB-induced cytokine release, levels of IFN-γ, IL-2, TNF-α, GM-CSF, and IL-6 were measured using Luminex (Figure 22). Consistent with findings from CEA-TCB, everolimus did not completely inhibit CD20-TCB-mediated target cell death and T cell activation, but it potently reduced cytokine release induced by CD20-TCB at concentrations above 12.5 nM.

[0263] Example 4. The JAK1 / 2 inhibitor ruxolitinib prevents TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0264] To evaluate the inhibitory effect of ruxolitinib on TCB-mediated target cell death, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), MKN45 NucLight Red (NLR) target cells, and 10 nM CEA-TCB in media supplemented with escalating concentrations of ruxolitinib (Figure 1). The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading of target cell death. Ruxolitinib doses ranging from 100 nM (approximately 30.7 ng / mL) to 6.25 nM (approximately 1.9 ng / mL) partially reduced 10 nM CEA-TCB-mediated death of MKN45 NLR target cells (Figures 9A and B).

[0265] At the end of the assay (69 hours), PBMCs were stained with live / dead staining to examine the effect of ruxolitinib on PBMC viability. At concentrations ranging from 100 nM (approximately 30.7 ng / mL) to 6.25 nM (approximately 1.9 ng / mL), ruxolitinib did not directly affect PBMC viability in samples treated with 10 nM CEA-TCB (Figure 10). The expression of CD25 and CD69 on live CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Ruxolitinib dose-dependently affected the expression of CD25 and CD69 in both CD4+ T cells and CD8+ T cells (Figure 11). The effect of escalating doses of ruxolitinib on CD69 expression on CD4+ T cells and CD8+ T cells was not as pronounced as its effect on CD25 expression on CD4+ T cells and CD8+ T cells.

[0266] To determine the effect of ruxolitinib on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured by Luminex. In the presence of escalating doses of ruxolitinib, levels of IFN-γ, TNF-α, IL-2, IL-6, MCP-1, IL-8, IL-10, IL-4, and GM-CSF in samples treated with 10 nM CEA-TCB were found to be significantly lower compared to samples not treated with ruxolitinib (Figure 12). Ruxolitinib strongly downregulated overall CEA-TCB-induced cytokine release.

[0267] While ruxolitinib does not completely inhibit target cell death and T cell activation caused by TCBs, it potently reduces cytokine release even at the lowest dose tested.

[0268] Similar experiments were conducted using CD20-TCB. WSU DLCL2 cells were co-cultured with PBMCs in the presence of 1 nM CD20-TCB, with ruxolitinib doses gradually increasing from 0 nM to 1000 nM (Figure 13). Death of CTV-labeled WSU target cells (Figure 14A) and the expression of CD25 and CD69 on CD4+ and CD8+ cells (Figure 15) were measured at 24 hours as readings of the effects of ruxolitinib on TCB efficacy and T cell activation, respectively. Finally, to evaluate the effect of sirolimus concentration escalation on CD20-TCB-induced cytokine release, levels of IFN-γ, IL-2, TNF-α, GM-CSF, and IL-6 were measured using Luminex (Figure 19). Ruxolitinib did not completely inhibit CD20-TCB-mediated target cell death and T cell activation, but it potently reduced IL-6 and IFN-γ release induced by CD20-TCB concentrations above 25 nM. Unlike mTOR inhibitors, ruxolitinib did not have a strong effect on the release of TNF-α, IL-2, and GM-CSF.

[0269] Example 5. Effects of mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and JAK inhibitors (ruxolitinib) on anti-TNF-α antibody, anti-IL-6R antibody, dexamethasone, and dasatinib on TCB-mediated target cell death, T cell activation, and cytokine release.

[0270] To evaluate the effects of mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and JAK inhibitors (ruxolitinib) on TCB-mediated target cell death compared to anti-TNF-α antibodies, anti-IL-6R antibodies, dexamethasone, and dasatinib, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), MKN45 NucLight Red (NLR) target cells, and 10 nM CEA-TCB in media supplemented with different compounds (Figure 1). The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading of target cell death. Neutralizing anti-TNF-α antibodies and anti-IL-6R antibodies (5 μg / ml) did not affect the dynamics of target cell death or the maximum target cell death compared to TCB alone. 50 nM JAK inhibitors (ruxolitinib) and 50 nM mTOR inhibitors (temsirolimus, sirolimus, and everolimus) had a similar effect on target cell death as 1 μM and 0.1 μM dexamethasone, and the addition of 50 nM dasatinib completely switched off TCB-induced target cell death (Figure 23).

[0271] At the end of the assay (66 hours), the expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was measured by flow cytometry to evaluate the effects of different compounds on T cell activation. mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and JAK inhibitors (ruxolitinib) had a milder effect on CD25 and CD69 expression on CD4+ T cells and CD8+ T cells than dexamethasone or dasatinib, but anti-TNF-α antibodies and anti-IL-6R antibodies did not affect T cell activation (Figures 24 and 25).

[0272] To determine the effects of different compounds on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured by Luminex. The use of kinase inhibitors and dexamethasone resulted in an overall reduction of TCB-induced cytokine release compared to neutralizing antibodies against specific cytokines such as TNF-α and IL-6 (Figure 26). Dasatinib completely prevented CEA-TCB-induced cytokine release, T cell activation, and target cell death, while mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and JAK inhibitors (ruxolitinib) independently inhibited cytokine release, showing milder effects on T cell activation and target cell death. The JAK1 / 2 inhibitor ruxolitinib did not reduce IL-2 levels as strongly as the mTOR inhibitors (temsirolimus, sirolimus, and everolimus) (Figure 26B).

[0273] The effects of mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and JAK inhibitors (ruxolitinib) on CEA-TCB-induced cytokine release are comparable to those of dexamethasone and dasatinib, and are potent compared to anti-TNF-α antibodies and anti-IL-6R antibodies. On the other hand, mTOR inhibitors and JAK inhibitors have lower efficacy in cell death and less impact on T cell activation compared to dasatinib.

[0274] Similar experiments were performed with other TCBs. WSU cells were co-cultured with PBMCs in the presence of escalating doses of CD20-TCB and mTOR inhibitors (temsirolimus, sirolimus, everolimus), JAK inhibitors (ruxolitinib), dasatinib, dexamethasone, or anti-TNF-α or anti-IL-6R antibodies. B cell death was measured as a reading of the effect of various compounds on TCB efficacy at 24 hours (Figures 27 and 28). CD25 and CD69 expression on CD4+ and CD8+ T cells was measured by flow cytometry as a reading of T cell activation at 24 hours (Figures 29, 30, and 31). Finally, to evaluate the effects of different treatments on TCB-induced cytokine release, cytokine levels (TNF-α, IFN-γ, IL-2, IL-6, IL-4, IL-10, GM-CSF, and IL-1β) were analyzed by Luminex (Figures 32 and 33). As seen in CEA-TCB, mTOR (temsirolimus, sirolimus, and everolimus) and JAK (ruxolitinib) inhibitors were as effective as dexamethasone and dasatinib against CD20-TCB-induced cytokine release and were more potent than anti-TNF-α and anti-IL-6R antibodies in reducing overall cytokine release. Unlike dasatinib, mTOR (temsirolimus, sirolimus, and everolimus) inhibitors and JAK (ruxolitinib) inhibitors did not prevent B cell death and did not switch off CD20-TCB-induced T cell activation, suggesting that they do not strongly affect the efficacy of TCB.

[0275] In summary, mTOR inhibitors and JAK inhibitors have lower efficacy in cell death and less impact on T cell activation than dasatinib (a Src inhibitor) and dexamethasone. Instead, their effects on cell death and T cell activation are comparable to those of anti-TNF-α antibodies or anti-IL-6R antibodies. On the other hand, mTOR inhibitors such as dexamethasone and dasatinib, as well as JAK inhibitors, reduce cytokine release more potently than anti-TNF-α antibodies or anti-IL-6R antibodies. The difference in activity between mTOR inhibitors and JAK inhibitors indicates an uncoupling of TCB-induced cytokine release and cytotoxicity, suggesting that these compounds may be attractive alternatives or complements to steroids or IL-6 / IL-6R blockade for CRS relief.

[0276] Example 6. Effects of sirolimus, temsirolimus, everolimus, and ruxolitinib on CD20-TCB-induced cytokine release from pre-activated effector cells.

[0277] To evaluate whether mTOR inhibitors (temsirolimus, sirolimus, and everolimus) and a JAK inhibitor (ruxolitinib) can prevent further cytokine release induced by CD20-TCB treatment, they were added to an in vitro cell death assay 18 hours after activation. In this assay, CTV-labeled WSUDLCL2 tumor cells were co-cultured with PBMCs for 18 hours in the presence of escalating doses of CD20-TCB. At 18 hours, 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus were added to the system (Figure 34). To verify whether T cells were activated before the addition of 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus, tumor cell death, T cell activation, and cytokine release were measured at 18 hours. To evaluate the effect of adding 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus on TCB-induced cytokine release, cytokine release, T cell activation, and tumor cell death were measured at 44 hours.

[0278] At 18 hours, treatment with CD20-TCB resulted in the death of CTV-labeled WSU DLCL2 tumor cells (Figure 35), and CD25 was upregulated in both CD4+ and CD8+ T cells (Figure 36), indicating that T cells were activated before the addition of different inhibitors in the assay system. The addition of 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus did not affect the death of CTV-labeled WSU DLCL2 tumor cells (Figure 37) and T cell activation (Figure 38) measured at 44 hours. However, the addition of mTOR inhibitors (temsirolimus, sirolimus, and everolimus) halted the release of IL-2, IFN-γ, IL-6, and GM-CSF between 18 and 44 hours, and also halted, albeit to a lower degree, the release of TNF-α and IL-1β (Figure 39). The addition of a JAK inhibitor (ruxolitinib) prevented further production of IFN-γ and IL-6 between 18 and 44 hours, and also prevented, albeit to a lower degree, the production of GM-CSF and TNF-α, but did not prevent further production of IL-2 (Figure 39).

[0279] Furthermore, these results were confirmed in three donors at a fixed CD20-TCB concentration of 1 nM. The addition of 100 nM ruxolitinib, 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus did not affect further CTV-labeled WSU DLCL2 tumor cell death (Figure 40) and T cell activation (Figures 41 and 42) between 18 and 44 hours. However, the addition of 100 nM temsirolimus, 100 nM sirolimus, or 100 nM everolimus prevented further release of IFN-γ, IL-2, and IL-6, and to a lower degree, release of TNF-α and IL-1β between 18 and 44 hours (Figure 43). The addition of 100 nM ruxolitinib prevented further release of IFN-γ and IL-6, and to a lesser extent, prevented the release of TNF-α and IL-1β, but did not prevent IL-2 release (Figure 43).

[0280] Overall, these data suggest that mTOR (temsirolimus, sirolimus, and everolimus) and JAK (ruxolitinib) inhibitors can rapidly switch off CD20-TCB-induced cytokine release from pre-activated effector cells without significantly affecting CD20-TCB efficacy.

[0281] Example 7. The JAK1 / 2 inhibitor ruxolitinib prevents TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0282] The effect of ruxolitinib on TCB-induced tumor cell death and cytokine release was evaluated using an additional TCB, MAGEA4-TCB (SEQ ID NOs: 37-56). Similar to Example 4, a cell death assay was performed using peripheral blood mononuclear cells (PBMCs), A375 NucLight Red (NLR) target cells, and 8nM MAGEA4-TCB in medium supplemented with ruxolitinib at increasing concentrations ranging from 0nM to 100nM. The effect of ruxolitinib on MAGEA4-TCB-induced target cell death was evaluated by capturing the loss of red fluorescent protein signal over time as a cell death reading using the Incucyte® system (Essen Bioscience). Finally, the supernatant was collected at the end of the assay (72 hours), and cytokines were measured by Luminex to evaluate the effect of increasing concentrations of ruxolitinib on MAGEA4-TCB-induced cytokine release.

[0283] Ruxolitinib did not prevent tumor cell death induced by MAGEA4-TCB (Figure 44), but levels of IFN-γ (Figure 45A), TNF-α (Figure 45C), IL-8 (Figure 45G), IL-6 (Figure 45E), MCP-1 (Figure 45H), IL-10 (Figure 45I), and IL-1β (Figure 45F) decreased as the concentration of ruxolitinib increased. Levels of GM-CSF (Figure 45D) and IL-2 (Figure 45B) were unaffected by ruxolitinib, consistent with the data generated for CEA-TCB and CD20-TCB. Therefore, the JAK1 / 2 inhibitor ruxolitinib may be an attractive approach to mitigate MAGEA4-TCB-induced cytokine release without affecting its efficacy or IL-2 and GM-CSF levels.

[0284] Example 8. The mTOR inhibitors sirolimus, temsirolimus, and everolimus prevent TCB-mediated cytokine release while minimizing their impact on TCB-mediated target cell death.

[0285] The effects of sirolimus, temsirolimus, and everolimus on TCB-induced tumor cell death and cytokine release were evaluated using an additional TCB, MAGEA4-TCB. Similar to Examples 1-3, cell death assays were performed using peripheral blood mononuclear cells (PBMCs), A375 NucLight Red (NLR) target cells, and 8nM MAGEA4-TCB in media supplemented with serolimus, temsirolimus, and everolimus at increasing concentrations ranging from 0nM to 100nM. The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading of target cell death. Finally, the supernatant was collected at the end of the assay (72 hours), and cytokines were measured by Luminex to evaluate the effects of increasing concentrations of sirolimus, temsirolimus, and everolimus on MAGEA4-TCB-induced cytokine release.

[0286] Sirolimus, temsirolimus, and everolimus did not prevent MAGEA4-TCB-induced tumor cell death (Figure 46A, B, C), but levels of most of the tested cytokines, including IFN-γ (Figure 47A), IL-2 (Figure 47B), TNF-α (Figure 47C), IL-8 (Figure 47G), IL-6 (Figure 47E), MCP-1 (Figure 47H), and IL-10 (Figure 47I), decreased as the concentrations of sirolimus, temsirolimus, and everolimus increased. Consistent with the data generated for CEA-TCB and CD20-TCB, the mTOR inhibitors sirolimus, temsirolimus, and everolimus may be an attractive approach to mitigating MAGEA4-TCB-induced cytokine release without affecting their efficacy.

[0287] Example 9. The JAK inhibitor baricitinib can efficiently prevent TCB-induced cytokine release without affecting its efficacy.

[0288] To evaluate the inhibitory effect of the JAK1 / 2 inhibitor baricitinib on CD20-TCB-mediated target cell death and cytokine release, peripheral blood mononuclear cells (PBMCs) were co-cultured with CTV-labeled WSU target cells and CD20-TCB in medium supplemented with gradually increasing concentrations of baricitinib. Tumor cell death was measured by flow cytometry after 24 hours by removing dead CTV cells. The supernatant was collected, and cytokines were measured by Luminex. Furthermore, the expression of CD69 and CD25 on CD4+ T cells and CD8+ T cells was measured by flow cytometry to evaluate the effect of baricitinib on T cell activation.

[0289] As a result, baricitinib concentrations in the range of 0 nM to 100 nM did not impair CD20-TCB-induced tumor cell death (Figures 48 and 49) and T cell activation, as indicated by the expression of CD25 and CD69 on CD4+ (Figures 50A, C, and 51) and CD8+ (Figures 50B, D, and 52) T cells. At higher concentrations of 1 μM, baricitinib slightly reduced CD20-TCB-induced tumor cell death (Figures 48 and 49) and T cell activation (Figures 50A-D, 51, and 52). Similar to other JAK inhibitors such as ruxolitinib, dose-escalation of baricitinib reduced levels of IFN-γ, TNF-α, GM-CSF, IL-6, and IL-8 (Figures 53A, C, D, E, and F; Figures 54A, C, D, E, and F), but did not reduce IL-2 (Figures 53B, 54B).

[0290] Baricitinib did not prevent CD20-TCB-induced death and T-cell activation of CTVWSU tumor cells, but it potently reduced CD20-TCB-induced cytokine release at doses ranging from 12.5 nM to 100 nM. Therefore, the JAK inhibitor baricitinib may be used in addition to ruxolitinib to reduce CD20-TCB-induced cytokine release without affecting its efficacy.

[0291] Example 10. The effect of the JAK inhibitor baricitinib on TCB-induced tumor cell death, T cell activation, and cytokine release is equivalent to that of the JAK inhibitor ruxolitinib.

[0292] To verify whether the effects of baricitinib on TCB-induced cytokine release, T cell activation, and tumor cell death are equivalent to those of ruxolitinib, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), MKN45 NucLight Red (NLR) target cells, and 10 nM and 1 nM CEA-TCB in media supplemented with escalating concentrations of ruxolitinib and baricitinib. The time-dependent loss of red fluorescent protein signaling was captured using the Incucyte® system (Essen Bioscience) as a reading for target cell death. At 72 hours, CD25 expression on CD4+ and CD8+ T cells was measured by flow cytometry to evaluate the effects of baricitinib and ruxolitinib on CEA-TCB-induced T cell activation. Finally, the supernatant was collected at the end of the assay (72 hours), and cytokines were measured using Luminex to evaluate the effects of baricitinib and ruxolitinib on CEA-TCB-induced cytokine release. The percentage of cytokine inhibition was calculated as the percentage of cytokines found in the absence of kinase inhibitors, allowing for a comparison of the effects of baricitinib and ruxolitinib on CEA-TCB-induced cytokine release.

[0293] Both baricitinib and ruxolitinib did not prevent the death of MKN45 NLR tumor cells induced by 1 nM CEA-TCB at escalating concentrations ranging from 0 nM to 100 nM (Figures 55A and B). At higher concentrations of 1 μM, both baricitinib and ruxolitinib partially prevented the death of MKN45 NLR tumor cells (Figures 55A and B). Similar to ruxolitinib, escalating concentrations of baricitinib reduced CD25 expression on CD4+ (Figure 56A) and CD8+ (Figure 56B) T cells, demonstrating that baricitinib's effect on CEA-TCB-induced T cell activation was comparable to that of ruxolitinib. The degree of inhibition of IFN-γ, TNF-α, GM-CSF, IL-6, and IL-8 levels (Figures 57A, C, D, E, and F) was similar for escalating concentrations of ruxolitinib and baricitinib. Consistent with what was observed with ruxolitinib, IL-2 levels did not decrease with escalating baricitinib concentrations (Figure 57B).

[0294] A comparison of baricitinib and ruxolitinib was performed using another TCB, MAGEA4-TCB. Similar to CEA-TCB, cell death assays were performed using peripheral blood mononuclear cells (PBMCs), A375 NucLight Red (NLR) target cells, and 25 nM MAGEA4-TCB in media supplemented with escalating concentrations of ruxolitinib and baricitinib ranging from 0 nM to 100 nM. The time-dependent loss of red fluorescent protein signal was captured using the Incucyte® system (Essen Bioscience) as a reading for target cell death. To evaluate the effects of baricitinib and ruxolitinib on MAGEA4-TCB-induced cytokine release, cytokines in the supernatant collected at the end of the assay (72 hours) were measured by Luminex.

[0295] Consistent with data generated using CEA-TCB, the effect of baricitinib on MAGEA4-TCB-induced tumor cell death (Figure 58A) was comparable to that of ruxolitinib (Figure 58B) at escalating concentrations from 0 nM to 100 nM. Furthermore, the effect of baricitinib on MAGEA4-TCB-induced GM-CSF, IL-2, IFN-γ, IL-2, TNF-α, IL-1β, and IL-6 release (Figures 59A-F) was also comparable to that of ruxolitinib (Figures 60A-F) at concentrations ranging from 0 nM to 100 nM.

[0296] In summary, baricitinib's effects on CEA-TCB and MAGEA4-TCB-induced tumor cell death, T cell activation, and cytokine release are comparable to those of ruxolitinib. Therefore, in addition to ruxolitinib, baricitinib presents an attractive approach for mitigating TCB-induced release.

[0297] Example 11. The JAK inhibitor ruxolitinib and the mTOR inhibitor sirolimus prevent CAR-T cell-induced cytokine release.

[0298] To evaluate the effects of the JAK inhibitor ruxolitinib and the mTOR inhibitor sirolimus on cytokine release induced by CAR-T cells, we performed a cell death assay in which PGLALA and CD16 universal CAR-T cells (CAR-T cells containing CARs including anti-P329G-Fc scFv (bound to PGLALA Fc) or CD16 (bound to wild-type Fc)) were co-cultured with CTV WSU ​​tumor cells in the presence of escalating concentrations of PGLALA Fc and wild-type Fc anti-CD20 IgG in a medium supplemented with 100 nM ruxolitinib or 100 nM sirolimus. To verify whether ruxolitinib and sirolimus prevent tumor cell death by CAR-T cells, CTV WSU ​​tumor cell death was measured by flow cytometry at 24 hours. To verify whether ruxolitinib and sirolimus reduce cytokine release induced by CAR-T cells, cytokines in the assay supernatant were measured by Luminex at 72 hours.

[0299] As a result, neither sirolimus nor ruxolitinib prevented tumor cell death by PGLALA (Figure 61A) and CD16 (Figure 61B) CAR-T cells. For both PGLALA (Figure 62) and CD16 (Figure 63) CAR-T cells, ruxolitinib reduced the release of IFN-γ (Figures 62B and 63B), TNF-α (Figures 62D and 63D), and GM-CSF (Figures 62A and 63D), but not IL-2 (Figures 62C and 63C), which is consistent with the findings regarding TCBs. Finally, sirolimus potently reduced the release of all cytokines tested, namely IFN-γ (Figures 62B and 63B), TNF-α (Figures 62D and 63D), GM-CSF (Figures 62A and 63A), and IL-2 (Figures 62C and 63C).

[0300] Overall, these data suggest that the JAK1 / 2 inhibitor ruxolitinib and the mTOR inhibitor sirolimus may be attractive approaches to prevent CAR-T cell-induced cytokine release without affecting CAR-T cell efficacy.

[0301] Example 12. The mTOR inhibitors sirolimus, temsirolimus, and everolimus, and the JAK inhibitor ruxolitinib, potently reduce cytokine release but do not prevent CD19-TCB-dependent cell death and T cell activation.

[0302] The effects of the mTOR inhibitors sirolimus, everolimus, and temsirolimus, as well as the JAK1 / 2 inhibitor ruxolitinib, on TCB-induced T cell toxicity, T cell activation, and cytokine release were evaluated using another TCB, CD19-TCB (SEQ ID NOs. 5, 7-9, 11, 64-74, 76-78, 80). PBMCs were evaluated in the presence of different kinase inhibitors, including the Src inhibitor dasatinib, and CellTrace TMViolet (CTV)-labeled SUDLH-8 tumor cells were co-cultured with gradually increasing concentrations of CD19-TCB (Figure 64). At the end of the assay (24 hours), the death of CTV-labeled SUDLH-8 cells was measured by flow cytometry after removing dead SUDLH-8 cells by viable / dead staining. The expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Finally, cytokine levels in the assay supernatant were measured to evaluate the effects of mTOR, JAK, and Src inhibitors on CD19-TCB-induced cytokine release.

[0303] As a result, unlike the Src inhibitor dasatinib, mTOR inhibitors and JAK inhibitors did not prevent CD19-TCB-dependent SUDLH-8 death (Figures 65A and 66). Consistent with their effect on death, mTOR and JAK inhibitors, in contrast to the Src inhibitor dasatinib, did not block the expression of CD25 and CD69 on CD4+ and CD8+ T cells (Figures 65B-E and 67). Finally, the JAK1 / 2 inhibitor ruxolitinib prevented the release of CD19-TCB-induced IFN-γ, TNF-α, IL-6, and GM-CSF, and to a lesser extent, also prevented the release of IL-2, while mTOR inhibitors potently reduced the release of all four cytokines (Figure 68).

[0304] Overall, the differences in activity of mTOR, JAK, and Src inhibitors revealed the uncoupling of CD19-TCB-induced T cell cytotoxicity and cytokine release. Furthermore, these data suggest that the mTOR inhibitors sirolimus, temsirolimus, and everolimus, and the JAK1 / 2 inhibitor ruxolitinib, may mitigate CD19-TCB-induced cytokine release, while not preventing tumor cell death or T cell activation. The Src inhibitor dasatinib is rather present as an antidote for extratumor toxicity or high-grade CRS where switching off T cell functionality is necessary to block both cytokine release and death.

[0305] Example 13. The JAK inhibitors baricitinib and tofacitinib have equivalent efficacy to ruxolitinib in CD19-TCB-induced tumor cell death, T cell activation, and cytokine release.

[0306] To compare the effects of the JAK inhibitors baricitinib and tofacitinib on CD19-TCB-induced T cell toxicity, T cell activation, and cytokine release with ruxolitinib, PBMCs were co-cultured with CTV-labeled SUDLH-8 tumor cells and increasing concentrations of CD19-TCB in the presence of 100 nM ruxolitinib, 100 nM baricitinib, and 100 nM tofacitinib (Figure 69). At the end of the assay (24 hours), the death of CTV-labeled SUDLH-8 cells was measured by flow cytometry after removing dead SUDLH-8 cells by viable / dead staining. The expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was also measured by flow cytometry as a reading of T cell activation. Finally, to evaluate the effect of JAK inhibitors on CD19-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured.

[0307] Similar to ruxolitinib, baricitinib and tofacitinib did not prevent CD19-TCB-dependent death of CTV-labeled SUDLH-8 tumor cells (Figure 70), nor did they prevent the expression of CD25 and CD69 on CD4+ (Figure 71A and B) T cells and CD8+ (Figure 71C and D) T cells. Furthermore, the JAK inhibitors baricitinib and tofacitinib prevented CD19-TCB-induced IFN-γ, TNF-α, IL-6, and GM-CSF release to a similar degree as ruxolitinib, and prevented IL-2 release to a lesser extent (Figure 72). Baricitinib and tofacitinib appeared to have comparable efficacy to ruxolitinib, preventing CD19-TCB-induced cytokine release without blocking in vitro T cell activation and T cell cytotoxicity.

[0308] Finally, this experiment suggests that baricitinib and tofacitinib could be two additional JAK inhibitors to mitigate CD19-TCB-induced cytokine release, serving as alternatives to ruxolitinib.

[0309] Example 14. Comparison of the JAK inhibitor ruxolitinib, the mTOR inhibitors sirolimus, temsirolimus, and everolimus, and the Src inhibitor dasatinib with current CRS reduction approaches.

[0310] To verify whether the use of JAK and mTOR inhibitors is equivalent to current approaches used to mitigate TCB-induced cytokine release, we compared the effects of kinase inhibitors in vitro with the use of the corticosteroid dexamethasone, as well as anti-TNF-α and anti-IL-6R antibodies. Therefore, PBMCs were co-cultured with CTV-labeled SUDLH-8 tumor cells and increasing concentrations of CD19-TCB in the presence of mTOR, JAK, and Src inhibitors, as well as dexamethasone, anti-TNF-α antibody (aTNF-α; Biolegend #502922 (antibody Mab11)), and anti-IL-6R antibody (aIL-6R; Roche in-house) (Figure 73). At the end of the assay (24 hours), to evaluate the effects of different mitigation approaches on CD19-TCB-dependent cell death, CTV-labeled SUDLH-8 cell death was measured by flow cytometry after excluding dead SUDLH-8 cells by viable / dead staining. Next, the expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was also measured by flow cytometry as readings for the effect on T cell activation. Finally, to examine the effect of JAK inhibitors on CD19-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured.

[0311] Similar to dexamethasone, anti-TNF-α antibodies, and anti-IL-6R antibodies, the mTOR inhibitors sirolimus, temsirolimus, and everolimus, as well as the JAK1 / 2 inhibitor ruxolitinib, did not prevent CD19-TCB-dependent death of CTV SUDLH-8 cells—this differed from the Src inhibitor dasatinib (Figure 74). Furthermore, mTOR and JAK inhibitors, as well as dexamethasone, anti-TNF-α, and anti-IL-6R, did not prevent the expression of CD25 (Figures 75A and C, 76A and C) and CD69 (Figures 75B and D, 76B and D) on CD4+ T cells and CD8+ T cells, in contrast to the Src inhibitor dasatinib, which completely blocked T cell activation. Finally, the effects of the mTOR inhibitors sirolimus, temsirolimus, and everolimus, as well as the JAK1 / 2 inhibitor ruxolitinib, on CD19-TCB-induced IFN-γ and TNF-α were equivalent to those of dexamethasone (Figure 77). The effects of mTOR inhibitors on CD19-TCB-induced IL-2 and GM-CSF were equivalent to those of dexamethasone, but the effect of the JAK1 / 2 inhibitor ruxolitinib on these two cytokines was weaker (Figure 77). The effects of JAK and mTOR inhibitors on the reduction of CD19-TCB-induced IFN-γ, IL-2, TNF-α, and GM-CSF were more potent than those of anti-IL-6R antibodies, which only slightly reduced IFN-γ, IL-2, TNF-α, and GM-CSF levels, or more potent than those of anti-TNF-α antibodies, which specifically reduced TNF-α and, to a lesser extent, reduced IFN-γ, IL-2, and GM-CSF. Finally, the Src inhibitor dasatinib showed complete inhibition of CD19-TCB-induced cytokine release (Figure 77), which correlated with inhibition of cell death and T cell activation.

[0312] In summary, this experiment suggests that the effects of the mTOR inhibitors sirolimus, temsirolimus, and everolimus, and the JAK1 / 2 inhibitor ruxolitinib are comparable to those of the corticosteroid dexamethasone, which reduces CD19-TCB-dependent cytokine release without preventing T cell cytotoxicity or T cell activation. Furthermore, the effects of the mTOR inhibitors sirolimus, temsirolimus, and everolimus, and the JAK1 / 2 inhibitor ruxolitinib on CD19-TCB-induced cytokine release were stronger than those of IL-6R and TNF-α blockade. In conclusion, these data highlight that JAK inhibitors and mTOR inhibitors may be alternative approaches to mitigating CD19-TCB-induced cytokine release, replacing the use of anti-IL-6R antibodies, anti-TNF-α antibodies, and even corticosteroids.

[0313] Example 15. Effects of sirolimus (as an exemplary mTOR inhibitor), ruxolitinib (as an exemplary JAK inhibitor), and dasatinib (as an exemplary Src inhibitor) on CD19-TCB-induced cytokine release from pre-activated effector cells.

[0314] To evaluate whether the mTOR inhibitor sirolimus, the JAK1 / 2 inhibitor ruxolitinib, and the Src inhibitor dasatinib could prevent further cytokine release induced by CD19-TCB treatment, these were added to an in vitro cell death assay 24 hours after activation (Figure 78). In this assay, CTV-labeled NALM-6 tumor cells were co-cultured with PBMCs for 24 hours in the presence of escalating doses of CD19-TCB. At 24 hours, 100 nM ruxolitinib, 100 nM sirolimus, or 100 nM dasatinib was added to the system. To verify whether T cell activation occurred before the addition of different kinase inhibitors, tumor cell death and cytokine release were measured at 24 hours (Figures 79 and 80). Finally, cytokine release and tumor cell death were measured at 48 hours, and the effects of adding 100 nM ruxolitinib, 100 nM sirolimus, or 100 nM dasatinib on CD19-TCB-induced cytokine release were evaluated in comparison to their effects on tumor cell death.

[0315] At 24 hours, treatment with CD19-TCB resulted in the death of CTV-labeled NALM-6 tumor cells (Figure 79), and the release of IFN-γ (Figure 80A), TNF-α (Figure 80B), IL-2 (Figure 80C), and IL-6 (Figure 80D), indicating that T cells were activated before the addition of kinase inhibitors. The addition of 100 nM ruxolitinib or 100 nM sirolimus did not prevent the death of CTV-labeled NALM-6 tumor cells as measured at 48 hours (Figure 79), while the addition of 100 nM dasatinib moderately reduced the death of NALM-6 tumor cells. However, the addition of 100 nM sirolimus or 100 nM dasatinib prevented further release of IFN-γ, TNF-α, IL-2, and IL-6 between 24 and 48 hours (Figure 80), while the addition of 100 nM ruxolitinib only prevented further release of IFN-γ, TNF-α, and IL-6, and to a lesser extent, release of IL-2 (Figure 80).

[0316] Overall, this experiment suggests that the mTOR inhibitor sirolimus and the JAK1 / 2 inhibitor ruxolitinib can rapidly stop CD19-TCB-induced cytokine release from pre-activated effector cells without affecting the efficacy of CD19-TCB. On the other hand, the Src inhibitor dasatinib can rapidly switch off CD19-TCB-induced cytokine release from pre-activated effector cells while also reducing CD19-TCB-induced T cell cytotoxicity.

[0317] Example 16. The effects of the JAK inhibitor ruxolitinib, the Src inhibitor dasatinib, and the mTOR inhibitor sirolimus on reducing CD19-TCB-induced cytokine release in humanized NSG mice are equivalent to the effects of the corticosteroids dexamethasone and methylprednisolone, and prior treatment with obinutuzumab.

[0318] The effects of prior treatment with the JAK1 / 2 inhibitor ruxolitinib, the mTOR inhibitor sirolimus, the Src inhibitor dasatinib, and obinutuzumab (Gazyva®), as well as the corticosteroids dexamethasone and methylprednisolone, on CD19-TCB-induced cytokine release and B cell depletion were evaluated in vivo. Therefore, humanized NSG mice were pre-treated with obinutuzumab (Gazyva®) and then treated with 0.5 mg / kg CD19-TCB, or concurrently treated with 0.5 mg / kg CD19-TCB and (i) 4 x 5 mg / kg sirolimus, (ii) 6 x 30 mg / kg ruxolitinib, (iii) 6 x 50 mg / kg dasatinib, (iv) 2 x 1 mg / kg, 1 x 0.5 mg / kg and 1 x 0.25 mg / kg dexamethasone, or (v) 2 x 10 mg / kg, 1 x 5 mg / kg and 1 x 2.5 mg / kg methylprednisolone (Figure 81). To best replicate the pharmacodynamic profiles of ruxolitinib, dasatinib, and sirolimus in a clinical setting and to verify whether the resulting exposure was sufficient to prevent CD19-TCB-induced cytokine release, dasatinib and ruxolitinib were administered orally twice daily, while sirolimus was administered orally twice daily on day 1, and then once daily thereafter.

[0319] At 48 and 72 hours, blood was collected via tail vein bleeding, and the number of CD20+ B cells was measured by flow cytometry (Figures 82A and B) to evaluate the effects of different treatments on CD19-TCB-induced B cell depletion. At 48 and 72 hours, ovinituzumab (Gazyva®) prior treatment (GpT) followed by CD19-TCB treatment caused complete B cell depletion, similar to treatment with CD19-TCB alone. On the other hand, ruxolitinib (ruxo) and sirolimus (siro), like dexamethasone (dexa) and methylprednisolone (MP), slightly prevented B cell depletion, had a milder inhibitory effect than the Src inhibitor dasatinib (dasa), and did not completely prevent the efficacy of CD19-TCB (Figure 82A). At 72 hours, the effects of ruxolitinib and sirolimus were comparable to those of dexamethasone, but appeared to be more potent than methylprednisolone in preventing B cell depletion (Figure 82B), indicating a small inhibitory effect on CD19-TCB activity. At 72 hours, dasatinib was no longer able to completely block B cell depletion. Its half-life is approximately 6-7 hours, and dasatinib was administered only twice daily, so the lack of exposure may explain the partial activation of CD19-TCB, resulting in B cell depletion. At the end of the experiment (72 hours), spleens were collected and B cell counts were measured by flow cytometry (Figure 83). Consistent with blood observations, ruxolitinib and sirolimus, like dexamethasone, only partially prevented CD19-TCB-induced CD20+ B cell depletion. However, their inhibitory effects were stronger than those of methylprednisolone (Figure 83). At 72 hours, dasatinib did not prevent CD20+ B cell depletion in the spleen, likely due to insufficient exposure (Figure 83). As expected, prior treatment with obinutuzumab (Gazyva®) resulted in complete CD20+ B cell depletion due to the dual activity of two depletion antibodies (Figure 83).

[0320] Finally, serum was collected from the blood 6 hours after CD19-TCB treatment, and cytokine levels were measured by Luminex to evaluate the effects of different treatments on CD19-TCB-induced cytokine release (Figure 84). The effects of sirolimus, ruxolitinib, dexamethasone, and methylprednisolone on CD19-TCB-induced IFN-γ (Figure 84A) and IL-6 release (Figure 84D) were comparable to prior treatment with obinutuzumab (Gazyva®). The effects of sirolimus, dexamethasone, and methylprednisolone on CD19-TCB-induced IL-2 (Figure 84B) and TNF-α (Figure 84C) were comparable to prior treatment with Gazyva. However, the effect of ruxolitinib appeared to be slightly weaker in reducing IL-2 and TNF-α. Overall, the effects of mTOR and JAK inhibitors were found to be equivalent to those of the corticosteroids dexamethasone and methylprednisolone, as well as the effects of prior treatment with obinutuzumab (Gazyva®), in reducing CD19-TCB-induced cytokine release, due to the milder effect of ruxolinib on IL-2 and TNF-α release.

[0321] Consistent with in vitro findings, concurrent treatment with ruxolitinib or sirolimus and CD19-TCB, like dexamethasone and methylprednisolone, was able to control CD19-TCB-induced cytokine release in humanized NSG mice, but could not completely prevent B cell depletion. Furthermore, the effects of ruxolitinib, sirolimus, dexamethasone, and methylprednisolone in preventing CD19-TCB-induced cytokine release were comparable to prior treatment with obinutuzumab (Gazyva®), although the latter induced more potent B cell depletion.

[0322] Example 17. The JAK inhibitor fedratinib prevents CEA-TCB-mediated cytokine release while minimizing its impact on TCB-mediated target cell death.

[0323] To evaluate the effects of another JAK inhibitor, fedratinib, on TCB-mediated target cell death, T cell activation, and cytokine release, we performed cell death assays using peripheral blood mononuclear cells (PBMCs), NucLight Red (NLR) MKN45 tumor cells, and 10 nM CEA-TCB in culture media supplemented with escalating concentrations of fedratinib. The time-dependent loss of red fluorescent protein signaling was captured using the Incucyte® system (Essen Bioscience) as a reading for target cell death. Fedratinib doses ranging from 12.5 nM to 1 μM partially reduced 10 nM CEA-TCB-mediated MKN45 NLR target cell death, while doses below 1 μM had only a slight effect (Figure 85).

[0324] At the end of the assay (72 hours), the expression of CD25 and CD69 on CD4+ T cells and CD8+ T cells was measured by flow cytometry as a reading of T cell activation. Fedratinib, at concentrations below 1 μM, did not affect the expression of CD69 and CD25 on CD4+ T cells (Figure 86A, B) and CD8+ T cells (Figure 86C, D).

[0325] To determine the effect of fedratinib on CEA-TCB-induced cytokine release, cytokine levels in the assay supernatant were measured by Luminex. In the presence of fedratinib concentrations ranging from 50 nM to 1 μM, levels of IFN-γ, IL-2, TNF-α, IL-6, and IL-8 were reduced (Figure 87).

[0326] Overall, these data suggest that while fedratinib reduces CEA-TCB-induced cytokine release, it does not prevent T cell cytotoxicity or T cell activation.

[0327] Example 18. mTOR and JAK inhibitors do not suppress CD19-TCB antitumor activity in lymphoma PDX-carrying mice.

[0328] To evaluate the effects of mTOR and JAK inhibition on CD19-TCB antitumor activity compared to prior treatment with Src inhibition, dexamethasone, or obinutuzumab (GpT), a humanized NSG mouse xenograft (PDX) model derived from lymphoma patients was used. First, a cell death assay was used to verify whether PDX cells were killed by treatment with CD19-TCB in vitro. Lymphoma PDX cells were co-cultured with PBMCs (E:T=10:1) in the presence of CD19-TCB. Lymphoma PDX cells were efficiently depleted by CD19-TCB in vitro (Figure 88A), resulting in T cell activation, as indicated by the expression of CD25 and CD69 on CD4+ and CD8+ T cells (Figures 88B-E). Next, PDX-carrying mice were treated with a vehicle, sirolimus (5 mg / kg), ruxolitinib (30 mg / kg), dasatinib (20 mg / kg), or dexamethasone (1 mg / kg twice, 0.5 mg / kg, 0.25 mg / kg four times) alone, or in combination with CD19-TCB (0.5 mg / kg), CD19-TCB (0.5 mg / kg) as monotherapy, or in combination with obinutuzumab prior treatment (GpT) (30 mg / kg). Different kinase inhibitors and dexamethasone were administered one hour before the first treatment with CD19-TCB, and then once or twice daily for three days to suppress cytokine release mainly occurring at the time of the first infusion (Figure 89). Furthermore, to prevent residual cytokine secretion, they were also administered one hour before each subsequent treatment (Figure 89). Administration of both dexamethasone and sirolimus as monotherapy induced a reduction in tumor growth, but it was not statistically significant (Figures 90 and 93). When combined with CD19-TCB, the resulting antitumor activity was comparable to that of CD19-TCB alone, but sirolimus and dexamethasone suppressed IL-2, IFN-γ, TNF-α, and IL-6 release at the time of initial infusion (Figures 90, 93, and 94). Similarly, concurrent treatment with ruxolitinib minimized interference with CD19-TCB antitumor activity, reduced IL-6, and further reduced IFN-γ, TNF-α, and IL-2 release (Figures 91 and 94).The effects of ruxolitinib, sirolimus, and dexamethasone on cytokine levels appeared stronger than those of prior obinutuzumab treatment, but their effects on antitumor efficacy were similar (Figures 90, 91, 93, and 94). Furthermore, dasatinib significantly reduced T cell-derived cytokines (IFN-γ, TNF-α, IL-2, and IL-6) at the time of initial infusion, but did not significantly suppress the CD19-TCB antitumor effect. This indicates that the inhibitory effect of dasatinib is reversible, and therefore the transient use of dasatinib in this experiment did not continuously block CD19-TCB-induced T cell cytotoxicity (Figures 92 and 94).

[0329] In summary, this data shows that transient use of the JAK inhibitor ruxolitinib and the mTOR inhibitor sirolimus does not impair the antitumor effect while suppressing T cell-mediated cytokine release during the initial infusion of CD19-TCB, supporting the use of these compounds to mitigate TCB-related CRS.

[0330] Example 19. Effects of ruxolitinib (JAK1 / 2 inhibitor), mTOR inhibitors (sirolimus, everolimus, temsirolimus), and dasatinib (Src inhibitor) on CD20-TCB-induced cytokine release and B cell depletion in non-tumor-carrying humanized NSG mice.

[0331] This experiment investigated whether the in vivo combination of the short PK / PD properties of small molecule kinase inhibitors and the long PK / PD properties of CD20-TCB efficiently switches off cytokine release in humanized NSG mice. Furthermore, by measuring CD19+ B cells in peripheral blood, the effects of JAK and mTOR inhibitors on CD20-TCB-mediated B cell depletion were evaluated compared to the Src inhibitor dasatinib.

[0332] As shown in Figure 95, humanized NSG mice were treated with 0.15 mg / kg of CD20-TCB alone or in combination with an mTOR inhibitor (sirolimus, temsirolimus, everolimus), a JAK inhibitor (ruxolitinib), or a Src inhibitor (dasatinib), or were pre-treated with obinutuzumab (Gazyva®). Different doses of mTOR, JAK, and Src kinase inhibitors were tested to determine the optimal dose for reducing CD20-TCB-induced cytokine release while minimizing interference with B cell depletion. For sirolimus, doses of 2, 5, and 10 mg / kg were tested, while for the other mTOR inhibitors, temsirolimus and everolimus, only the highest dose of 10 mg / kg was used. For ruxolitinib, doses of 30 and 60 mg / kg were tested, and for dasatinib, doses of 10 and 50 mg / kg were tested. To replicate the clinical administration route, different kinase inhibitors were administered orally once or twice daily, as shown in Figure 95. Blood was collected from mice 4 and 24 hours after treatment with CD20-TCB (Figure 95), and serum was collected for cytokine level measurement using Luminex. Furthermore, blood was collected 48 and 72 hours (end) after treatment with CD20-TCB, and the percentage of CD19+ B cells in human CD45+ cells was measured by flow cytometry (Figure 95).

[0333] As a result, concurrent treatment with sirolimus at 2, 5, and 10 mg / kg, everolimus at 10 mg / kg, or temsirolimus at 10 mg / kg (mTOR inhibitors) failed to prevent CD20-TCB-induced B cell depletion, as indicated by the percentage of CD19+ B cells in human CD45+ cells in peripheral blood (Figures 96A-C). However, mTOR inhibitors sustainably reduced CD20-TCB-induced cytokine release, as indicated by the levels of IFN-γ (Figures 97A, B), IL-2 (Figures 98A, B), TNF-α (Figures 99A, B), IL-6 (Figures 100A, B), IP-10 (Figures 101A, B), MCP-1 (Figures 102A, B), IL-8 (Figures 103A, B), and GM-CSF (Figures 104A, B). Furthermore, the reduction in cytokine release induced by mTOR inhibitors was comparable to prior treatment with dasatinib and obinutuzumab (Gazyva®) in this model (Figures 97-104). Overall, unlike the Src inhibitor dasatinib, which switched off TCB activity for up to 48 hours, mTOR inhibitors potently reduced CD20-TCB-mediated cytokine release while maintaining B cell depletion at doses of 2-10 mg / kg.

[0334] Concurrent treatment with 30 and 50 mg / kg of ruxolitinib (a JAK1 / 2 inhibitor) slightly prevented CD20-TCB-induced B cell depletion, as indicated by the percentage of CD19+ B cells in peripheral blood human CD45+ cells (Figure 96A-C). The inhibitory effect on B cell depletion appeared to be dose-dependent on ruxolitinib. Furthermore, as indicated by the levels of IFN-γ (Figure 97A, B), IL-2 (Figure 98A, B), TNF-α (Figure 99A, B), IL-6 (Figure 100A, B), IP-10 (Figure 101A, B), MCP-1 (Figure 102A, B), IL-8 (Figure 103A, B), and GM-CSF (Figure 104A, B), ruxolitinib sustainably reduced CD20-TCB-mediated cytokine release, except for IL-2 and GM-CSF release (Figure 97A, B). Overall, concomitant treatment with the JAK1 / 2 inhibitor ruxolitinib reduced CD20-TCB-mediated cytokine release, except for IL-2 and GM-CSF, while minimizing B cell depletion at doses of 30-60 mg / kg, unlike the Src inhibitor dasatinib, which completely switches off TCB activity for up to 48 hours.

[0335] In summary, these data indicate that the combination of mTOR and JAK inhibitors with CD20-TCB reduced cytokine release in humanized NSGs, consistent with in vitro observations. JAK inhibitors (ruxolitinib) and mTOR inhibitors (sirolimus, everolimus, and temsirolimus) minimized CD20-TCB-mediated B-cell depletion, in contrast to the Src inhibitor dasatinib. This suggests a potentially promising approach for preventing cytokine release during initial CD20-TCB infusion while maintaining antitumor efficacy. * * *

[0336] For clarity of understanding, the above invention is described in some detail by illustration and examples, but these descriptions and examples should not be construed as limiting the scope of the invention. All patent and scientific literature disclosures cited herein are expressly incorporated in their entirety by reference.

Claims

1. A medicament for the treatment of a disease in an individual, comprising a T cell engaging agent, wherein an inhibitor of Janus kinase (JAK) and / or mammalian target of rapamycin (mTOR) signaling is administered to the individual.

2. The pharmaceutical of claim 1, wherein administration of the inhibitor of JAK and / or mTOR signaling is for the prevention or reduction of adverse effects associated with administration of a T cell engaging agent.

3. A medicament for preventing or reducing adverse effects associated with the administration of a T cell engaging agent to an individual, the medicament comprising an inhibitor of JAK and / or mTOR signaling.

4. The pharmaceutical according to any one of claims 1 to 3, wherein the inhibitor of JAK and / or mTOR signaling is an mTOR inhibitor, optionally selected from the group consisting of sirolimus, temsirolimus, and everolimus.

5. The medicament according to any one of claims 1 to 4, wherein the inhibitor of JAK and / or mTOR signalling is a JAK inhibitor, optionally a JAK1 and / or JAK2 inhibitor, optionally ruxolitinib, baricitinib, tofacitinib or fedratinib.

6. A medicament according to any one of claims 1 to 5, wherein (the administration of) an inhibitor of JAK and / or mTOR signalling causes inhibition of adverse effects associated with the administration of a T cell engaging agent.

7. A medicament according to any one of claims 1 to 6, wherein (the administration of) an inhibitor of JAK and / or mTOR signalling does not cause inhibition of the desired effect associated with the administration of a T cell engaging agent.

8. The method of claim 6 or 7, wherein the inhibition is complete inhibition or is clinically meaningful and / or statistically significant inhibition.

9. Adverse effects include: (i) Cytokine release syndrome (CRS); (ii) fever, hypotension and / or hypoxia; and / or (iii) elevated serum levels of one or more cytokines, particularly one or more cytokines selected from the group consisting of IL-6, IFN-γ, IL-10, TNF-α, GM-CSF, MCP-1, and IL-1β. The pharmaceutical composition according to any one of claims 2 to 8,

10. The method of any one of claims 2 to 9, wherein the administration of the inhibitor of JAK and / or mTOR signalling is performed upon (clinical) manifestation of adverse effects (in an individual).

11. Administering an inhibitor of JAK and / or mTOR signaling (i) before, concomitant with, or after administration of a T cell engaging agent; (ii) intermittent or continuous; and / or (iii) Oral or parenteral, particularly intravenous The pharmaceutical composition according to any one of claims 1 to 10,

12. A medicament according to any one of claims 1 to 11, wherein administration of an inhibitor of JAK and / or mTOR signalling is concomitant with a first administration of a T cell engaging agent, optionally prior to, simultaneously with or following the first administration of a T cell engaging agent.

13. administering a T cell engaging agent (i) at an effective dose; (ii) parenterally, in particular intravenously; and / or (iii) a first administration of a T cell engaging agent to the individual The pharmaceutical composition according to any one of claims 1 to 12,

14. The pharmaceutical according to any one of claims 1 to 13, wherein the T cell engaging agent is a T cell bispecific antibody or a CAR-T cell.

15. The method of claim 14, wherein the bispecific T cell antibody binds to CD3 and a target cell antigen.

16. The medicament of claim 14 or 15, wherein the T cell bispecific antibody comprises an antigen-binding portion that binds to CD3 and an antigen-binding portion that binds to a target cell antigen.

17. The pharmaceutical composition according to claim 15 or 16, wherein the target cell antigen is carcinoembryonic antigen (CEA).

18. T cell bispecific antibodies (i) a first antigen-binding moiety that binds to CD3, the first antigen-binding moiety comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 5, and a HCDR3 of SEQ ID NO: 6; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO: 7, a LCDR2 of SEQ ID NO: 8, and a LCDR3 of SEQ ID NO: 9; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; and (ii) a second antigen-binding portion that binds to CEA, comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO: 12, a HCDR2 of SEQ ID NO: 13, and a HCDR3 of SEQ ID NO: 14; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO: 15, a LCDR2 of SEQ ID NO: 16, and a LCDR3 of SEQ ID NO: 17; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 18, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

19. The pharmaceutical composition of claim 17 .

19. The pharmaceutical composition according to claim 15 or 16, wherein the target cell antigen is CD20.

20. T cell bispecific antibodies (i) a first antigen-binding moiety that binds to CD3, the first antigen-binding moiety comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 5, and a HCDR3 of SEQ ID NO: 6; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO: 7, a LCDR2 of SEQ ID NO: 8, and a LCDR3 of SEQ ID NO: 9; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11; and (ii) a second antigen-binding moiety that binds to CD20, comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO:24, a HCDR2 of SEQ ID NO:25, and a HCDR3 of SEQ ID NO:26; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO:27, a LCDR2 of SEQ ID NO:28, and a LCDR3 of SEQ ID NO:29; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:30, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

31. The pharmaceutical composition of claim 19 .

21. The pharmaceutical agent according to any one of claims 14 to 16 and 19 to 20, wherein the bispecific T cell antibody is glofitamab.

22. The pharmaceutical according to claim 15 or 16, wherein the target cell antigen is HLA-A2 / MAGE-A4.

23. T cell bispecific antibodies (i) a first antigen-binding moiety that binds to CD3, the first antigen-binding moiety comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO: 37, a HCDR2 of SEQ ID NO: 38, and a HCDR3 of SEQ ID NO: 39; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO: 40, a LCDR2 of SEQ ID NO: 41, and a LCDR3 of SEQ ID NO: 42; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 43, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 44; and (ii) a second antigen-binding portion that binds to HLA-A2 / MAGE-A4, comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO:45, a HCDR2 of SEQ ID NO:46, and a HCDR3 of SEQ ID NO:47; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO:48, a LCDR2 of SEQ ID NO:49, and a LCDR3 of SEQ ID NO:50; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:51, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

52. The pharmaceutical composition of claim 22, comprising:

24. The pharmaceutical composition according to claim 15 or 16, wherein the target cell antigen is CD19.

25. T cell bispecific antibodies (i) a first antigen-binding moiety that binds to CD3, comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO:61, a HCDR2 of SEQ ID NO:5, and a HCDR3 of SEQ ID NO:62, or a heavy chain variable region comprising a HCDR1 of SEQ ID NO:64, a HCDR2 of SEQ ID NO:5, and a HCDR3 of SEQ ID NO:65; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO:7, a LCDR2 of SEQ ID NO:8, and a LCDR3 of SEQ ID NO:9; and / or (b) a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO:7, a LCDR2 of SEQ ID NO:8, and a LCDR3 of SEQ ID NO:9; a first antigen-binding portion comprising a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:63 or a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:66, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:11; and (ii) a second antigen-binding moiety that binds to CD19, comprising: (a) a heavy chain variable region comprising a heavy chain CDR (HCDR)1 of SEQ ID NO:67, a HCDR2 of SEQ ID NO:68, and a HCDR3 of SEQ ID NO:69; and a light chain variable region comprising a light chain CDR (LCDR)1 of SEQ ID NO:70, a LCDR2 of SEQ ID NO:71, and a LCDR3 of SEQ ID NO:72; and / or (b) a heavy chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:73, and a light chain variable region sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:

74. The pharmaceutical composition of claim 24 .

26. A medicament according to any one of claims 1 to 25, wherein the disease (to be treated by the T cell engaging agent) is a cancer, in particular a cancer expressing a target cell antigen of the T cell engaging agent.

27. 26. The method of claim 24 or 25, wherein the disease (to be treated by the T cell engaging agent) is an autoimmune disease, in particular lupus, more particularly systemic lupus erythematosus (SLE) or lupus nephritis (LN).